Western University Scholarship@Western

Digitized Theses

Digitized Special Collections

1989

In Vivo And In Vitro Regulation Of Pituitary Follicle-stimulating Hormone (fsh) Secretion By 3alpha-hydroxy-4-pregnen-20-one (3hp): A Highly Sensitive And Specific Inhibitor

Patricia Helen Wood

Follow this and additional works at: https://ir.lib.uwo.ca/digitizedtheses

Recommended Citation

Wood, Patricia Helen, "In Vivo And In Vitro Regulation Of Pituitary Follicle-stimulating Hormone (fsh) Secretion By 3alphahydroxy-4-pregnen-20-one (3hp): A Highly Sensitive And Specific Inhibitor" (1989). *Digitized Theses*. 1858. https://ir.lib.uwo.ca/digitizedtheses/1858

This Dissertation is brought to you for free and open access by the Digitized Special Collections at Scholarship@Western. It has been accepted for inclusion in Digitized Theses by an authorized administrator of Scholarship@Western. For more information, please contact tadam@uwo.ca, wlswadmin@uwo.ca.



Nationa! Library of Canada

Canadian Theses Service

Ottawa, Canada K1A 0N4 Bibliothèque nationale du Canada

Service des thèses canadiennes

tion.

NOTICE

The quality of this microform is heavily dependent upon the quality of the original thesis submitted for microfilming. Every effort has been made to ensure the highest quality of reproduction possible.

If pages are missing, contact the university which granted the degree.

Some pages may have indistinct print especially if the original pages were typed with a poor typewriter ribbon or if the university sent us an inferior photocopy.

Reproduction in full or in part of this microform is governed by the Canadian Copyright Act, R.S.C. 1970, c. C-30, and subsequent amendments. La qualité de cette microforme dépend grandement de la qualité de la thèse soumise au microfilmage. Nous avons tout fait pour assurer une qualité supérieure de reproduc-

AVIS

S'il manque des pages, veuillez communiquer avec l'université qui a conféré le grade.

La qualité d'impression de certaines pages peut laisser à désirer, surtout si les pages originales ont été dactylographiées à l'aide d'un ruban usé ou si l'université nous a fait parvenir une photocopie de qualité inférieure.

La reproduction, même partielle, de cette microforme est soumise à la Loi canadienne sur le droit d'auteur, SRC 1970, c. C-30, et ses amendements subséquents.



IN VIVO AND IN VITRO REGULATION OF PITUITARY FOLLICLE-STIMULATING HORMONE (FSH) SECRETION BY 3a-HYDROXY-4-PREGNEN-20-ONE (3HP): A HIGHLY SENSITIVE AND SPECIFIC INHIBITOR

Ъy

Patricia H. Wood

Department of Zoology

Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy

Faculty of Graduate Studies The University of Western Ontario London, Ontario June 1989



(c) Patricia H. Wood 1989

National Library of Canada Bibliothèque nationale du Canada

Canadian Theses Service

Service des thèses canadiennes

Ottawa, Canada K1A 0N4

The author has granted an irrevocable nonexclusive licence allowing the National Library of Canada to reproduce, loan, distribute or sell copies of his/her thesis by any means and in any form or format, making this thesis available to interested persons.

The author retains ownership of the copyright in his/her thesis. Neither the thesis nor substantial extracts from it may be printed or otherwise reproduced without his/her permission. L'auteur a accordé une licence irrévocable et non exclusive permettant à la Bibliothèque nationale du Canada de reproduire, prêter, distribuer ou vendre des copies de sa thèse de quelque manière et sous quelque forme que ce soit pour mettre des exemplaires de cette thèse à la disposition des personnes intéressées.

L'auteur conserve la propriété du droit d'auteur qui protège sa thèse. Ni la thèse ni des extraits substantiels de celle-ci ne doivent être imprimés ou autrement reproduits sans son autorisation.

ISBN 0-315-51714-X



ABSTRACT

The effect of the gonadal steroid, 3a-hydroxy-4-pregnen-20-one (3HP), in intact and castrate rats and in primary cultures of rat anterior pituitary cells and the possible interaction of 3HP with the signal transduction pathways of luteinizing hormone-releasing hormone (LHRH) was examined.

Intact or gonadectomized, male or female, prepubertal or adult rats treated with 3HP (0-200 ug/1.0 g BW; 1-4 days) showed a selective reduction in serum FSH levels (25%-60%) without any apparent effect on serum LH levels. The FSH-suppressing effect of 3HP was found to be doserelated, suggesting that 3HP action may be physiological. 3HP was effective in young male rats (10 d) and gonadectomized adult male rats, where 3HP showed its greatest suppression of serum FSH. Comparison of the effect of 3HP with that of some of its metabolites or other gonadal steroids showed that only 3HP had a selective FSH-suppressing effect.

In vitro, 3HP selectively inhibited the basal and LHRH-induced secretion of FSH, with no effect on LH secretion, in cells from both male and female rats. Inhibition of FSH secretion by 3HP was dose-dependent with the doses as low as 10^{-16} to 10^{-14} M exhibiting significant FSH-suppressing activity (by 35%). The cell content of FSH was unaffected by 3HP suggesting that synthesis, as well as release, of FSH is depressed by 3HP. As in the <u>in vivo</u> studies, none of the 18 other steroids tested, nor inhibin, had a similar selective FSH-suppressing action. It was concluded that FSH suppression by 3HP is specific to the structure of this molecule and that even minor alterations in the structure result in a loss of activity.

The effect of 3HP on the calcium signal and protein kinase C (PKC)

iii

activation produced by LHRH was examined in vitro. In experiments employing the calcium ionophore, A23187, FSH secretion, but not LH secretion, was stimulated beyond the level produced by LHRH alone. Furthermore, although stimulated by calcium, it appears that FSH, but not LH, secretion is relatively calcium-independent and will occur in the absence of elevated calcium as revealed by treatment with the calcium channel antagonists, verapamil and nifedipine. The evidence suggests that 3HP acts to modify the FSH response to the calcium signalling pathway and that 3HP action on LHRH-induced FSH secretion might occur via an increase in the requirement of FSH secretion for calcium. Inhibition of PKC activity does not mimic the effect of 3HP. However, the inhibition of FSH release brought about by 3HP can be lessened by the activation of PKC. The activity of 3HP may also be due in part to down-regulation of the FSH gene. These studies have provided insight into the mechanism of 3HP action and further studies may help to completely elucidate this mechanism.

ACKNOWLEDGEMENTS

First of all, I would like to thank Dr. John P. Wiebe for the opportunity to work in his research lab. My work stemmed from one of Dr. Wiebe's discoveries and I will always cherish the opportunity he gave me to pioneer the research in this area. He was always patient and willing to let me have a free hand. I would also like to thank my advisory committee, Dr. R. Hobkirk and Dr. W. Tam, who have played a key role in my success. A special thank-you to Dr. Martin Kavaliers, for providing ideas and materials for this research, and to Dr. Vinod Dave, for preparing many of the steroids I used in this project.

To the sundry people with whom I've shared the lab and my time I would like to say thank-you for all your patience, discussions and advice. A special thanks to Kevin Barr, "technician extraordinaire", for teaching me all I needed to know and being there when I needed help. The same goes for Richard Harris, "Herr Ober Techniker", who was always helpful when his time or expertise was needed. To all who have come and gone in the last five years I say thank-you: Kevin Buckingham, Ron Book, Susan Campbell, Caireen Brain, Mike Dallaire, Chris Dinsdale, Suleiman Igdoura, Kathy James, Patricia Kudo, Len Kosciukiewicz and Michael Temple.

Many friends have also passed through on .hell way to bigger and better things. To all of you: Mike Ansell, Becky Bannerman, Susan Campbell, Elaine Davis, Jackie Dixon, Terese Hansen, Al Hanson, and Angela Porter; thanks for all the good times and support.

Many thanks to all those who've manned the office over the years, especially Callie Cessarini, Marge Moulton and Mary Brown, without whom I never would've figured out how the system works.

۷

I wish to thank my family for their support (emotional and otherwise) while I worked towards this degree, especially Bob and Brenda, and Paul too, who stood by me in this. I hope I've made you proud.

Finally, thank-you for all your patient support and just for being there, Andy. The trials are over and the future is ours to share.

In loving memory of Anne Wood whose spirit and determination live on forever

TABLE OF CONTENTS

CERTIFICATE	OF EXAMINATIONii
ABSTRACT	iii
ACKNOWLEDGEM	ENTSv
DEDICATION	vii
TABLE OF CON	TENTSviii
LIST OF PLAT	ESx
LIST OF TABL	ESxi
LIST OF FIGU	RES
ABBREVIATION	Sxv
CHAPTER 1 1	NTRODUCTION
1.1	The Hypothalamic-Pituitary-Gonadal-Axis
1.2	Regulation of Gonadotropin Secretion In Vivo4 1.2.1 Gonadotropin secretion in the male4 1.2.2 Gonadotropin secretion in the female: a brief
1.3	review
1.4	Hormone Receptor Mechanisms231.4.1 Action and signal transduction of LHRH231.4.2 Mechanism of action of steroids27
1.5	A Novel Gonadal Steroid, 3a-Hyaroxy-4-pregnen-20-one29 1.5.1 The discovery of 3a-hydroxy-4-pregnen-20-one (3HP)
1.6	1.5.2 Properties of 3HP
Chapter 2 M	ATERIALS AND METHODS
2.1	Chemicals
2.2	2.1.3 General

		2.2.2 Surgical procedures
	2.3	
		2.3.1 Preparation of steroids
		2.3.2 Treatment regimens
	~ /	2.3.3 Serum sampling and storage
	2.4	
		2.4.1 Preparation of cell cultures
		2.4.2 Treatment of calf serum42
		2.4.3 Determination of cell number and viability43
		2.4.4 Protein determination43
		2.4.5 Steroid treatments44
		2.4.6 Drug treatments44
		2.4.7 Media and cell sampling45
	2.5	
		2.5.1 Preparation of sephadex columns45
		2.5.2 Radioiodination48
		2.5.3 Storage and preparation of standards and
		primary antibodies
		2.5.4 Radioimmunoassay of serum and media samples50
		2.5.5 Assay reliability and sensitivity51
	2.6	Statistical Analysis
Chapter	3 R	ESULTS 53
	3.1	FSH-Suppressing Effect of 3HP In Vivo53
		3.1.1 Prepubertal intact male rats
		3.1.2 Prepubertal gonadectomized rats
		3.1.3 Adult male rats
	3.2	Studies on Primary Cultures of Rat Anterior Pituitary
	2.2	Cells
		3.2.1 FSH-suppressing effect of 3HP in vitro
		3.2.2 Other gonadal hormones
		3.2.3 Structural isomers of 3HP and other C ₂₁
		steroids
		3.2.4 Studies on the mechanism of action of 3HP119
		5.2.4 Studies on the mechanism of action of Shr
Chester	. / D	DISCUSSION
chapter	4 U	19/099108
	4.1	3HP Selectively Suppresses FSH Secretion In Vivo136
	4.2	
	4.2	4.2.1 Comparison with other gonadal steroids
		4.2.2 3HP and inhibin effects in vitro140
	1.2	4.2.3 Specificity of 3HP action142
	4.3	
		Brief Comment
	4.4	Insight Into the Lochanism of 3HP Action147
ov- o · ·		
SUMMARY	••••	
		• • •
REFEREN	ICES	
VITA		
		······································

.

LIST OF PLATES

Plate	Description	Page
1	Typical rat anterior pituitary cells in culture	78

LIST OF TABLES

Table	Description	Page
1	Summary of effects of gonadal hormones on <u>in vivo</u> gonadotropin secretion in the male rat	14
2	Summary of effects of gonadal hormones on <u>in vitro</u> gonadotropin secretion	24
3	Effect of number of doses of 3HP on gonadotropin secretion in intact, juvenile male rats	
4	Effect of 3HP and LHRH on cell content of gonadotroping in cultured male and female anterior pituitary cells	
5	Effect of 17β-estradiol on gonadotropin secretion in cultures of female anterior pituitary cells	105
6	Effect of 3HP and dihydrotestosterone or 17β-estradiol progesterone in cultures of female anterior pituitary cells	
7	Effect of pregnenes and androstene structurally-related to 3HP on gonadotropin secretion in primary cultures of female anterior pituitary cells	
8	Effect of pregnanes structurally-related to 3HP on gona tropin secretion in female anterior pituitary cells in culture	

LIST OF FIGURES

Figure	Description	Page
1	Hypothalamic-pituitary-gonadal axis in the male ra	6
2	Hypothalamic-pitu tary-gonadal axis in the female ra	t8
3	Chemical structure of the allylic gonadal steroid, 3 hydroxy-4-pregnen-20-one (3HP)	
4	Schematic representation of the protocol followed fo all <u>in vivo</u> experiments	
5	Schematic representation of the protocol followed fo all <u>in vitro</u> experiments	r 47
6	Effect of 3HP on serum FSH and LH levels in the 26 d old intact male rat	ay •••••55
7	Effect of a single injection of 3HP on serum FSH and in 10 and 20 day old intact male rats	
8	Effect of a single injection of 3β HP on serum FSH an levels in 25 day old intact male rats	
9	Effect of 5a-pregnane-3,20-dione and 3a-hydroxy-5a- pregnan-20-one on gonadotropin secretion in 25 day o intact male rats	
10	Effect of 3HP in gonadectomized male and female prep ertal rats	
11	Effect of 3a-hydroxy-4-pregnen-20-one-3-acetyl on go tropin secretion in gonadectomized prepubertal male	
12	Effect of 17β-estradiol, dihydrotestosterone and 17α hydroxyprogesterone on serum FSH and LH levels in go adectomized prepubertal male rats	n-
13	Effect of 3α-hydroxy-4-pregnen-20-one-3-acetyl an 3β-hydroxy-4-pregnen-20-one-3-acetyl on serum FSH an levels in adult intact male rats	d LH
14	Effect of 3a-hydroxy-4-pregnen-20-one-3-acetyl on se FSH and LH levels in intact and gouadectomized adult male rats	
15	Effect of LHRH on FSH and LH secretion in primary cultures of male and female anterior pituitary cells	80
16	Effect of 3HP and/or LHRH on FSH and LH secretion in primary cultures of male rat anterior pituitary cell after a 4 or 24 h incubation	8

17	Effect of 3HP and/or LHRH on FSH and LH secretion in primary cultures of female rat anterior pituitary cells after a 4 or 24 h incubation85
18	Effect of 3HP on basal FSH and LH secretion in primary cultures of fem/le rat anterior pituitary cells
19	Effect of 3HP on LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells90
20	Effect of progesterone on basal and LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells
21	Effect of 5a-dihydroprogesterone on basal and LHRH- induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells
22	Effect of testosterone on basal and LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells
23	Effect of dihydrotestosterone on basal and LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells101
24	Effect of 20a-hydroxy-4-pregnen-20-one on basal and LHRH- induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells104
25	Comparison of the effect of 3HP and porcine follicular fluid inhibin on basal and LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells108
26	Effect of 3β-hydroxy-4-pregnen-20-one on basal and LHRH- induced LH secretion in primary cultures of female rat anterior pituitary cells112
27	Effect of 3a-hydroxy-5a-pregnan-20-one on basal and LHRE-induced LH secretion in primary cultures of female rat anterior pituitary cells116
28	Effect of 3β-hydroxy-5β-pregnan-20-one on basal and LHRH-induced LH secretion in primary cultures of female rat anterior pituitary cells118
29	Effect of 3HP and the calcium ionophore, A23187, on basal and LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells
30	Effect of 3HP and the calcium channel antagonist, verapamil, on basal and LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary

	cells125
31	Effect of 3HP and the calcium channel antagonist, nifedipine, on basal and LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells
32	Effect of 3HP and the protein kinase C inhibitor, H-7, on basal and LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells131
33	Effect of 3HP and the protein kinase C activator, SC-9, on basal and LHRH-induced FSH and LH secretion in primary cultures of female rat anterior pituitary cells133
34	A modified view of the hypothalamic-pituitary-gonadal axis in the rat144

ABBREVIATIONS

HP3a-Hydroxy-4-pregnen-20-one178-Estration1,3,5(10)-Estratience.3,178-diol; estrogen17a-Hydroxyprogesterone17a-Hydroxy-4-pregnence.3,20-dioneA23187Calimycin; calcium ionophoreANOVAAnalysis of varianceBSpecific bound radioactivity (sample)BTotal specific bound radioactivityBXABody weightC1919-Carbon steroid; androstene or androstaneC2121-Carbon steroid; pregnene or pregnanecmCentimeterC002Carbon dioxidecpmCounts per minute (radioactivity)Dihydrotestosterone178-Hydroxy-50-androstan-3-oneEDTAEthylenediaminetetrasacetic acidFSHFolicle-stimulating hormone8GramgeGABAGamma-aminobutyric acidGXGondactomizedH-7Protein kinase C inhibitorhtp:hour175hour175I176Kreb's ringer phosphateLHLuteinizing hormoneKdKidoaltonsKFPKreb's ringer phosphateLHLuteinizing hormone-LRRLuteinizing hormoneMMMolarM199Medium 199; culture mediumminMilligramminMilligramminMilligramminMilligramminMilligramMACNanogramNIDDKNanogramNBNanogramNSBNonspecific bindingPTotal	Звнр		38-Hydroxy-4-pregnen-20-one
17a-Hydroxyprogesterone17a-Hydroxy-4-pregnene-3,20-dioneA23187Caliwycin; calcium ionophoreANOVAAnalysis of varianceBSpecific bound radioactivity (sample)BTotal specific bound radioactivityBABovine serum albuminBWBody weightC1919-Carbon steroid; androstene or androstaneC2121-Carbon steroid; pregnene or pregnaneCmCentimeterC02Carbon dioxidecpmCourts per minute (radioactivity)Dihydrotestosterone178-Hydroxy-50-androstan-3-oneEDTAEthylenediamineterracetic acidFSHFolicle-stimulating hormonegGramGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorPThour1251Iodine-125 (radioisotope)IgGImmunoglobin GKRPKreb's ringer phosphateLHRHLuteinizing hormoneHRHMolarM199Medium 199; culture mediummcMillituremgNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometerMNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometerMNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometerMNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometerPFF-1 <td></td> <td></td> <td></td>			
A23187Calimycin; calcium ionophoreANOVAAnalysis of varianceBSpecific bound radioactivity (sample)BTotal specific bound radioactivityBSABovine serum albuminBWBody weightC1919-Carbon steroid; androstene or androstaneC21Carbon steroid; pregnene or pregnanecmCentimeterC02Carbon dioxidecpmCounts per minute (radioactivity)Dihydrotestosterone17β-Hydroxy-50-androstan-3-oneBTAFolicle-stimulating hormonegGaugeGABAGamma-aminobutyric acidGXGondectomizedH-7Protein kinase C inhibitorhT251Iodine-125 (radioisotope)IgGImmunoglobin GKdKillicurinM111MilitoriaM111MilitoriammMolarM199Medium 199; culture mediummcMilitoriamlMilitoriamsNanogramNIDDKNanogramNIDDKNanometerMMNanometerMMNanometerMNanometerMNanometerMNanometerMNanometerMNanometerMNanometerMNanometerMNanometerMNanometerMNanometerMNanometerMNanometerMNanometerMNanometer<			
ANOVAAnalysis of varianceBSpecific bound radioactivity (sample)B_Total specific bound radioactivityBSABovine serum albuminBWBody weightC1919-Carbon steroid; androstene or androstaneC2121-Carbon steroid; pregnene or pregnaneCmCarbon dioxideCpmCarbon dioxideCpmCourts per minute (radioactivity)Dihydrotestosterone178-Hydroxy-50-androstan-3-oneEDTAEthylenediaminetetraacetic acidFSHFolicle-stimulating hormonegGramGGaugeGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorH251Iodine-125 (radiostope)IgGImmunglobin GKK4KilodaltonsKRPKreb's ringer phosphateLHRHLuteinizing hormone-releasing hormoneMMolarM1999Medium 199; culture mediummcMilligramminMilligramminMilligramminMilligramMNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanomelerMHNanomelerPF-1Porcine follicular fluid inhibinPFF-1Porcine follicular fluidPFF-1Porcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneKIARadioimmunoassay <td></td> <td>yprogesterone</td> <td></td>		yprogesterone	
BSpecific bound radioactivity (sample)BTotal specific bound radioactivityBSABovine serum albuminBWBody weightC1919-Carbon steroid; androstene or androstaneC2121-Carbon steroid; pregnene or pregnamecmCentimeterCO2Carbon dioxidecpmCounts per minute (radioactivity)Dihydrotestosterone178-Hydroxy-50-androstan-3-oneEDTAEthylenediaminetetraacetic acidFSHFollicle-stimulating hormonegGramGGaugeGABAGamma-aminobutyric acidGXGondectomizedH-7Protein kinase C inhibitorPrhour1251Iodine-125 (radioisotope)IgGImmunoglobin GKdKiloaltonsKRPKreb's ringer phosphateLHRLuteinizing hormoneMMolarM199Medium 199; culture mediummcMilligramminMilligramminMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanomolarNSBNonspecific bindingPF-1Proctine follicular fluidPFF-1Proctine follicular fluidPFF-1Proctine follicular fluidPFF-1Proctine follicular fluidPFF-1Proctine follicular fluidPFF-1Proctine follicular fluidPFF-1Proctine follicular fluidPFF-1 <td></td> <td></td> <td></td>			
B SATotal specific bound radioactivityBSABovine serum albuminBWBody weightC1919-Carbon steroid; androstene or androstaneC2121-Carbon steroid; androstene or pregnamecmCentimeterCO2Carbon dioxidecpmCourts per minute (radioactivity)Dihydrotestosterone178-Bydroxy-50-androstan-3-oneEDTAEthylenediaminetetraacetic acidFSHFolicle-stimulating hormonegGramGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhur125IIodine-125 (radioisotope)IgGImmunoglobin GKRPKreb's ringer phosphateLHLuteinizing hormoneHHRHLuteinizing hormoneMMolarM199Medum 199; culture mediummcMilligramminMinutemlMillimelarmgNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanomelarNSBNonspecific bindingPFF-1Porcine follicular fluidPFF-1Protein kinase C ProgesteroneKIAKadoimmunoassay	ANOVA		
BWBody weightC1919-Carbon steroid; androstene or androstaneC2121-Carbon steroid; pregnene or pregnanecmCentimeterC02Carbon dioxidecpmCounts per minute (radioactivity)Dihydrotestosterone17β-Hydroxy-Sa-androstan-3-oneEDTAEthylenediaminetetracetic acidFSHFollicle-stimulating hormonegGaugeGABAGama-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhtIodine-125 (radioisotope)IgGImmunoglobin GKKPKreb's ringer phosphateLHLuteinizing hormoneLHRLLuteinizing hormoneHHMolarminMilligramminMilligramminMilligramminMillimetermMNanogramNIDDKNanometermMNanogramNBSBNonspecific bindingPFF-1Porcine follicular fluidPFF-1Porcine follicular fluidPFF-1Porcine follicular fluidPFF-1Porcine follicular fluidPFFPorcine follicular fluidPFF-1Porcine follicular fluidPFFPorcine follicular fluidPFF<			
BWBody weightC1919-Carbon steroid; androstene or androstaneC2121-Carbon steroid; pregnene or pregnanecmCentimeterC02Carbon dioxidecpmCounts per minute (radioactivity)Dihydrotestosterone17β-Hydroxy-Sa-androstan-3-oneEDTAEthylenediamineterracetic acidFSHFollicle-stimulating hormonegGaugeGABAGama-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhtIodine-125 (radioisotope)IgGImmunoglobin GKKPKreb's ringer phosphateLHLuteinizing hormoneLHRILuteinizing hormoneHHMolarminMinute <t< td=""><td>B_Q</td><td></td><td></td></t<>	B _Q		
C1919-Carbon steroid; androstene or androstaneC2121-Carbon steroid; pregnene or pregnaneCmCentimeterC02Carbon dioxidecpmCounts per minute (radioactivity)Dihydrotestosterone178-Hydroxy-5a-androstan-3-oneEDTAEthylenediaminetetraacetic acidFSHFollicle-stimulating hormonegGramGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhprhour1251Iodine-125 (radioisotope)IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHRLuteinizing hormoneMMolarM199Medium 199; culture mediummcMilligramminMilligramminMilligramminMilligramminMilligramMNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesmNanometerMMNonspecific bindingPTotal culture proteinPFF-1Porcine follicular fluidPFF-1Porcine folli			
C12121-Carbon steroid; pregnene or pregnaneCmCentimeterCO2Carbon dioxidecpmCounts per minute (radioactivity)Dihydrotestosterone178-Hydroxy-5a-androstan-3-oneEDTAEthylenediaminetertaacetic acidFSHFollicle-stimulating hormonegGramGGaugeGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorprhour125IIgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHRHLuteinizing hormoneMMolarM199Medium 199; culture mediummcMilligrammlMilligrammlMilligrammlMillimetermMNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanomelarPFF-IPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmuncasasy			• •
cmCentimeterCO2Carbon dioxideCpmCounts per minute (radioactivity)Dihydrotestosterone178-Hydroxy-5a-androstan-3-oneEDTAEthylenediaminetertaacetic acidFSHFollicle-stimulating hormonegGramGGaugeGABAGarma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorHz51Iodine-125 (radioisotope)IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHRLuteinizing hormoneLHRHLuteinizing hormoneMMolarM199Medium 199; culture mediummcMilligramminMinutemlMilligrammlMillimetermMNanomelarNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanomelarPFF-IPorcine follicular fluidPFF-IPorcine follicular	^C 19		
CO2Carbon dioxidecpmCounts per minute (radioactivity)Dihydrotestosterone178-Hydroxy-5α-androstan-3-oneEDTAEthylenediaminetetraacetic acidFSHFollicle-stimulating hormonegGramGGaugeGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorbirhour1251Iodia-125 (radioisotope)IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormoneLHRHMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMillicuriemgNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimunoasay			
cpmCounts per minute (radioactivity)Dihydrotestosterone17β-Hydroxy-5α-androstan-3-oneEDTAEthylenediamineterraacetic acidFSHFollicle-stimulating hormonegGramGGaugeGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhttp://picstation.comImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHRHLuteinizing hormone-releasing hormoneMMolarM110arMilligramminMilligramminMilligrammMMolarMMillimolarngNanogramNIDDKNanometerMMNanometerMMNanomolarNSBPhosphate buffered salinePFF-IProcine follicular fluidPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IRadioimunoasayKKRadioimunoasay			
Dihydrotestosterone17B-Hydroxy-5a-androstan-3-oneEDTAEthylenediaminetetraacetic acidFSHFollicle-stimulating hormonegGramGGaugeGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhrhour125IIIodine-125 (radioisotope)IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMilligramminMinutemlMillimetermMMolarNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanometernMNanometernFProcine follicular fluidPFF-IProcine follicular fluidPFF-IProcine follicular fluidPFF-IProcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimunoasay			
EDTAEthylenediaminetetraacetic acidFSHFollicle-stimulating hormonegGramGABAGaugeGABAGonadectomizedH-7Protein kinase C inhibitorhThour125IIdoine-125 (radioisotope)IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHRLuteinizing hormoneMMolarM199Medium 199; culture mediummcMilligramminMilligrammfMillimolarNTDDKNanogramNBSBNonspecific bindingPTotal culture proteinPFFProtein kinase CPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IRosphate buffered salinePFF-IPorcine follicular fluidPFF-IRosphate SalinePFF-IRotein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimunoasay		****	-
FSHFollicle-stimulating hormonegGramGGaugeGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhThour125 ₁ Iodine-125 (radioisotope)IFGImmunoglobin GKdKilodaltonsKKPKreb's ringer phosphateLHLuteinizing hormoneLHHLuteinizing hormoneHMMolarM199Medium 199; culture mediummcMilligrammlnMilligrammlnMillimolarngNanogeramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarPFTotal culture proteinPFProcine follicular fluidPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IRadioimunoasayKIARadioimunoasay	-	tosterone	
gGramGGaugeGABAGauma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhriterationhouriterationiterationiterationiterationiterationgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMilligramminMinutemlMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanometerPFFProstic bindingPTotal culture proteinPBSPhosphate buffered salinePFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
GGaugeGABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhr5iIIodine-125 (radioisotope)IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMilligrammlnMilligrammlnMillimetermMMillimetermMMaionar Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanometerMMNanometerMMNanomolarPFFPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPKCProgen-3,20-dioneRIAARadioimmunoaseay			
GABAGamma-aminobutyric acidGXGonadectomizedH-7Protein kinase C inhibitorhrhour125IIIodine-125 (radioisotope)IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMillicuriemgMilligrammlnMinutemlMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBPosphate buffered salinePFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
GXGonadectomizedH-7Protein kinase C inhibitorhrhor1251Iodine-125 (radioisotope)IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMinutemlMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanometernMNanometernFPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	-		
H-7Protein kinase C inhibitorhrhour125I odine-125 (radioisotope)IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMillinetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanomolarNSBNonspecific bindingPTotal culture proteinPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPFF-IPorcine follicular fluidProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			•
IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMinutemlMillimetermMMillimotarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanometernMNanografic bindingPTotal culture proteinPBSPhosphate buffered salinePFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	H-7		
IgGImmunoglobin GKdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMinutemlMillimetermMMillimotarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanometernMNanografic bindingPTotal culture proteinPBSPhosphate buffered salinePFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	br_		hour
KdKilodaltonsKRPKreb's ringer phosphateLHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMinutemlMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPFFPorcine follicular fluidPFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	¹²⁵ I		Iodine-125 (radioisotope)
KRPKreb's ringer phosphateLHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMinutemlMillilitremmMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPFFProcine follicular fluidPFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	IgG		Immunoglobin G
LHLuteinizing hormoneLHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMinutem1MilliftremmMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanometernMNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	Kd		Kilodaltons
LHRHLuteinizing hormone-releasing hormoneMMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMinutemlMillilitremmMillimotarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnMNanomotarNSBNonspecific bindingPTotal culture proteinPFFPorcine follicular fluidPFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
MMolarM199Medium 199; culture mediummcMillicuriemgMilligramminMinutemlMillilitremmMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPFFPorcine follicular fluidPFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneKIARadioimmunoassay			-
M199Medium 199; culture mediummcMillicuriemgMilligramminMinutemlMillilitremmMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPFFPorcine follicular fluidPFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneKIARadioimmunoassay			
mcMillicuriemgMilligramminMinutemlMillilitremmMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
mgMilligramminMinutemlMillilitremmMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			•
minMinutemlMillilitremmMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFF-IPorcine follicular fluidPFF-IPorcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
mlMillilitremmMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFF-IPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			-
mmMillimetermMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFF-1Porcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
mMMillimolarngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFF-1Porcine follicular fluidPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
ngNanogramNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFFPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
NIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFFPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
Kidney DiseasesnmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFFPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
nmNanometernMNanomolarNSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFFPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			-
NSBNonspecific bindingPTotal culture proteinPBSPhosphate buffered salinePFFPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	nm		•
PTotal culture proteinPBSPhosphate buffered salinePFFPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	nM		Nanomolar
PTotal culture proteinPBSPhosphate buffered salinePFFPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	NSB		Nonspecific binding
PFFPorcine follicular fluidPFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	Р		
PFF-IPorcine follicular fluid inhibinPKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay	PBS		
PKCProtein kinase CProgesterone4-Pregnen-3,20-dioneRIARadioimmunoassay			
Progesterone 4-Pregnen-3,20-dione RIA Radioimmunoassay			
RIA Radioimmunoassay			
-	•	ne	•
KNA KIDONUCIEIC acid			
	KNA		KIDONUCIEIC ACIO

RP-1 RP-2	Reference preparation 1 (NIDDK) Reference preparation 2 (NIDDK)
s.c. SC-9	Subcutaneous Protein kinase C activator
SCM	Sertoli cell culture medium
sec	Second
SEM	Standard error cf the mean
Testosterone	17β-Hydroxy-4-antrosten-3-one
U	Unit
gц	Microgram
1ىر	Microlitre
μM	Micromolar
хg	Times gravity

The author of this thesis has granted The University of Western Ontario a non-exclusive license to reproduce and distribute copies of this thesis to users of Western Libraries. Copyright remains with the author.

Electronic theses and dissertations available in The University of Western Ontario's institutional repository (Scholarship@Western) are solely for the purpose of private study and research. They may not be copied or reproduced, except as permitted by copyright laws, without written authority of the copyright owner. Any commercial use or publication is strictly prohibited.

The original copyright license attesting to these terms and signed by the author of this thesis may be found in the original print version of the thesis, held by Western Libraries.

The thesis approval page signed by the examining committee may also be found in the original print version of the thesis held in Western Libraries.

Please contact Western Libraries for further information: E-mail: <u>libadmin@uwo.ca</u> Telephone: (519) 661-2111 Ext. 84796 Web site: <u>http://www.lib.uwo.ca/</u>

INTRODUCTION

It is well established that gonadal steroids play an important role in the differentiation, development and regulation of the reproductive systems of mammals. The interaction of neural signals, hypothalamic releasing factors, pituitary hormones and gonadal steroids provide a fine control of all reproductive processes. The current understanding is that this system (neural-hypothalamic-pituitary-gonadal axis) is very complex and that there may be a number of factors involved that are not yet defined. This thesis attempts to add to the body of knowledge concerning reproductive controls in the mammal and to define a role in these processes for a relatively novel gonadal steroid, 3α -hydroxy-4pregnen-20-one (3HP).

1.1 THE HYPOTHALAMIC-PITUITARY GONADAL AXIS

1.1.2 The Endocrine Hypothalamus

The hypothalamus is located at the base of the mammalian brain surrounding the third ventricle (Paxinos and Watson, 1986). The releasing factor for gonadotropic hormones is synthesized, and released in a pulsatile manner (Bourguinon <u>et al</u>, 1987), by neurons within the medial basal hypothalamus and transported to the median eminence for storage (Hadley, 1984). Luteinizing hormone-releasing hormone (LHRH) is a decapeptide whose structure was first elucidated by Baba, Matsuo and Schally (1971). LHRH is transported via the hypophysial portal vascular system from the median eminence (Schally <u>et al</u>, 1977) to the anterior pituitary where it greatly enhances the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in numerous mammals

1

including rats, rabbits, pigs, horses and humans, among others, regardless of the route of administration (Schally et al, 1976).

1.1.2 The Anterior Pituitary

The adenohypophysis or anterior pituitary gland is located in a pocket of the sphenoid bone at the base of the brain (Paxinos and Watson, 1986) and communicates with the median eminence of the hypothalamus via the hypophysial portal system (Schally <u>et al</u>, 1977). Numerous tropic hormones are synthesized by the cells of the anterior pituitary including LH and FSH produced by gonadotropes (Hadley, 1984). Gonadotropes mature early in the rat (in the first week of life) and 75% of gonadotropes contain both FSH and LH secretory granules while 14.2% contain LH, and 11% contain FSH secretory granules only (Childs <u>et al</u>, 1981). These secretory granules are seen to be depleted after stimulation of anterior pituitary gonadotropes by LHRH (Nakamura <u>et al</u>, 1985). Simultaneous measurement of LHRH and serum FSH and LH in intact and castrate rats has shown that circulating levels of FSH and LH are highly correlated to the release of LHRH (Levine and Duffy, 1988).

1.1.3 The Gonad

The male gonad, or testis, consists of two compartments; (1) the seminiferous tubules which produce sperm in an environment carefully controlled by Sertoli cells and (2) the interstitium where the cells of Leydig produce androgens for the maintenance of the male reproductive tissues (Burgos <u>et al</u>, 1970). Pituitary gonadotropins (FSH and LH) regulate testicular function. Luteinizing hormone activates Leydig cells (Solano et al, 1988) and has a positive effect on the production of androgens, particularly testosterone (17β-hydroxy-4-androsten-3-one), by these cells (Eik-Nes, 1975). LH action in the interstitium results in increased activity of 3β-hydroxysteroid dehydrogenase, an important enzyme in testicular androgen synthesis (Shikita and Hall, 1967; Wiebe, 1973a). Traditionally, testosterone has been thought to be the prime regulator of gonadotropin secretion, particularly LH, in male mammals (Zanisi et al, 1973).

Follicle-stimulating hormone binds specifically to Sertoli cells, resulting in a stimulation of spermatogenesis (Means et al, 1980; Means, 1975 provides a good review). Evidence has accumulated which indicates that rat Sertoli cells not only "nurse" the developing spermatozoa but also are capable of producing hormones themselves. In 1970, Lacy and Pettit definitively described steroidogenic activity in seminiferous tubules. Sertoli cells from young rats were further shown to metabolize C_{19} steroids under FSH stimulation (Welsh and Wiebe, 1976; Welsh and Wiebe, 1978), to metabolize pregnenolone $(3\beta-hydroxy-5-pregnen-20-one)$ and progesterone (4-pregnene-3,20-dione) (Wiebe, 1978b; Tilbe and Wiebe, 1981) and to synthesize steroids de novo from acetate (Wiebe and Tilbe, 1979). The primary products of rat Sertoli cell progesterone metabolism are C₂₁ steroids (see Wiebe, 1985 and Wiebe et al, 1988 for reviews). Recent work has shown that inhibin (a polypeptide hormone) is also produced in seminiferous tubules under the influence of FSH and plays a role in the feedback inhibition of pituitary FSH secretion (Au et al, 1986; McLachlan et al, 1987; deKretser and Robertson, 1989).

Gonadotropins from the anterior pituitary regulate ovarian function in famale mammals. FSH is responsible for the recruitment and growth of collicies in the ovary (Hirshfield, 1979). The primary stimulus of steroidogensis in the ovary is luteinizing hormone. LH binds to thecal cells in ovarian follicles and stimulates the production of androgens from cholesterol (Fortune and Armstrong, 1979; Gore-Langton and Armstrong, 1988). The 1 androgens are further converted to 17βestradiol (1,3,5(10)-estratriene-3,17β-diol) by granulosa cells under the influence of FSH early in the follicular stage of the ovarian cycle (Dorrington and Armstrong, 1979; Gore-Langton and Armstrong, 1988). It is 17β -estradiol which provides negative feedback regulation of gonadotropin secretion in the female, while progesterone produced by the granulosa cells later in the cycle, causes a surge in gonadotropins (Gore-Langton and Armstrong, 1988). There is also evidence that ovarian follicles produce inhibin which has a negative effect on FSH secretion (Ling et al, 1985; Fukuda et al, 1986; Martin et al, 1986).

Figure 1 and Figure 2 summarize the function of the hypothalamicpituitary-gonadal axis in the male and female mammal, respectively.

1.2 REGULATION OF GONADOTROPIN SECRETION IN VIVO

Many studies have been performed over the years to discern the mechanisms by which reproductive function is regulated. Experiments on intact and gonadectomized animals have shown that gonadal steroids play a major role in regulating gonadotropin secretion and that there are some differences in regulatory mechanisms between males and females.

1.2.1 Gonadotropin Secretion in the Male

The concentration of gonadotropic hormones in the blood of male rate is controlled by feedback mechanisms involving the gonads. Serum LH levels mormally range from 25-100 ng (NIDDK rat LH reference preparation 4

Figure 1: Hypothalamic-pituitary-gonadal axis in the male rat. Luteinizing hormone-releasing hormone (LHRH) is synthesized in, and secreted from, the endocrine hypothalamus of the brain. LHRH travels to the pituitary via the hypophysial portal (vascular) system where the gonadotropes are stimulated to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH) into the bloodstream. LH stimulates the production of androgens within the Leydig cells of the testis (particularly testosterone) which in turn have a negative feedback effect on the hypothalamus and pituitary to decrease the release of LH. FSH binds to Sertoli cells in the testis and stimulates spermatogenesis, steroid metabolism and the production of the polypeptide, inhibin. Current views are that inhibin secreted into the seminal fluid and subsequently taken up into the bloodstream is responsible for negative feedback control of FSH release in the male.





Figure 2: Hypothalamic-pituitary-gonadal axis in the female rat. Luteinizing hormone-releasing hormone (LHRH) is synthesized in, and secreted from, the endocrine hypothalamus of the brain. LHRH travels to the pituitary via the hypophyseal portal (vascular) system where the gonadotropes are stimulated to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH) into the bloodstream. LH stimulates the production of androgens within the thecal layer of ovarian follicles. FSH stimulates the granulosa cells to produce 17β -estradiol from the androgen precurors produced by the thecal cells, which has a negative feedback effect on the hypothalamus and pituitary to decrease gonadotropin release, from the thecal androgen precursers. Later in the ovarian cycle, granulosa cells produce progesterone which plays a role in the stimulation of the pre-ovulatory gonadotropin surge. Ovarian follicles also produce inhibin which is involved in the inhibition of FSH secretion from the anterior pituitary.



.

OVARIAN FOLLICLE

1; RP-1)/m1 with usual values for adult animals of 60-100 ng/m1 (Dohler and Wuttke, 1975; McLean <u>et al</u>, 1977). Serum FSH is somewhat higher, with average adult values of around 500 ng/m1 (RP-1) (Dohler and Wuttke, 1975; Lorenzen and Ramaley, 1981; McLean <u>et al</u>, 1977). McLean and his co-workers (1977) also found that, in the adult male rat, serum FSH varies diurnally from a low of 400-800 ng/m1 to a high of 1100-1300 ng/m1. Gonadectomy, or castration, of the male rat removes the source of hormones which negatively control gonadotropin secretion and results in 3-4 fold increases in serum LH and 2-3 fold increases in serum FSH (Lorenzen and Ramaley, 1981; Hiatt <u>et al</u>, 1987). Secretion of LHRH from the hypothalamus is also increased after gonadectomy and is highly correlated to the rise in serum gonadotropins following castration (Urbanski <u>et al</u>, 1988; Levine and Duffy, 1988).

Many factors are involved in the regulation of circulating gonadotropin levels in the male. Androgens (C_{19} steroids) are produced in considerable quantities by testicular Leydig cells (Eik-Nes, 1975) and play a major role in regulating the secretion of pituitary gonadotropins, particularly LH. Testosterone, when administered to the intact male rat, is capable of suppressing serum LH levels and has a somewhat lesser effect on serum FSH levels (Gray <u>et al</u>, 1980). A similar role for testosterone in the intact male rat was demonstrated by active immunization against testosterone, which results in increases in serum gonadotropins (Nieschlag <u>et al</u>, 1975). In the castrate rat, testosterone at high doses (¹300 µg/100 g body weight (BW)) can completely suppress the post-gonadectomy rise in serum gonadotropins (Eldridge <u>et al</u>, 1974; Summerville and Schwartz, 1981). Most studies show a parallel inhibition of gonadotropins with a preferential reduction of Lh secretion with doses of testosterone in the 10-300 μ g/100 g BW range (Gay and Dever, 1971; Dufy-Barbe and Franchimont, 1971; Swerdloff and Walsh, 1973).

Many steroids have been investigated using the gonadectomized male rat model. In the gonadectomized male rat, dihydrotestosterone (17 β hydroxy-5a-androstan-3-one) selectively inhibits LH secretion at doses of 20 or 70 μ g/100 g BW when administered for 4 days (Demoulin et al, 1973; Swerdloff et al, 1973) and gives a parallel inhibition of LH and FSH secretion at higher doses, with the emphasis on depressing LH secretion (Demoulin et al, 1973; Swerdloff et al, 1973; Eldridge et al, 1974; Verjans and Eik-Nes, 1977). It appears that dihydrotestosterone is more potent than testosterone in reducing the secretion of gonadotropins from the pituitary (Loseva et al, 1980). Of considerable interest is the fact that extremely low doses of dihydrotestosterone (less than 10 µg/100 g BW/day) increase basal FSH secretion while LH levels are suppressed (Mittler et al, 1981; Karanth et al, 1984) and increase the sensitivity of pituitary LH to LHRH induction while FSH sensitivity to LHRH is reduced (Karanth et al, 1984). Furthermore, 50 ng of crystalline testosterone implanted in the lateral septum of male rats has a positive effect on the secretion of LH and FSH (Carreras et al, 1987).

Several other androgens are implicated in the regulation of pituitary function. The most studied of these is 5α -androstane- 3α , 17β diol which adequately reduces serum LH in the gonadectomized male rat at doses as low as 20 µg/100 g BW but does not suppress FSH secretion until higher doses of 1000 µg/100g BW are employed (Demoulin <u>et al</u>, 1973; Sweroloff <u>ac al</u>, 1973; Verjans and Eik-Nes, 1977). Among androgens shown to selectively reduce serum LH levels in the gonadectomized male rat are: 5α -androstane- 3β , 17β -diol (Swerdloff <u>et al</u>, 1973; Loseva <u>et al</u>, 1980); 4-androstene-3, 17-dione; 4-androstene- 3α , 17β -diol; 5-androstene- 3α , 17β -diol and 3β -hydroxy- 5α -androstan-17-one (epiandrosterone) (Swerdloff et al, 1973).

There is considerable evidence that 17β -estradiol is produced in the male gonad and may play a role in regulating pituitary secretion (Eik-Nes, 1975; van der Molen et al, 1973; Winter and Troen, 1985). Studies show that, similar to testosterone and dihydrotestosterone, 17β estradiol treatment gives rise to a parallel inhibition of serum LH and FSH in the gonadectomized male rat, with LH levels depressed more than those of FSH (Gay and Dever, 1971; Swerdloff and Walsh, 1973; Swerdloff et al, 1973; Eldridge et al, 1974). However, Demoulin et al (1973) showed that a low dose of 17β -estradiol (4 x 0.085 µg/rat) results in a considerable increase in serum FSH. In similar studies, active immunization of intact male rats against 17^β-estradiol showed a clear role for 17β -estradiol in the negative feedback control of LH secretion (Nieschlag et al, 1975) while treatment of healthy men with the 17β estradiol antagonist, clomiphene citrate, results in a sharp rise in serum LH levels with a lesser effect on serum FSH levels (Winter and Troen, 1985). The authors of these experiments suggest that 17β estradiol endogenously acts to restrain the release of hypothalamic LHRH.

The testis has the capacity to produce 21-carbon steroids (pregnenes/pregnanes;Lacy and Pettit, 1970; Wiebe, 1985). In the gonadectomized male rat, progesterone has no effect on the secretion of gonadotropins from the adenohypophysis (Swerdloff <u>et al</u>, 1973; Eldridge <u>et al</u>, 1974). Swerdloff <u>et al</u> (1973) also a tested a number of other C_{21}

11

steroids in the castrate male rat including 17a-hydroxy-4-pregnene-3,20dione (17a-hydroxyprogesterone), 20a-hydroxy-4-pregnen-3-one and 3β hydroxy-5-pregnen-20-one (pregnenolone) among others, all of which have no effect on circulating levels of gonadotropins. McPherson and Mahesh (1982) found that a "surge" of LH and FSH in the gonadectomized male rat could be produced by 100 µg/100 g BW progesterone after 4 days of estrogen-priming (2 µg/100 g BW). Evidence also exists to suggest that adrenal C_{21} steroids are involved in the regulation of pituitary gonadotropin secretion. Cortisol (118,17a,21-trihydroxy-4-pregnene-3,20dione) suppresses the LH, but not the FSH, response to LHRH in gonadectomized male rats (Ringstrom and Schwartz, 1985) and adrenalectomy of prepubertal male rats decreases serum FSH and the FSH response to LHRH induction (Nazian, 1982). Debeljuk and deRettori (1982) and Motta et al (1981) provide comprehensive reviews of the effects of gonadal hormones on the secretion of gonadotropins and conclude that the regulation of FSH secretion is not completely understood nor explained by the effects of gonadal steroids.

Evidence has existed since the 1930's which suggests the involvement of the seminiferous tubules in the regulation of FSH secretion (McCullagh, 1932). This regulator of FSH was shown to be a product of rat Sertoli cells in the early 1970's (VanThiel <u>et al</u>, 1972; Krueger <u>et al</u>, 1974) and later in the decade was dubbed "inhibin" (a name first proposed by McCullagh) for its FSH-suppressing property (Steinberger and Steinberger, 1976; Keogh <u>et al</u>, 1976). Inhibin is a polypeptide of molecular weight 32,000 daltons containing two subunits joined by a disulphide bridge (Ling <u>et al</u>, 1985; Fukuda <u>et al</u>, 1986). deKretser and Robertson (1989) and Vale <u>et al</u> (1988) provide good reviews on the isolation and physiology of inhibin. Numerous studies have shown that inhibin suppresses serum FSH levels in intact (Sheth et al, 1980; Sheth and Vijayalakshmi, 1981; Lipner and Dhanarajan, 1984) and gonadectomized (Shahmanesh et al, 1980; Summerville and Schwartz, 1981; Thomas and Nikitovitch-Winer, 1984) male rats. Most studies suggest that inhibin works at the pituitary level to regulate the synthesis and secretion of FSH (and perhaps LH) (Lipner and Dhanarajan, 1984; Shahmanesh et al, 1980). Morris and Azmatullah (1982) have shown that inhibin does not modulate the pituitary FSH response to LHRH in the castrate rat while other investigators have suggested that inhibin accounts for perhaps only 20-80% of FSH regulation and that another gonadal product may be involved (Summerville and Schwartz, 1981; Decker et al, 1981; Sheth and Vijayalakshmi, 1981). Finally, inhibin production and Sertoli cell content of inhibin is maximal in the prepubertal rat (8-21 days) when FSH levels are low, but then decline while FSH levels rise, suggesting that inhibin may be an important regulator of FSH only in the prepubertal male rat (Sheth et al, 1980; Au et al, 1986; UlteevanGessel and deJong, 1987; Rivier et al, 1988).

Table 1 summarizes the effect of gonadal hormones on the secretion of pituitary gonadotropins in the male rat.

1.2.2 Gonadotropin Secretion in the Female: A Brief Review

Gonadotropin secretion in the female has been much more extensively studied than in the male and is therefore better understood. A brief review is presented here for comparative purposes. LH and FSH secretion in the female is cyclic in nature with a peak in the secretion of both gonadotropins occuring just prior to ovulation. Normal serum LH levels

	INT	ACT	G	X	
Hormone ¹	FSH	LH	FSH	LH	References
Testosterone	* `	♥	*	♥	Gray <u>et al</u> (1980); Nieschlag <u>et</u> <u>al</u> (1975); Eldridge <u>et al</u> (1974); Summerville and Schwartz (1981); Gay and Dever (1971); Dufy-Barbe and Franchimot (1971); Swerdloff and Walsh (1973)
50 ng in lateral septum	•	A	ns	ns	Carreras <u>et al</u> (1987)
Dihydrotesosteron	<u>ie</u> ns	ns	*	*	Demoulin <u>et al</u> (1973); Swerdloff <u>et al</u> (1973); Eldridge <u>et al</u> (1974); Verjans and Eik-nes (1977)
low doses	4	¥	¥	¥	Mittler <u>et al</u> (1981); Karanth <u>et</u> <u>al</u> (1984)
<u>5α-Androstane-</u> 3α,17β-diol	ns	ns	*	♥	Demoulin <u>et al (</u> 1973); Swerdloff <u>et al (1973); Verjans and Eik-nes</u> (1977)
Other androgens	ns	ns		*	Swerdloff <u>et al</u> (1973); Loseva <u>et</u> <u>al</u> (1980)
<u>17β-Estradiol</u>	*	•	*	•	Gay and Dever (1971); Swerdloff <u>et al</u> (1973); Swerdloff and Walsh (1973); Eldridge <u>et al</u> (1974); Nieschlag <u>et al</u> (1975); Winter and Troen (1985)
low dose	ñs	ns	4		Demoulin <u>et al</u> (1973)
Progesterone	ns	ns		ھے بچ	Swerdloff <u>et al</u> (1973); Eldridge <u>et al</u> (1974)
Progesterone + 17β-estradiol	ns	ns	¥	¥	McPherson and Mahesh (1982)
<u>Glucocorticoids</u>	A		¥	¥	Nazian (1982); Ringstrom and Schwartz (1985)
<u>Inhibin</u>	¥		[-]	Sheth <u>et al</u> (1980); Lipner and Dhanarajan (1984); Shahmanesh <u>et</u> <u>al</u> (1980); Thomas and Nikitovich- Winer (1984); [Morris and Azmu- tullah (1982)]

Table 1: Summary of the effects of gonadal hormones on the <u>in vivo</u> secretion of gonadotropins in the male rat.

Table 1: continued ¹ see text for details of doses, etc. GX, gonadectomized ns, not studied --, no effect arrows indicate relative increase/decrease in gonadotropin secretion

.

are 25-60 ng/ml (RP-1) in the prepubertal female , around 50 ng/ml in metestrous and diestrous adults and between 1200-1800 ng/ml in the proestrous and estrous adult (Dohler and Wuttke, 1975). The level of circulating FSH is very high in the infantile female (800-900 ng/ml), lower in the prepubertal female (150-200 ng/ml), with similar levels in metestrus and diestrus adults, and surges to around 400 ng/ml in proestrus and estrus adults (Dohler and Wuttke, 1975). Gonadectomy of female rats results in 4-fold increases in FSH secretion and an approximately 3-fold increase in LH secretion (Lorenzen and Ramaley, 1981; Hiatt <u>et al</u>, 1987).

The ovarian steroids, 17β -estradiol and progesterone are the primary regulators of gonadotropin secretion in the female rat. 17β estradiol inhibits the release of gonadotropins in ovariectomized female rats (Motta et al, 1981; McPherson et al, 1975; Matt et al, 1986) but potentiates the pituitary response to LHRH (Debeljuk and deRettori, 1982). If 17β -estradiol administration is conconcurrent with, or followed by, treatment with progesterone, a surge in the release of gonadotropins is initiated (Fink and Henderson, 1977; McPherson et al, 1975) probably via 17β -estradiol induction of progesterone receptors in the hypothalamus and pituitary (Attardi, 1984; Mahesh and Muldoon, 1987; Calderon et al, 1987). The 5 α -reduced metabolite of progesterone, 5 α pregnane-3,20-dione, produced in the pituitary and hypothalamus, appears to be responsible for the surge in FSH secretion in the estrogen-primed ovariectomized female rat (Karavolas et al, 1976, Motta, 1982; Motta et al, 1981; Murphy and Mahesh, 1984a) while 3a-hydroxy-5a-pregnan-20-one (anothe: progesterone metabolite) appears to be responsible for the similar surge in LH (Motta et al, 1981; Motta, 1982; Murphy and Mahesh,

1984b). Several C_{19} steroids with a 4-ene configuration were shown to have the same abilities as estrogen (Kraulis <u>et al</u>, 1978a) and several adrenal C_{21} steroids were shown to have the same effect as progesterone in inducing gonadotropin surges (Kraulis <u>et al</u>, 1978). Inhibin is produced in rat ovarian follicles (Vale <u>et al</u>, 1988; deKretser and Robertson, 1989) and possesses FSH-suppressing activity which is both specific and age-dependent (Hermans <u>et al</u>, 1980; McLachlan <u>et al</u>, 1987).

1.3 REGULATION OF GONADOTROPIN SECRETION IN VITRO

The ongoing modulation of gonadotropin secretion in the live animal is difficult to assess. The models used in the studies outlined in the previous section must take into account that many other factors besides the pituitary (eg. the central nervous system) may have an influence on the results of the various <u>in vivo</u> experiments. Current research often relies on an <u>in vitro</u> system, where anterior pituitary cells (and sometimes hypothalami) from rats are maintained in short-term primary cultures to examine the possible effects of hormones under more controlled experimental conditions.

1.3.1 Basal Gonadotropin Secretion

Gonadotropes in primary cultures of anterior pituitary cells tonically secrete FSH and LH and retain the ability to respond to gonadal steroids or other hormones. The effect of androgens in this system is well documented. Most studies agree that concentrations of testosterone in the medium of 1 nM or greater will increase the basal release of FSH and not affect LH release (Steinberger and Chowdhury, 1977; Leveque and Grotjan, 1982; Kennedy and Chappel, 1985; Campen and Vale, 1988) although an older report by Tang and Spies (1975) suggests that 10 nM testosterone increases basal LH secretion as well. Denef et al (1980) reported that concentrations of testosterone up to 50 nM have no effect on basal gonadotropin secretion. Evidence also suggests that testosterone enhancement of FSH release involves increased FSH synthesis (Kennedy and Chappel, 1985). Dihydrotestosterone, the 5α reduced metabolite of testosterone, will also enhance basal FSH secretion without affecting LH secretion at doses of 1 nM or greater (Leveque and Grotjan, 1982; Massicotte et al, 1984a; Massicotte et al, 1984b; Campen and Vale, 1988) and this effect, too, involves the stimulation of FSH synthesis (Leveque and Grotjan, 1982). Similar studies by Schwaninger et al (1987) showed no effect of dihydrotestosterone on basal gonadotropin secretion when used in cultures at concentrations between 1 nM and 100 mM which agrees with a report by Denef et al (1980). Campen and Vale (1988) demonstrated that androstenedione (4-androstene-3,17-dione) behaves similarly to testosterone and dihydrotestosterone, increasing the basal release of FSH by cultured pituitary cells.

The <u>in vitro</u> secretion of gonadotropins is also regulated by 17β -estradiol. 17β -Estradiol (10 nM) stimulates the basal secretion of both FSH and LH (Tang and Spies, 1975; Debeljuk <u>et al</u>, 1978; Steinberger and Chowdhury, 1977; Massicotte <u>et al</u>, 1984a; Massicotte <u>et al</u>, 1984b). Miller and Wu (1981) showed a similar effect of 1 nM 17β -estradiol in cultures of rat pituitary cells, but noted that similar treatment of culture! sheep, pig or cow adenohypophyseal cells results in decreased basal release of FSH. Miller and Wu (1981) also demonstrated that the

18

effect of 17β -estradiol involves an increase in FSH synthesis. Progesterone alone will augment the basal release of FSH at high concentrations (100 nM) (Massicotte et al, 1984a and 1984b; Leveque and Grotjan, 1982) but has no effect on the secretion of gonadotropins in cultured rat pituitary cells at lower (10 nM) doses (Tang and Spies, 1975). Leveque and Grotjan (1982) also indicated that FSH synthesis was stimulated by progesterone. Batra and Miller (1985) and Batra et al (1986) have shown that progesterone (100 nM) inhibits the secretion of FSH in ovine pituitary cells in culture. Many studies have used the technique of estrogen-priming to further elucidate the effect of progesterone on gonadotropin secretion since 173-estradiol is known to induce the production of progesterone receptors in the pituitary and hypothalamus in vivo (Attardi, 1984; Calderon et al, 1987; Mahesh and Muldoon, 1987). Massicotte and colleagues (1984a and 1984b) have shown that pretreatment of cells with 10 nM 17β -estradiol considerably increases the release of both gonadotropins after treatment with 100 nM progesterone and that this effect is synergistic.

Other C_{21} steroids have been examined for their ability to modify the <u>in vitro</u> function of pituitary cells. Tang and Spies (1975) have shown that 10 nM 20 α -hydroxy-4-pregnen-3-one will inhibit the basal secretion of FSH. The glucocorticoids, cortisol and corticosterone (11 β ,21-dihydroxy-4-pregnene-3,20-dione), inhibit the basal release of LH and stimulate the basal release of FSH when used at a concentration of 60 ng/ml or 600 ng/ml (Suter and Schwartz, 1985a). Synthesis of the gonadotropins was affected in a similar manner by the glucocorticoids.

The selective effect of inhibin on FSH secretion has been extensively studied in vitro. One of the first such studies indicated

that porcine follicular fluid (PFF) inhibin selectively reduces the release of FSH in cultured pituitary cells (Lagace et al, 1979). Massicotte et al (1984a) investigated the effects of inhibin from Sertoli cell culture medium (SCM) on gonadotropin secretion in rat anterior pituitary cells in culture. They found that SCM selectively inhibited basal FSH secretion in a dose dependent manner, but this inhibition could be overcome by the stimulatory effects of 10 nM dihydrotestosterone, 100 nM progesterone or 10 nM 17β -estradiol plus 100 nM progesterone. They (Massicotte et al, 1984b) achieved similar results with inhibin from granulosa cell culture medium. Similarly, Fukuda et al (1987) used purified 32 Kd inhibin from PFF and found that doses as low as 1 ng/ml selectively inhibited the secretion and synthesis of FSH and that this effect is mimicked by the protein synthesis inhibitor, cycloheximide. Purified 32 Kd inhibin from ovine rete testis fluid is also an effective inhibitor of in vitro FSH secretion at concentrations of 1 pM or greater and testosterone can not modify this effect (Campen and Vale, 1988). However some controversy still exists: purified 31 Kd inhibin from bovine follicular fluid (0.1 U/ml or more) depresses the secretion and synthesis of both FSH and LH in cultured pituitary cells (Farnworth et al, 1988).

1.3.2 LHRH-Induced Gonadotropin Secretion

Cultured anterior pituitary cells from rats retain the ability to respond to luteinizing hormone-releasing hormone (LHRH) with an increase in gonadotropin secretion (Liu and Jackson, 1984; Jinnah and Conn, 1985). Maximum stimulation of LH release <u>in vitro</u> can be attained with 10 nM LHRH (Drouin and Labrie, 1976; Pohl <u>et al</u>, 1987). More information on the role of gonadal hormones in the regulation of pituitary gonadotropin secretion has been gleaned from studies which employ LHRH stimulation of gonadotropin secretion.

Most studies agree that testosterone at concentrations of 10 nM or more will enhance the FSH response (ie. FSH secretion in response) to LHRH (Tang and Spies, 1975; Leveque and Grotjan, 1982; Kennedy and Chappel, 1985) and increase the synthesis of FSH after LHRH stimulation (Leveque and Grotjan, 1982; Kennedy and Chappel, 1985). Drouin and Labrie (1976) found that the same dose (10 nM) of testosterone inhibits the LH response, and synthesis of LH, to 0.1 nM LHRH and, although the FSH response (i.e. secretion) to LHRH is unaffected by testosterone, the synthesis of FSH is stimulated. Denef et al (1980) showed that 0.5 to 50 nM testosterone inhibited both the FSH and LH response to LHRH. Only the study of Kao and Weisz (1976) disagrees with the concensus and claims that $1 \mu g/ml$ testosterone enhances the LH response and inhibits the FSH response to LHRH (in the form of hypothalamic extract). Dihydrotestosterone behaves similarly to testosterone in cultured pituitary cells; 10 nM concentrations of dihydrotestosterone increase the secretion and synthesis of FSH in response to LHRH (Massicotte et al, 1984a and 1984b; Leveque and Grotjan, 1982; Schwaninger et al, 1987). LHRH-induced LH secretion and synthesis is inhibited by dihydrotestosterone at doses of 0.1 nM or greater (Drouin and Labrie, 1976; Massicotte et al, 1984a and 1984b; Schwaninger et al, 1987). One study suggests that the LHRH-induced secretion of both FSH and LH is decreased by dihydrotestosterone at doses of up to 50 nM (Denef et al, 1980). Campen and Vale (1988) have found that, in their culture system, the androgens, testosterone, dihydrotestosterone and androstenedione (3

nM), inhibit the LHRH-induced secretion of LH and FSH. Girre <u>et al</u> (1980) found that 5α -androstane- 3β , 17β -diol 'nhibits the LHRH-induced release of FSH at doses of 100 ng/ml or greater.

 17β -estradiol has a facilitating effect on gonadotropin secretion from cultured adenohypophyseal cells. Ten nM 17β -estradiol significantly increases FSH release in response to 0.3 nM LHRH (Massicotte et al, 1984a and 1984b) and enhances the LH response to 1 nM LHRH (Hsueh et al, 1979). Lagace et al (1980), Kotsuji et al (1988) and Liu and Jackson (1988) found a similar effect of 17β -estradiol on LHRH-induced FSH and LH secretion. Progesterone is more selective and only facilitates the LHRH-induced release of FSH. FSH release under the influence of various doses of LHRH is significantly enhanced by the addition of 100 nM progesterone to the incubation medium (Lagace et al, 1980; Leveque and Grotjan, 1982; Massicotte et al, 1984a and 1984b). In an interesting study, Kiesel et al (1987) showed that contraceptive progestins (eg. cyproterone, ethinodiol acetate and norethisterone) decrease both the LH and FSH response to LHRH. Pretreatment or simultaneous treatment of anterior pituitary cells in culture with 17β -estradiol (10 nM) and 100 nM progesterone greatly enhances the FSH stimulating effect of progesterone and even elicits a slightly greater LHRH-induced LH response than seen with progesterone alone (Lagace et al, 1980; Leveque and Grotjan, 1982; Massicotte et al, 1984a and 1984b). A good review of the early work on gonadal steroid effects on LHRH-induced gonadotropin secretion is given by Labrie et al (1978).

Glucocorticoids also influence the gonadotropin response to LHRH <u>in vitro</u>. Corticosterone decreases LH secretion in response to LHRH without affecting LH synthesis and increases the synthesis and secretion 22

of FSH in response to LHRH treatment (Suter and Schwartz, 1985; Kamel and Kubajak, 1987).

Inhibin, the putative regulator of FSH secretion, is not selective when it comes to LHRH-induced gonadotropin secretion. All studies agree that inhibin, regardless of its source, reduces the LHRH-induced synthesis and secretion of FSH and the release of LH (Lagace et al, 1979; Massicotte et al, 1984a and 1984b; Fukuda et al, 1987; Campen and Vale, 1988). This inhibitory effect, which is enhanced by the androgens (Campen and Vale, 1988) and opposed by the synergistic combination of 17β -estradiol and progesterone (Massicotte et al, 1984a and 1984b), occurs approximately 4 hr after treatment and is mimicked by cycloheximide (Fukuda et al, 1987). Ceveral studies have recently shown that inhibin decreases the binding of, and probably the receptors for, LHRH in cultured pituitary cells and even decreases the ability of LHRH to up-regulate its own receptors (Wang et al, 1988; Wang et al, 1989). These last three studies suggest that inhibin acts via an inhibition of protein synthesis in pituitary cells. For good reviews of the current state of knowledge about inhibin see deKretser and Robertson (1989) or Vale et al (1988).

Table 2 summarizes the effect of steroid and gonadal hormones on the release of gonadotropins by cultured rat anterior pituitary cells.

1.4 HORMONE RECEPTOR MECHANISMS

1.4.1 Action and Signal Transduction of LHRH

LHRH is synthesized and secreted in a pulsatile manner from the hypothalamus (Melrose <u>et al</u>, 1987; Bourguinon <u>et al</u>, 1987). Gonadal steroids are required for the maturation of LHRH-neurons (Barnea <u>et al</u>,

Table 2: Summary of the effect of hormones on basal and LHRH-induced gonadotropin secretion in primary cultures of rat anterior pituitary cells

Hormone ¹	Basal		LHRH-Induced		
	FSH	ĽH	FSH	LH	Reference
Testosterone	4		[]	[♥]	Tang and Spies (1975); Drouin and Labrie (1976); Steinberger and Steinberger (1977); Leveque and Grotjan (1982); Kennedy and Chappel (1985); Campen and Vale (1982); [Denef <u>et al</u> (1980)]
Dihydrotestosterone	•		[↓]	[🐳]	Drouin and Labrie (1976); Le- veque and Grotjan (1982); Ma- ssicotte <u>et al</u> (1984a and b) Schwaninger <u>et al</u> (1987); Campen and Vale (1988); [Denef <u>et al</u> (1980)]
<u>17β-Estradiol</u>	•	¥	•	•	Tang and Spies (1975); Debel- juk <u>et al</u> (1978); Steinberger and Chowdhury (1977); Hsueh <u>et al</u> (1979); Lagace <u>et al</u> (1980), Miller and Wu (1981); Massicotte <u>et al</u> (1984a and b) Kotsuji <u>et al</u> (1988); Liu and Jackson (1988)
Progesterone			¥		Lagace <u>et al</u> (1980); Leveque and Grotjan (1982); Massic- otte <u>et al</u> (1984a and b)
<u>Progesterone +</u> 17β-estradiol	•	4	*	٨	Lagace <u>et al</u> (1980); Leveque and Grotjan (1982); Massic- otte <u>et al</u> (1984a and b)
<u>Glucocorticoids</u>	•	¥	A	*	Suter and Schwartz (1985); Kamel and Kubajak (1987)
<u>Inhibin</u>	♥	[1]	♥	V	Lagace <u>et al</u> (1979); Massic- otte <u>et al</u> (1984a and b); Fukuda <u>et al</u> (1987); Campen and Vale (1988); [Farnworth <u>et al</u> (1988)]

1, see text for details of doses, etc. --, no effect arrows indicate relative increase/decrease 1988) and for the ongoing regulation of LHRH production and processing in the adult (Karsch <u>et al</u>, 1987; Culler <u>et al</u>, 1988).

At the level of the pituitary, LHRH binds to specific receptors (Wynn <u>et al</u>, 1986) and induces the secretion of LH and FSH (Liu and Jackson, 1984; Jinnah and Conn, 1985). Evidence suggests that this stimulation of gonadotropin release by LHRH also involves the upregulation of gonadotropin messenger RNA and and therefore gonadotropin synthesis (Stanzec et al, 1986; Kim <u>et al</u>, 1988; Wierman <u>et al</u>, 1989).

Pituitary LHRH receptor number is regulated by gonadal steroids and LHRH itself. Duncan <u>et al</u> (1983) showed that gonadectomy results in increased LHRH receptor number in rat pituitaries and that treatment of such rats with either 17β -estradiol (females) or testosterone (males) restores the pre-gonadectomy number of LHRH receptors. Similar results were obtained in experiments with male rabbits (Limonta <u>et al</u>, 1986). After binding to pituitary cells, LHRH is internalized (Wynn <u>et al</u>, 1986). Prolonged stimulation of gonadotropes with LHRH makes them refractory to further stimulation (Liu and Jackson, 1984; Jinnah and Conn, 1985) indicating LHRH receptor down-regulation, while 30 min pulses of LHRH, which mimic endogenous rhythms, up-regulates or increases LHRH receptor number in the anterior pituitary (Katt <u>et al</u>, 1985).

It was recently concluded that the signal transduction mechanism of LHRH involves the turnover of membrane phospholipids and therefore the production of diacylglycerol and inositol triphosphate, and the subsequent mobilization of calcium and activation of protein kinase C (PKC) (see reviews of LHRH action and receptors: Naor and Childs, 1986; Conn <u>et al</u>, 1987; Clayton, 1989). In studies employing ³H-myo-inositol 25

or ^{32}P -phosphoinositol, LHRH activation of cultured anterior pituitary cells was shown to result in increased incorporation of the radiolabelled precursors into inositol phosphates, and most importantly, into inositol triphosphate, simultaneous with increased release of LH (Naor <u>et al</u>, 1986; Huckle and Conn, 1987). Naor <u>et al</u> (1986) and Huckle and Conn (1987) also showed that, although phosphoinositide turnover induced by LHRH is independent of calcium, calmodulin or PKC, it is the products of this turnover that elevate intracellular calcium levels (LHRH-induced LH secretion is calcium dependent) and activate PKC, which ultimately results in increased LH release. In a related study, Andrews <u>et al</u> (1986) showed that guanosine triphosphate stimulated an ATP-dependent increase in inositol phosphate production coupled to LH release in permeabilized pituitary cells. This suggests that a guanine nucleotide regulatory (G) protein is functionally linked to the LHRH receptor recognition site.

The elevation of intracellular calcium in gonadotropes is essential to the induction of LH release by LHRH. Chang <u>et al</u> (1986) have shown that LHRH rapidly increases cytoplasmic calcium concentrations in Quin-2 (a compound which fluoresces when exposed to calcium) loaded cultured gonadotropes. In patch clamp studies, Mason and Waring (1986) showed that LHRH opens an inward current, calcium permeable, ion channel in gonadotropes via an i...ernal messenger. Furthermore, studies in which voltage sensitive calcium channels are blocked by drugs such as verapamil and nifedipine demonstrated that the LHRH-induced secretion of LH is inhibited under those conditions (Chang <u>et al</u>, 1986; Chang <u>et al</u>, 1989). 'n these experiments LH release is not totally inhibited and it was suggested that calcium release from intracellular stores initiates LH release, while influx of calcium from external sources maintains the response. In all of the above-mentioned studies, the calcium ionophore A23187 mimicked the effects of LHRH on LH release.

The response of pituitary cells to LHRH also involves the activation of protein kinase C (PKC) by diacylglycerol (from phosphoinositide turnover) and calcium (Naor and Childs, 1986; Conn et al, 1987; Clayton, 1989). Phorbol esters and diacylglycerol, which activate PKC, (Nishizuka, 1986) enhance the secretion of LH in cultured anterior pituitary cells (Negro-Vilar and Lapetina, 1985; Liu and Jackson, 1987; McArdle et al, 1988). It was suggested that activation of PKC by LHRH is involved in the longer-term maintainance of the LH response to LHRH since PKC activation not only increases glycosylation of pituitary LH (Liu and Jackson, 1987), but the immediate effects of LHRH are more closely mimicked by the calcium ionophore A23187 or high concentrations of potassium (a secretagogue) (Naor and Childs, 1986; Conn et al, 1987; Clayton, 1989). PKC activation by LHRH might also play a role in LHRH receptor regulation since refractoriness of LH release to LHRH is calcium independent and involves some other post-receptor mechanism (Jinnah and Conn, 1985). Inhibition of glycosylation with tunicamycin interferes with the restoration of pituitary responsiveness to LHRH (Jinnah and Conn, 1985).

1.4.2 Mechanism of Action of Steroids

The majority of steroid actions are mediated through nuclear receptors which regulate gene expression. Receptors for gonadal steroids and glucocorticoids are localized in the nucleus of target cells (O'Malley and Schrader, 1976; Clarke, 1984; King and Greene, 1984; Welshons <u>et al</u>, 1985) and further, are associated with non-histone proteins of the nuclear matrix (Barrack, 1984; Barrack, 1987; Spelsberg <u>et al</u>, 1987). Activation of the steroid-receptor complex, at least in the chick oviduct progesterone receptor, appears to involve receptor subunit phosphorylation (Garcia <u>et al</u>, 1987). Steroids regulate gene expression in many of the target tissue systems studied. Progesterone and estrogen stimulate the synthesis of vitellogenin and albumin in the chick liver and oviduct systems (O'Malley and Schrader, 1976; Chambon <u>et</u> <u>al</u>, 1984). A recent study by Shupnik <u>et al</u> (1988) showed that 17ßestradiol suppresses the transcription of gonadotropin genes in the rat. Genes regulated by steroids are ubiquitous, with many occurring in the brain, hypothalamus and pituitary (see Beato <u>et al</u>, 1987; Harlan, 1988; Spelsberg et <u>al</u>, 1989 for complete reviews).

New evidence suggests that steroids also interact with and/or bind to plasma membranes. Towl, and Sze (1983) first showed that gonadal steroids bind to synaptic plasma membranes with considerable affinity (dissociation constants in the nanomolar range). Progesterone can increase the membrane potential and the release of acetylcholine in frog neuromuscular junctions (Meiri, 1986). A specific binding site for 17βestradiol has been found on the membranes of rat anterior pituitary cells (Bression <u>et al</u>, 1986) and both 17β -estradiol and testosterone induce the formation of exo-endocytotic pits in hypothalamic neurons (Garcia-Segura <u>et al</u>, 1987). Endogenous steroids also modulate the activity of gamma amino-butyric acid (GABA) receptor-benzodiazapine receptor complexes in the central nervous system. Pregnenolone sulphate and A-ring reduced metabolites of pregnenolone antagonize the activity of GABA complexes and have thus been dubbed "neurosteroids" (Lambert <u>et</u> <u>al</u>, 1987; Majewska and Schwartz, 1987). The analgesic properties of 3ahydroxy-5a-pregnan-20-one involves its interaction with the GABA complex: its action is blocked by GABA antagonists, reduced by opiate and benzodiazepine antagonists and enhanced by calcium channel antagonists (Kavaliers and Wiebe, 1987).

Steroids may also interact with the signal transduction mechanism of protein hormones such as LHRH. Several studies have indicated that 17β -estradiol enhances LHRH-induced secretion of LH and FSH by interaction with the calcium and/or diacylglycerol (PKC) pathways after cell activation by LHRH (Liu and Jackson, 1987; Liu and Jackson, 1988).


1.5 A NOVEL GONADAL STEROID, 3g-HYDROXY-4-PREGNEN-20-ONE

1.5.1 The Discovery of 3a-hydroxy-4-pregnen-20-one (3HP)

In the late 1970's and early 1980's Wiebe and coworkers studied the ability of isolated rat Sertoli cells to synthesize and metabolize steroids. These studies showed that isolated Sertoli cells from rats could metabolize androgens (Welsh and Wiebe, 1978), metabolize progesterone and pregnenolone (Wiebe, 1978b; Wiebe <u>et al</u>, 1980) and synthesize C_{21} steroids <u>de novo</u> from acetate (Wiebe and Tilbe, 1979). Sertoli cell steroidogenesis is stimulated by FSH (Welsh and Wiebe, 1976; Tilbe and Wiebe, 1981). In the above studies one of the more abundant metabolites was dubbed "#4" for the elusive nature of its identity. Careful work employing gas chromatography, high performance liquid chromatography, thin layer chromatography, mass spectrometry and chemical manipulation finally identified this compound as 3α-hydroxy-4-pregnen-20-one (3HP; Figure 3) (Wiebe, 1982) which accounts for 7% of the products of Sertoli cell progesterone metabolism (Wiebe et al,

Figure 3: Chemical structure of the allylic gonadal steroid, 3α -hydroxy-4-pregnen-20-one (3HP). 3HP is a C₂₁ steroid containing the allyl group in ring A. 3HP differs from progesterone only by the substituent at position 3 in the A ring: progesterone has a ketone group here while 3HP has an hydroxyl group in the α -orientation. Stereochemically, 3HP has rings A and B in a single plane with the 3α -hydroxyl group sticking out from the plane of rings A and B.

3^{α} -HYDROXY-4-PREGNEN-20-ONE (3HP)



1980). 3HP does not appear to be produced by Leydig cells. 3HP has since been shown to be a product of domestic hen thecal cells (Marrone <u>et al</u>, 1985) and cultured rat granulosa cells (Wiebe pers. comm., 1988). Although 3HP is a labile molecule, a synthetic technique has been developed and milligram quantities of the steroid can be synthesized (Wiebe <u>et al</u>, 1985). Wiebe (1985) provides a good review of Sertoli cell steroidogenesis-particularly the production of 3HP.

1.5.1 Properties of 3HP

Sertoli cell steroid metabolism is stimulated by FSH (Tilbe and Wiebe, 1981). Careful studies showed that the production of 3HP is agedependent with peak amounts produced by Sertoli cells from 10-17 day old rats and steady smaller amounts produced well into adulthood (Wiebe, 1982). This relatively high level of 3HP coincides with the time when FSH levels are low in the male rat (Dohler and Wuttke, 1975), FSH binding in Sertoli cells is maximal (Salhanick and Wiebe, 1980) and meiosis is about to begin (Wiebe, 1982). Wiebe <u>et al</u> (1988) review the Sertoli cell-specific production of 3HP.

Recent work (Wiebe and Kavaiers, 1988) has demonstrated that 3HP has an analgesic effect when injected intracerebroventricularly. 3HP analgesia appears to involve interaction with the GABA receptor complex in the central nervous system since GABA, benzodiazepine and opioid antagonists block its effect while the dihydropyridine-sensitive calcium channel antagonists enhanced the analgesic effect of 3HP (Wiebe and Kavaliers, 1988).

1.6 OBJECTIVES AND APPROACHES

The main objective of this study was to determine whether 3HP plays a role in the regulation of gonadotropin secretion in the male rat. Many gonadal steroids play a part in the regulation of LH and FSH secretion (Table 1) and 3HP too, may play a role. In particular, regulation of FSH secretion in the male rat is not fully understood and it seems likely that 3HP might play a role since 3HP is produced in considerable quantities by rat Sertoli cells (and not Leydig cells) in an age- and FSH-dependent fashion. The unique structure of 3HP may also confer unique properties upon it.

This problem was approached using the prepubertal male rat model (both intact and gonadectomized) treated with 3HP and the circulating levels of gonadotropins were examined using radioimmunoassay (RIA). Rat anterior pituitary cells in culture were also employed to further examine the effect of 3HP on gonadotropin secretion.

These models were chosen since 3HP was first isolated from rat Sertoli cells and there is a wealth of information regarding the role of gonadal steroids in the regulation of pituitary gonadotropin secretion in the rat.

Specifically, an attempt was made to answer the following questions:

- (1) What effect does 3HP have on gonadotropin secretion (particularly FSH secretion) in the male rat?
- (2) Is this effect dose-dependent and therefore of physiological significance?
- (3) Is this effect age-dependent?
- (4) Is this effect distinct from that of functionally-related

steroids?

- (5) Does 3HP have a similar effect on cultured anterior pituitary cells?
- (6) Is the in vitro 3HP effect dose-dependent?
- (7) Is this effect unique to 3HP or is it similar to that of funtionally or structurally related steroids?
- (8) By what mechanism does 3HP act? Does it interact with the signal transduction pathway of LHRH?

MATERIALS AND METHODS

2.1 CHEMICALS

2.1.1 Steroids

The following steroids were purchased from Sigma Chemical Company (St. Louis, Mo.): 17β -hydroxy-4-androsten-3-one (testosterone), 17β hydroxy-5a-androstan-3-one (dihydrotestosterone), 1,3,5(10)-estratriene-3,17B-diol (17B-estradiol; estrogen), 4-pregnene-3,20-dione (progesterone), 17a-hydroxy-4-pregnene-3,20-dione (17a-hydroxyprogesterone), 20ahydroxy-4-pregnen-3-one (20a-dihydroprogosterone), 208-hydroxy-4-pregnen-3-one (20β -dihydroprogesterone), 5α -pregnane-3,20-dione (5α -dihydroprogesterone), 5ß-pregnane-3,20-dione (5ß-dihydroprogesterone), 3β~ hydroxy- 5α -pregnan-20-one and 3β -hydroxy- 5β -pregnan-20-one. 3α -Hydroxy- 5α -pregnan-20-one and 3α -hydroxy-5 β -pregnan-20-one were purchased from Steraloids (Wilton, N.H.). 3a-Hydroxy-4-androsten-17-one, 3a-hydroxy-4pregnen-20-one 3a-dihydroprogesterone; 3HP), 3B-hydroxy-4-pregnen-20one, 3a-hydroxy-4-pregnen-20-one-3-acety1, 3a,20a-dihydroxy-4-pregnene and 3a,20B-dihydroxy-4-pregnene were synthesized in our laboratory as described (Wiebe et al, 1985; Wiebe et al, 1986).

2.1.2 Drugs and Hormones

Synthetic luteinizing hormone-releasing hormone (pGlu-his-trp-sertyr-gly-leu-arg-pro-gly-NH₂, acetate salt; LHRH), verapamil (α -[3-[[2-(3,4-dimethoxyphenyl)ethyl]-methlyamino]propyl]-3,4-dimethoxy- α -(l-methylethyl)benzeneacetonitrile) and nifedipine (1,4-dihydro-2,6-dimethyl-4-(2-nitro-phenyl)-3,5-pyridinedicarboxylic acid dimethyl ester) were

35

purchased from Sigma Chemical Company (St. Louis, Mo.). The calcium ionophore A23187 (calimycin) was supplied by Boehringer-Mannheim (West Germany). The protein kinase C inhibitor H-7 (1-(5isoquinolinesulfony1)-2-methylpiperazine dihydrochloride) and protein kinase C acitivator SC-9 (N-(phenylhexy1)-5-chloro-1-naphthalenesulfonamide) were purchased from Seikagaku America (St. Petersburg, Fl.). I am indebted to Dr. Martin Kavaliers for the generous gift of the A23187, verapamil, nifedipine, H-7 and SC-9.

2.1.3 General

Medium 199 (M199), collagenase Type I, trypsin, penicillin-G and Sephadex G-75 were from Sigma Chemical Company (St. Louis, Mo.). Streptomycin-sulphate, lactoperoxidase and bovine serum albumin were from Boehringer-Mannheim (West Germany).

The rest of the chemicals used in these experiments were of reagent grade and were purchased from either Sigma Chemical Company (St. Louis, Mo.) or BDH (Toronto, Ont.).

2.2 ANIMALS

2.2.1 Source and Housing

All rate used in this study were of the Sprague-Dawley strain and were either purchased from Charles River Breeders (St. Constant, Que.) ' or were bred in our own facilities from Charles River stock. Rate were housed at no more than 3 adults or 6 juveniles per cage and kept on a 14-hr light, 10-hr dark photoperiod ('ights on at 0600 h, off at 2000 h) at 24°C. Food (Purina or Agwayer rat chow) and water were supplied ad libitum. Newborn rate were kept with mothers until weaning at 21 days of age. All mature females used in this study were random-cycling.

2.2.2 Surgical Procedures

All gonadectomies were performed under aseptic conditions using light ether anesthesia. For pubertal male rats a small (1 cm) incision was made in the mid-ventral region of the scrotum; in prepubertal male rats an incision was made mid-ventrally just anterior to the penis. The testis was externalized and the epididymis was carefully trimmed away from the lateral surface of the testis. A suture (4-0 silk) was securely tied at the anterior end of the testis to ligate the epididymis and blood vessels before removal of the testis itself. The remaining tissue was then replaced into the scrotal cavity and the procedure repeated for the other testis. The incision was closed with 9 mm wound clips.

Female rats were ovariectomized via a small dorsal incision just anterior to the hip and lateral to the midline. The ovary was externalized, a hemostat applied to the oviduct and ovarian artery and the ovary and fatty tissue carefully trimmed away. The hemostat was left in place for about 30 sec and then removed. The incision was closed with a 9 mm wound clip and the procedure repeated for the other side.

All animals were allowed to recover under a heat lamp for about 2 hr post-surgery and then returned to the animal quarters. A further 2 days rest was allowed before animals were used in any experiment.

2.3 IN VIVO EXPERIMENTS

2.3.1 Preparation of Steroids

All steroids were initially dissolved in glass-distilled ethanol (mg/ml), the required amount added to a sterile serum vial and then

dried down under a stream of nitrogen. Glass-distilled ethanol (to make up 10% of the total volume of solution) was added to the vial to dissolve the steroid, followed by sterile saline-Tween 80 (0.9% sodium chloride, 0.1% Tween 80 in distilled water) to total volume. For high doses of steroids, glass beads were added to keep the suspension uniform. Solutions were made fresh on the first day of treatment, stored at 4° C and warmed to room temperature before use.

2.3.2 Treatment Regimens

Doses were given on a per 100 g body weight (BW) basis, where body weight was considered to be the calculated average body weight of animals on the middle day of the experiment. For example, if the average weight of rats on day 1 of the experiment was 60 g and the experiment was to continue for 5 days, then the calculated average weight on day 3 was 70 g, assuming a 5 g/day weight gain in the prepubertal rat. Steroids were administered subcutaneously (s.c.) in 100 µl of vehicle using a 23G needle and a 1 ml syringe. Intact animals were injected in the morning between 1000 and 1200 h for days 1-4 of the experiment and were sacrificed 24 hr after the last injection. Treaments on gonadectomized animals were begun on the 3rd day after surgery (day 1), when the post-castration rise in serum gonadotropins is complete in the juvenile animal, and continued every morning for a total of 4 treatments and rats were sacrificed on the morning of day 5.

2.3.3 Serum Sampling and Storage

On day 5 of the experiment, animals were sacrificed by decapitation with a small mammmal guillotine (Harvard Bioscience) after being rendered unconscious in a carbon dioxide (CO_2) chamber. Trunk blcod was collected and allowed to clot for 4 hr at room temperature. Serum was separated by centrifugation at 1500 x g for 15 min in a refrigerated Beckman TJ-6 centrifuge and removed with a clean pasteur pipette. Serum was stored at -20° C until assayed for gonadotropins.

Figure 4 shows an overall scheme of the protocol employed for the in vivo studies of gonadotropin secretion in the rat.

2.4 IN VITRO EXPERIMENTS

The procedures outlined here for the isolation, maintenance and experimental manipulation of anterior pituitary cells in culture are a modification of the technique of Kennedy and Chappel (1985). Modifications were based on the literature outlined in Table 2.

2.4.1 Prepartion of Cell Cultures

Random-cycling adult female rats were used unless otherwise indicated in the Results. Kats were rendered unconscious in a CO₂ chamber and swiftly decapitated. The rest of the procedure was carried out under scerile conditions in a tissue culture hood using Falcon sterile tissue culture ware (Becton-Dickinson). Skin was cut away from the dorsal surface of the cranium to expose the underlying muscle and bone. Scissors were used to open the cranium along the suture between the parietal and squamosal bones and the roof of the skull lifted off. The brain was carefully reflected with a smooth scoop to expose the underlying pituitary gland. The enclosing membrane was removed with fine forceps and then the pituitary was removed and placed on ice in sterile Kreb's Ringer Phosphate (KRP; 118 mM sodium chloride, 4.7 mM potassium Figure 4: Schematic representation of the protocol followed for all <u>in</u> <u>vivo</u> experiments. See sections 2.2.2 and 2.3 for further details. Note that in experiments conducted on intact animals the actual regimen began at part 2:**TREATMENT**.

IN VIVO PROTOCOL

GONADECTOMY light ether anesthesia

2 days rest

٠

TREATMENT 4 consecutive days vehicle: saline with 10% glass-distilled ethanol and 0.1% Tween 80

SACRIFICE day 5 decapitation

trunk blood collected and allowed to clot 4hrs

serum stored at -20°C

RADIOIMMUNOASSAY

determine serum FSH and LH levels on duplicate samples

chloride, 5.5 mM glucose, 116 · A magnesium sulfate, 190 µM calcium chloride, 710 µM sodium bicarbonate and 4 mM glutamine made up in 10 mM Sorenson's phosphate buffer [8.4 mM dibasic sodium phosphate and 1.6 mM monobasic potassium phosphate], pH 7.4) supplemented with penicillin-G (100 U/ml) and streptomycin-sulfate (100 µg/ml). Pituitaries were washed 6x with sterile, supplemented KRP and minced with razor blades before being transferred to a 15 ml conical tube containing collagenase (0.25%) in unsupplemented KRP. Cells were dispersed at 37°C in a shaking water bath (American Optical) for 45 min, then pelleted in a clinical centrifuge (IEC) at 80 x g for 10 min. The supernatant was removed and cells brought up in fresh culture medium (M199 with Hank's salts supplemented with 4 mM glutamine, 10% charcoal-treated fetal calf serum 100 U/ml penicillip G and 10 µg/ml streptomycin-sulfate, pH 7.4). Cells were disaggregated by repeated aspiration (approximately 200 x) in a Pasteur pipette and a small (100 µl) aliquot taken to determine cell number and viability. Cells were diluted in fresh culture medium to final culture concentration $(3-8 \times 10^5 \text{ cells/ well})$ in a stir-flask (Wheaton) to maintain a uniform density and plated at either 2 ml per well in a 6-well plate or 1 ml per well in a 24-well plate. Cells were then incubated at $37^{\circ}C$ and 95%-air, 5%-CO₂ in a Narco 5100 incubator for 72 hr before use.

2.4.2 Treatment of Calf Serum

Fetal calf serum was treated with 1% charcoal and 0.1% dextran for 4 hr at room temperature to remove endogenous steroids. Serum was centrifuged at 20,000 x g in a refrigerated Sorval RC2B centrifuge for 40 min to remove charcoal. The supernatant was decanted into the M199 and the total medium sterile-filtered before use.

2.4.3 Determination of Cell Number and Viability

Trypan blue dye solution (10 μ l; 0.4% trypan blue, 137 mM sodium chloride and 4.4 mM monobasic potassium phosphate, pH 7.2) was added to the 100 μ l aliquot of concentrated cell suspension and the mixture allowed to stand for 4 min. Cells were loaded into a hemocytometer and viable and non-viable cells were counted in the 10 large squares. Cell number was determined as the total number of viable cells/ml of suspension. Viability was determined as the percent of total cells which remained unstained by the trypan blue. Only anterior pituitary cell preparations whose viability was greater than 90% were used in this study.

2.4.4 Protein Determination

From 3-5 samples, equivalent to 2 wells of culture supension, were taken from the diluted culture suspension throughout the seeding procedure. Each sample was centrifuged at 80 x g in a clinical centrifuge at room temperature, washed once at room temperature in phosphate buffered saline (PBS; 2.7 mM potassium chloride, 1.5 mM monobasic potassium phosphate, 137 mM sodium choride and 8.1 mM dibasic sodium phosphate pH 7.4) and suspended in 500 μ 1 PBS. Samples were sonicated for 10 sec at setting 2 (Insonator, Ultrasonic Systems, Inc.) and stored at -20°C until assayed. Protein was determined by the method of Bradford (1976). Briefly, 3 ml of Bradford reagent (0.67% Coomassie brilliant blue dissolved in a solution of 33% of 95% ethanol and 67% of 85% phosphoric acid diluted 6.7 times with distilled water for use) was

added to 200 µl of cell sample and allowed to stand for 10 min. Samples were then read at 595 nm on a Unicam SP1800 spectrophotometer (Canlab) and the protein value determined from a standard curve produced with bovine serum albumin (BSA).

2.4.5 Steroid Treatments

On the day of treatment, culture medium was removed and cells washed with sterile, supplemented KRP. Experimental medium (M199 with Hank's salts and 4 mM glutamine, pH 7.4) was added to all wells followed by the various treatments. Steroids were diluted in glass-distilled ethanol and added in a 20 μ l (2 ml well) or 10 μ l (1 ml well) volume to give the final culture concentration as indicated. LHRH was dissolved in 0.01 M acetic acid and sterile-filtered before being added in a 20 μ l (2 ml well) or 10 μ l (1 ml well) volume to give a final culture concentration of 10 nM (except where noted). Controls received the appropriate amount of ethanol and/or 0.01 M acetic acid only. Cells were returned to the incubator for a further 4 or 24 hr before sampling.

2.4.6 Drug Treatments

Several drugs were employed in an attempt to discern the mechanism of action of the inhibition of basal and LHRH-induced FSH secretion by 3HP in anterior pituitary cells in culture. The calcium channel blockers verapamil and nifedipine and the calcium ionophore A23187 were dissolved in glass-distilled ethanol (500 μ l) and added to 50 ml of experimental medium to give a final concentration of 100 μ M. 3HP and LHRH dojes were given as in section 2.4.5 (above).

The protein kinase C inhibitor, H-7, was dissolved in PBS (4 mg/ml)

and 216.5 μ l added to 50 ml of experimental medium to give a final concentration of 50 μ M. The protein kinase C activator SC-9 was dissolved in glass-distilled ethanol (4 mg/ml) and 201 μ l added to 50 ml of experimental medium to give a final concentration of 100 μ M. 3HP and LHRH treatments were given as above (Section 2.4.5).

2.4.7 Media and Cell Sampling

After 4 or 24 hr incubation, medium from each well was collected with a clean pasteur pipette and stored at -20° C in disposable glass tubes (12 x 75 mm) until assayed for gonadotropin content. In cases where cells were also collected, the following procedure was used: medium was removed and 500 µl of 0.1% trypsin (Sigma, Type II) in PBS was added to each well and the cells allowed to incubate at 37° C for 5 min. Cells were then gently scraped from the surface of each dish, the dishes were rinsed with 500 µl of PBS and the resulting sample centrifuged at 800 x g (Beckman TJ-6) for 5 min. The supernatant was discarded, 1 ml of fresh PBS added to the cell pellet and each sample sonicated for 5 sec at setting #2 on an Insonator (Ultrasonic Systems, Inc.). Samples were again centrifuged as above and the supernatant retained for assay of cell content of gonadotropins. These samples were stored at -20° C in polypropylene culture tubes (12 x 75 mm).


Figure 5 shows a generalized scheme of the procedures used in the in vitro studies.

2.5 RADIOIMUNOASSAY OF GONADOTROPINS

2.5.1 Preparation of Sephadex Columns

Columns for the separation of iodinated hormones from the reaction

Figure 5: Schematic representation of the protocol followed for all \underline{in} <u>vitro</u> experiments. See section 2.4 for full details on procedures used. Note that some incubations were carried out for only 4 hr while the majority were allowed to continue for 24 hr.



buffers were prepared using 10 ml disposable glass pipettes. Sephadex G-75 gel was swollen overnight at 4°C in distilled water before pouring. PBS was added to keep the gel moist and the system allowed to flow until a 6 ml packed bed of gel was established. Five percent BSA in PBS was run into the gel to saturate any sites where large proteins may adsorb. Two bed volumes of PBS (ie. 12 ml) were used to ensure that all the nonadsorbed BSA was flushed from the gel. The eluent was allowed to drain just to the surface of the gel to prepare the column for use.

2.5.2 Radioiodination

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provided the hormones for iodination. Preparations used were rat follicle-stimulating hormone (rFSH-I-5, rFSH-I-6 and rFSH-I-7) and rat luteinizing hormone (rLH-I-5, rLH-I-6 and rLH-I-7). These preparations were provided as lyophilized powders and were rehydrated with PBS to a working concentration of 100 μ g/ml and stored at -70°C in 25 µl aliquots in disposable 1.5 ml microcentrifuge tubes. Aliquots were thawed on ice just prior to iodination. Iodinations were carried out in a lead-shielded fume hood using the lactoperoxidase method of Mougdal et al (1978). Iodine-125 (¹²⁵I, 2.5 millicuries; ICN Biochemicals) were added to 1.25 µg of hormone preparation and mixed with slight agitation (in the microcentrifuge tube). Lactoperoxidase (10 µl; 100 µg/ml in 0.4 M sodium acetate, pH 5.5) was then added with slight agitation. Dilute hydrogen peroxide (5 μ 1;0.001%) was then added and the reaction vessel agitated for 30 sec and allowed to sit for 60 sec. The hydrogen peroxide step was repeated once and the reaction terminated with 100 µl of 5% BSA in PBS. The reaction mixture was then carefully layered onto the gel bed

of a Sephadex G-75 column. BSA in PBS (0.1%; 100 µl) was used to rinse the microcentrifuge tube and the rinse was layered onto the gel. The clamp was opened to allow the sample to flow into the gel and then closed. The reservoir segment of the column was attached and carefully filled with the eluent (0.1% BSA in PBS). The clamp was opened and 10drop fractions of eluate collected in 10 disposable glass culture tubes (12 x 75 mm). Each fraction was sampled (5 μ l) and counted in a Beckman Gamma 4000 gamma spectrometer equipped with a DP5000 microprocessor. Fractions containing the first peak of radioactivity were pooled (usually numbers 3, 4 or 5) as they contained the iodinated hormone (Sephadex G-75 columns exclude large proteins and retain small molecules such as ions in the buffer and unreacted 125I). The pooled labelled hormone was aliquoted (100 μ 1) and stored at -20^OC in disposable glass tubes (12 x 75 mm) until use. All iodinated hormones were discarded 45 days after iodination (they begin to lose their ability to bind to specific antibodies after this time).

2.5.3 Storage and Preparation of Standards and Primary Antibodies

The hormone standards were provided by the NIDDK in lyophylized form and were rehydrated with distilled water and stored at -70° C in the following aliquots: 100 µl rLH RP-1 or rFSH RP-1 (100 µg/ml), 25 µl rLH RP-2 (5 µg/ml) and 25 µl rFSH RP-2 (10 µg/ml). On the day of the assay, these standards were serially diluted in assay buffer (see below) to known amounts per tube on the day of the assay. The primary antibodies were provided in a 1 ml volume at a dilution of 1:12.5 for NIDDK-antirFSH-S-11 and 1:18.75 for NIDDK-anti-rLHh-S-8 and were further diluted to 1:62.5 and 1:75, respectively, with antibody diluent (see below) and stored at -70oC in 25 ul aliquots until the day of the assay. Primary antibodies had been raised in rabbits against the rat hormones.

2.5.4 Radioimmunoassay of Serum and Media Samples

Serum, media and cell samples were assayed for gonadotropirs by RIA as follows. Duplicate samples of serum (200 µl) or medium or cell homogenate (150 μ 1) were added to 12 x 75 mm disposable glass tubes and the volume brought up to 500 µl with assay buffer (10 mM diabasic sodium phosphate, 10 mM monobasic sodium phosphate, 148 mM sodium chloride with 1% bovine serum albumin and 0.01% thimerosal as a preservative). Primary antibodies were diluted with antibody diluent (10 mM dibasic sodium phosphate, 10 mM monobasic sodium phosphate, 50 mM ethylenediaminetetraacetic acid [EDTA] with 2% normal rabbit serum) to a factor of 1:31,250 (anti-rFSH) or 1:45,000 (anti-rLH) and added in a 200 µl volume to the assay tubes. Iodinated FSH (20,000 cpm/tube) or LH (40,000 cpm/tube), depending on the assay being performed, was then added to all tubes in a 100 µl volume of label diluent (10 mM dibasic sodium phosphate, 10 mM monobasic sodium phosphate, 148 mM sodium chloride with 0.1% bovine serum albumin and 0.01% thimerosal as a preservative). The final dilution of the antihodies was therefore 1:125,000 for anti-rFSH and 1:180,000 for anti-rLH. Total binding of label by antibody was determined in triplicate tubes containing only assay buffer and primary antiboly and non-specific binding (NSB) was determined in tubes containing only assay buffer and antibody diluent. Standards were also assayed in triplicate. All tubes were allowed to incubate at room temperature for 24 hr before the addition of the secondary antibody. A polyclonal serum goat anti-rabbit IgG (Daymar Laboratories Inc., Toronto, Ont.) was diluted with assay buffer and added in a 100 μ l volume to all tubes to precipitate the hormoneantibody complexes. After 24 hr, tubes were centrifuged at 4°C and 1500 x g for 15 min (Beckman TJ-6), the supernatant aspirated and the bound hormone counted for 1 min in a Beckman Gamma 4000 gamma radiation counter. Total specific radioactivity bound (B₀) was calculated as the total bound radioactivity in tubes with no exogenous hormone added minus the radioactivity bound in the absence of primary antibody (NSB). Specific bound radioactivity bound per tube minus the NSB value. The ratio of B:B₀ was plotted against the amount of hormone for all standards and this curve was used to calculate the amount of hormone present in each samples. All calculations were made with the aid of a computer program and all procedures are continuously validated by our lab.

2.5.5 Assay Reliability and Sensitivity

Reliability between RIA's was determined by inclusion of a sample of pooled male rat serum in every assay. The coefficient of variation for these samples was 16.75% (FSH) and 16.38% (LH) which is considered acceptable. Intra-assay variation, determined between replicate samples, was always less than 15%.

The RP-1 hormone standards used in the earlier work had the working range of 1.5-100 ng for LH and 10-1000 ng for FSH. The RP-2 standards were much more sensitive than the RP-1 standards; rFSH RP-2 and rLH RP-2 are 45x and 61x more potent, respectively, than their RP-1 counterparts. Therefore, a much lower working range of 0.05-10 ng for LH and 0.1-25 ng for FSH was used with the RP-2 standards. Data are presented in terms of RP-1 for the <u>in vivo</u> work and RP-2 for the <u>in vitro</u> work. Some of the culture data were originally obtained using RP-1 standards but were later converted to RP-2 equivalents (using NIDDK conversion factors) to facilitate comparisons between experiments.

2.6 STATISTICAL ANALYSIS

In all experiments a minimum of three replicates was used for every treatment group. For most of the studies, a simple comparison of the treatment means was carried out using the two-tailed Student's t-test unless otherwise indicated. The 3HP dose-response data were analysed by ANOVA and curves fitted for <u>in vitro</u> results using regression analysis. Experiments on the interaction of 3HP with the signal transduction pathway of LHRH were subjected to factorial analysis to confirm main effects and determine interactions among treatments.

RESULTS

3.1 FSH-SUPPRESSING EFFECT OF 3HP IN VIVO

3.1.1 Prepubertal Intact Male Rats

Figure 6 shows that 3α -hydroxy-4-pregnen-20-one (3HP) administered in various doses to intact 26 day old male rats for a period of 5 days resulted in a significant selective suppression of serum FSH levels at the three highest doses (20, 40 and 80 µg/100 g BW; p<0.001, p<0.01 and p<0.001, respectively). Circulating FSH was decreased to approximately 75% of the control level by all three doses. Serum LH levels were significantly increased by the 10 µg/100 g BW 3HP dose (p<0.05) but this is the only case where this result was seen. These results were pooled from several experiments conducted under identical conditions.


In an effort to determine the optimum number of injections of 3HP required to observe its FSH-suppressing effect in intact prepubertal male rats, groups of animals were treated with 80 μ g/100 g BW 3HP for 1-5 days and sacrificed either 8 or 24 hr after the first injection or 24 hr after each succeeding injection. Table 3 shows that, at all sampling times, FSH was specifically inhibited by 3HP (p<0.01). As early as 8 hr following a single injection, serum F5H was suppressed by about 50% (p<0.001). On the other hand, no significant effect on serum LH was observed. Based on this information, it was decided that all subsequent experiments using the intact prepubertal male rat model would be conducted using a single treatment with the steroid to be tested.

Sensitivity of the hypothalamic-pituitary-gonadal axis to 3HP is already present at a very young age. Various doses of 3HP were administered in a single injection to 10 and 20 day old male rats

53

Figure 6: Effect of 3α -hydroxy-4-pregnen-20-one (3HP) on serum FSH (\boxed{N}) and LH ($\boxed{1}$) levels in 26 day old intact male rats. Animals were given 4 daily s.c. injections of 3HP (0, 5, 10, 20, 40 or 80 µg/100 g BW) in saline vehicle and sacrificed on the fifth day (24 hr after the last injection). Measurements of serum FSH and LH by RIA were made on duplicate 200 µl samples. Bars represent the meantSEM of n=5-14 animals (the results of several experiments conducted under identical conditions were pooled for this figure) and results are expressed as ng RP-1/ml of serum.

*p<0.05, **p<0.01 and ***p<0.001 compared to vehicle-treated control</pre>



No. of injections	Serum FSH (ng/ml)	Serum LH (ng/ml)
Control	443.2±24.6	74.0±16.6
1 (8 hr)	222.7±30.9 ^b	68.1± 2.6
1 (24 hr)	268.0±22.6 ^b	80.4±10.9
2	349.7± 7.5 ^a	69.6± 8.0
3	291. 0±15.1 ^b	64.2±12.7
4	330.3±16.1 ^a	58.7±28.1
5	253.0±26.9 ^a	33.4±13.2

Table 3: Effect of the number of administered doses of 3a-hydroxy-4pregnen-20-one (3HP) on gonadotropin secretion in intact, juvenile male rats.

Intact 26 day old male rats were treated as described (Section 2.3) with 1-5 injections (s.c.) of 80 ug/100 g BW 3HP on a daily basis and sacrificed 24 hr after the last injection (except where indicated). Results shown are the mean±SEM of n=4-6 replicates and are expressed as ng RP-1/ml of serum.

^ap<0.01 and ^bp<0.001 compared to control.

(Figure 7) and all doses (20, 40 and 80 μ g/100 g BW) decreased serum FSH levels in the 20 day old rat (0.001). Only the 20 and 80 μ g/100 g BW doses of 3HP suppressed serum FSH in the 10 day old rat. Serum LH levels were not affected by 3HP at either age. Animals younger than 10 days were not employed as too many individuals would have to be pooled for a single measurement of serum gonadotropins by RIA.

To test the sensitivity of the <u>in vivo</u> model to the orientation of the hydroxyl group on the third carbon of 3HP, 25 day old intact male rats were treated with a single injection of 3ß-hydroxy-4-pregnen-20-one (3βHP; 0, 10 20, 40 80 or 160 μ g/100 g BW). Figure 8 shows that, at all doses except 20 μ g/100 g BW, 3βHP actually increased serum FSH levels (p<0.01) and had no effect on LH. The increase in serum FSH was not consistent and did not appear to be dose-related.

Since 3HP can easily be metabolized <u>in vivo</u> by endogenous enzymes the effect of two possible metabolites, 5α -pregnane-3,20-dione and 3α hydroxy- 5α -dihydroprogesterone, was tested. A single injection was given to intact 26 day old male rats at a dose of 0, 5 or 40 µg/100 g BW (Figure 9). Neither steroid affected FSH levels, while 40 µg/100 g BW 5α -pregnane-3,20-dione significantly increased serum LH levels (p<0.05).

3.1.2 Prepubertal Gonadectomized Rats

Since 3HP appeared to selectively reduce serum FSH levels in the intact prepubertal male rat, it was of interest to determine whether this FSH-suppressing effect could be elicited in the gonadectomized prepubertal rat, a model where gonadotropin secretion is elevated. Male and female prepubertal rats were gonadectomized and, after two days rest, treated with 4 daily injections of 0, 20, 40, 80 or 160 µg 3HP/100 Figure 7: Effect of a single s.c. injection of 3HP (0, 20, 40 or 80 μ g/100 g BW) on serum FSH and LH in 10 day old (\square and \square , respectively) and 20 day old (\square and \square , respectively) intact male rats. Animals were treated at the age indicated and sacrificed 24 hr later. RIA measurements were made on duplicate samples of 200 μ l. Bars represent the mean±SEM of n=4-8 animals and results are expressed as ng RP-1/ml of serum.

10d, 10 day old rats

20d, 20 day old rats

*p<0.05, **p<0.01, ***p<0.001 compared to vehicle-treated control</pre>





Figure 8: Effect of a single s.c. injection of 3B-hydroxy-4-pregnen-20one (3 β HP) (0, 10, 20, 40, 80 or 160 μ g/100 g BW) on serum FSH (\bigotimes) and LH (\boxdot) levels in 25 day old intact male rats. Animals were sacrificed 24 h after injection and RIA determinations made on duplicate 200 μ l samples. Bars represent the mean±SEM of n=4-7 animals and results are expresed as ng RP-1/ml of serum.

*p<0.05, **p<0.01 and ***p<0.001 compared to vehicle-treated control</pre>




) Figure 9: Effect of 5a-pregnane-3,20-dione (\square and \square) and 3ahydroxy-5a-pregnan-20-one (\square and \square) on serum FSH and LH levels, respectively, in 25 day old intact male rats. A single s.c. injection of either steroid at a dose of 0, 5 or 40 µg/100 g BW was given and serum FSH and LH determined on duplicate 200 µl samples taken 24 hr after treatment. Bars represent the mean±SEM of n=4-7 animals and are expressed as ng RP-1/ml of serum.

5HP, 5a-pregnane-3,20-dione

3,5HP, 3a-hydroxy-5a-pregnane-3,20-dione

*p<0.05 compared to vehicle-treated control</pre>



g BW (females) or 200 μ g/100 g BW 3HP (males) (Figure 10). Serum LH levels were not affected by 3HP treatment in males or females although gonadectomy did cause these levels to rise significantly over those of sham-operated controls (p<0.001). Serum FSH levels were suppressed by treatment with 20, 80 or 200 μ g/100 g BW 3HP in gonadectomized males (p<0.01) and by 20, 40 or 80 μ g/100 g BW 3HP in gonadectomized females (p<0.05). Maximum inhibition of FSH secretion occurred at the lowest dose administered (20 μ g/100 g BW) in males and females, to 62% and 56% of gonadectomized control levels, respectively. Gonadectomy significantly increased FSH secretion in both males and females (p<0.001).

Due to its labile nature, 3HP was acetylated (as described in Wiebe <u>et al</u>, 1985) in bopes that this would confer stability and a longer biological half-life to the steroid and result in more consistent <u>in</u> <u>vivo</u> results. 3α -Hydroxy-4-pregnen-20-one-3-acetyl (3HPA) was administered daily for 4 days to gonadectomized prepubertal male rats at doses of 0, 0.1, 0.5, 2.5, 12.5 and 62.5 µg/100 g BW. Sham-operated animals received vehicle only. Figure 11 shows that 3HPA selectively inhibited serum FSH levels in a dose-related manner (p<0.01; ANOVA) and, at a dose of 62.5 µg/100g BW, reduced FSH levels to near that of the sham-operated control (44% of gondectomized control). Serum LH was not affected by treatment with $3\dots A$ (p=0.2; ANOVA).

A comparison of the specific effect of 3HP with the well-known gonadotropin-suppressing effects of a few other gonadal steroids was made. 17β -estradiol, dihydrotestosterone and 17α -hydroxyprogesterone were administered to gonadectomized prepubertal male rats at 0 (control for all groups), 2.5 or 62.5 μ g/100 g BW for 4 days and sacrificed on Figure 10: Effect of 3HP on serum gonadotropin levels in gonadectomized male and female prepubertal rats. Animals were gonadectomized at 23 (male) or 24 (female) days of age and allowed two days rest. Treatment began on the third day following surgery and continued for a total of 4 daily s.c. injections of 0, 20, 40, 80 and 160 μ g 3HP/100 g BW (female) or 200 ug 3HP/100 g BW (male). Sham-operated animals were treated with saline vehicle only (0) for the duration of the experiment. Animals were sacrificed 24 hr following the last injection and serum FSH (males, \mathbf{N} ; females, \mathbf{N}) and LH (males, \mathbf{H} ; females, \mathbf{N}) levels determined on duplicate 200 μ l samples. Bars represent the mean±SEM of n=4-8 animals and results are expressed as ng RP-1/ml of serum.

M, males

F, females

*p<0.05, **p<0.01 and ***p<0.001 compared to vehicle-treated
gonadectomized control</pre>





Figure 11: Effect of 3a-hydroxy-4-pregnen-20-one-3-acety1 (3HPA) on gonado⁺:opin secretion in gonadectomized, prepubertal male rats. Animals were gonadectomized at 20 days of age and treated with 0, 0.1, 0.5, 2.5, 12.5 or 62.5 μ g/100 g BW 3HPA for 4 consecutive days from age 23-26 days. Sham-operated animals were treated with saline vehicle throughout the experiment. Animals were sacrificed 24 hr after the last treatment and serum FSH (\bigotimes) and LH (\boxdot) levels were determined on duplicate 200 μ l samples. Bars represent the mean±SEM of n=5-7 animals and are expressed as ng RP-1/ml serum. Analysis of variance (ANOVA) showed that 3HP significantly suppressed serum FSH levels (p<0.01) and had no effect on serum LH levels (p=0.2).

*p<0.05 and **p<0.01 compared to gonadectomized vehicle-treated control
(t-test)</pre>



the morning of the fifth day. All 3 steroids significantly (p<0.05) inhibited serum FSH and LH levels at the highest dose (62.5 μ g/100 g BW) (Figure 12). The 17a-hydroxyprogesterone treatment suppressed the level of both gonadotropins at the lower dose (2.5 μ g/100 g BW) (p<0.05). None of these steroids had a selective effect on FSH, nor were they as effective as 3HP at suppressing FSH levels at the lower dose (see Figure 11). Serum LH levels were always suppressed more than FSH by 17β-estradiol, dihydrotestosterone and 17a-hydroxyprogesterone.

3.1.3 Adult Male Rats

Since 3HP proved its efficacy in selectively inhibiting serum FSH levels in the prepubertal intact or gonadectomized male rat, it was of interest to determine the effect of 3HP on serum gonadotropin levels in the adult. Intact 55 day old male rats received a single injection of 12.5 μ g/100 g BW of either 3HPA or 3 β HPA and were sacrificed the following morning. Figure 13 shows that, while no significant effects on gonadotropin levels were observed, 3HPA did decrease serum FSH levels by 25% with no observable effect on LH while 3 β HPA increased FSH secretion by 35%, again with no effect on LH. At 55 days of age, these animals are just becoming sexually mature.

Another approach in the adult male rat was taken. Male rats were gonadectomized at 90 days of age and allowed 2 days rest. Intact animals of the same age were also used. All animals were treated with 62.5 μ g/100 g BW 3HPA (the most effective dose in the prepubertal castrate model-Figure 10) from age 93-96 days and sacrificed at 97 days of age. Figure 14 is a presentation of the results. 3HPA suppressed the rise in serum FSH in the gonadectomized adults to approximately 15% of the

Figure 12: Effect of 178-estradiol (\square , \square), dihydrotestosterone (\square , \square) and 17a-hydroxy-progesterone (\square , \square) on serum FSH and LH levels, respectively, in gonadectomized prepubertal male rats. Rats were gonadectomized at 22 days of age, treated from days 25-28 with 0 (control for all groups), 2.5 or 62.5 µg/100 g BW of the indicated steroid and sacrificed 24 hr after the last injection. Duplicate RIA measurements were made on 200 µl samples of serum. Bars represent the mean±SEM of n=3-5 animals and are expressed as ng RP-1/ml of serum.

C, control for all groups

 \mathbf{E}_2 , 17 β -estradiol

DHT, dihydrotestosterone

OHP, 17a-hydroxyprogesterone

*p<0.05, **p<0.01 and ***p<0.001 compared to gonadectomized vehicletreated control (C)




Figure 13: Effect of 3HPA and 3 β HPA on serum FSH (\bigotimes) and LH (\square) levels in adult intact male rats. 55 day old male rats were given a single s.c. injection of 12.5 µg/100 g BW of either 3HPA or 3 β HPA and sacrificed 24 hr later. Serum gonadotropin levels were measured in duplicate 200 µl samples. Bars represent the mean±SEM of n=4-6 animals and results are expressed as ng RP-1/ml of serum.





Figure 14: Effect of (3HPA) on serum FSH (\bigotimes) and LH (\bigotimes) levels in intact adult male rats and on serum FSH (\bigotimes) and LH (\bigotimes) in gonadectomized adult male rats. Animals were gonadectomized at 90 days of age and all animals were treated with daily s.c. injections of 3HPA (62.5 µg/100 g BW) from 93-96 days of age. Rats were sacrificed 24 hr following the last injection and RIA measurement of serum gonadotropins was made on duplicate 200 µl samples. Bars represent the mean±SEM of n=4-6 animals and results are expressed as ng RP-1/ml of serum.

Int, intact

GX, gonadectomized

*******p<0.001 compared to vehicle-treated control

^ap<0.05 compared to intact vehicle-treated control



gonadectomized control level (p<0.001) without affecting serum LH. 3HPA did not significantly affect serum gonadotropin levels in the intact adults.

3.2 STUDIES ON PRIMARY CULTURES OF RAT ANTERIOR PITUITARY CELLS

In order to further study 3HP suppression of FSH secretion in the rat, primary cultures of anterior pituitary cells were employed. This system allows for a thorough investigation of 3HP action under controlled conditions and requires .ewer animals for each experiment than are required <u>in vivo</u>. Typical cultures are shown in Plate 1.

3.2.1 FSH-Suppressing Effect of 3HP In Vitro

Primary cultures of anterior pituitary cells were prepared from mature male and female rats and incubated with various doses of luteinizing hormone-releasing hormone (LHRH) for 4 hr. Cultured anterior pituitary cells from female rats respond better, and at a lower dose, to LHRH than do those from male rats (Figure 15). Figure 15 shows that FSH and LH secretion was marimally stimulated (p<0.001) (300-600% of untreated control) by a concentration of 10 nM LHRH in primary cultures of female pituitary cells. Gonadotropin secretion in primary cultures of male pituitary cells was increased by only 70% (p<0.05) after treatment with 30 nM LHRH (Figure 15).

In an attempt to confirm <u>in vivo</u> results with 3HP, primary cultures of anterior pituitary cells from male rats were prepared and treated with 5 nM 3HP and/or 30 nM LHRH and incubated for 4 or 24 hr after treatment. 3HP selectively inhibited basal FSH secretion to 57% (p<0.05) and 75% (p<0.01) of control at 4 and 24 hr, respectively (Figure 16).





.

٠

.






Figure 15: Effect of luteinizing hormone releasing-hormone (LHRH) on FSH (circles) and LH (triangles) secretion in primary cultures of adult male (closed symbols) and female (open symbols) anterior pituitary cells. Cultures were prepared as described (Section 2.4.1), allowed a 72 hr incubation for attachment and then treated with either 0, 0.001, 0.1, 10 and 1000 nM LHRH (female) or 0, 0.003, 0.3, 30 and 3000 nM LHRH (male). Cultures were incubated a further 4 hr at which time medium was removed and gonadotropins measured by RIA. Points represent the mean \pm SEM of n=4 (female) or 6 (male) replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

*p<0.05, **p<0.01 and ***p<0.001 compared to control (C)





Figure 16: Effect of 3HP (5 nM) and/or LHRH (30 nM) on FSH (stripes) and LH (dots) secretion in primary cultures of adult male rat anterior pituitary cells after a 4 or 24 hr incubation. Cultures were prepared from 55 day old male rats as described (Section 2.4.1) and incubated 72 hr before treatment. Treatments were performed as described (Section 2.4.5) and incubation continued for 4 or 24 hr at which time medium was collected for analysis of gonadotropins by RIA. Bars represent the mean±SEM of n=6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr. *p<0.05 and **p<0.01 compared to respective control

^ap<0.05 compared to basal control

C:Control

T:3HP-treated




LHRH-induced FSH release was suppressed by 34% (p<0.05) and 48% (p<0.01) at 4 and 24 hr, respectively, by 3HP. LH secretion was not affected by 3HP in any of the experimental treatments. Note that 30 nM LHRH failed to elicit a significant increase in FSH secretion at either time period in these cultures, although LH secretion was stimulated by LHRH after a 4 hr incubation (p<0.05).

Similar results were obtained with anterior pituitary cells from adult female rats. Figure 17 shows that basal FSH secretion was significantly suppressed to 75% (p<0.05) and 63% (p<0.001) of the control level, 4 and 24 hr, respectively, after treatment with 10 nM 3HP. Unlike the results from the experiment with cultured male pituitary cells (above), cultures derived from adult females showed a significant surge in secretion of both gonadotropins after a 4 (p<0.05) or 24 hr (p<0.001) incubation with 10 nM LHRH (Figure 17). Treatment with 10 nM 3HP, in addition to the LHRH, decreased detectable FSH in the medium by 77% (p<0.01) and 58% (p<0.001) at 4 and 24 hr, respectively, after treatment. A comparison between 3HP-treated and control groups of the secreted LH shows these levels to be nearly identical (Figure 17).

Since cultures of anterior pituitary cells derived from adult female rats responded with a larger and more consistent increase in gonadotropin secretion after challenge by LHRH (Figures 15 and 17) than those from males (Figures 15 and 16), and showed a well-defined, selective reduction of FSH secretion in response to 3HP (Figure 17), female-derived cultures were routinely employed in all subsequent experiments. All incubations were subsequently carried out for 24 hr after treatment since the overall amounts of FSH and LH secreted into the medium were greater at 24 hr than at 4 hr and were therefore more

Figure 17: Effect of 3HP (10 nM) and/or LHRH (10 nM) on FSH (stripes) and LH (dots) secretion in primary cultures of adult female rat anterior pituitary cells after 4 or 24 hr of incubation. Cultures were prepared from 250-300 g females as described (Section 2.4.1) and inubated 72 hr before use. Treatments were carried out as described (Section 2.4.5) and medium sampled after 4 or 24 hr of incubation for analysis of gonadotropins by RIA. Bars represent the mean \pm SEM of n= 4-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

*p<0.05, **p<0.01 and ***p<0.001 compared to respective control
ap<0.05 and bp<0.001 compared to basal control</pre>



FSH SECRETION (ng/mg P/hr)


.

reliably measured by RIA.

Cultured female anterior pituitary cells were treated with a broad dose range of 3HP $(10^{-16}-10^{-4}$ M) and medium was sampled after a 24 hr incubation. The results are shown in Figure 18. <u>All</u> doses of 3HP inhibited FSH release (p<0.001; ANOVA). Maximum suppression of FSH secretion was seen at a dose of 10^{-8} M (10 nM) where FSH levels were only 22% (p<0.001) of the untreated control. LH secretion was not affected by 3HP (p=0.95; ANOVA). In the same experiment, cells were challenged with 10 nM LHRH during treatment with the above-mentioned doses of 3HP. All but the lowest dose used decreased LHRH-induced FSH secretion into the medium (p<0.001, ANOVA; Figure 19), with maximal suppression (91%) occurring at a dose of 10^{-12} M 3HP (p<0.001). LHRH (10 nM) considerably increased both FSH (p<0.05) and LH (p<0.001) secretion into the medium as compared with the basal control (Figure 18). LH secretion was not affected by treatment with 3HP (p=0.15; ANOVA).

The foregoing results showed that SHF can selectively inhibit FSH release <u>in vitro</u>, but did not resolve whether 3HP has any effect on gonadotropin synthesis. Table 4 shows the results of measurements of intracellular FSH and LH from the 4 hr incubations of cultured male and female pituitary cells shown in Figures 16 and 17. There is no difference in cell content of either gonadotropin after 3HP treatment in male-derived cultured pituitary cells. Since Figure 16 shows a marked decrease in FSH release in these same cells and there is no accumulation of FSH within these cells, it appears that there is a decrease in synthesis. The same is true of cultured anterior pituitary cells from female rats. A slight reduction in cell gonadotropins is seen after a 4 Figure 18: Effect of 3HP on basal FSH (\bigotimes) and LH (\square) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr after treatment with 0 (C:Control), 10⁻¹⁶, 10⁻¹⁴, 10⁻¹², 10⁻¹⁰, 10⁻⁸, 10⁻⁶ or 10⁻⁴ M 3HP after which medium was removed for analysis of gonadotropins by RIA. Bars represent the mean±SEM of n=5-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr. Basal FSH secretion was suppressed by 3HP in a dose-response manner (p<0.001; ANOVA). Regression analysis showed the relationship to have an R² value of 0.93.


*p<0.05, **p<0.01 and ***p<0.001 compared to control (t-test)</pre>



LH SECRETION (ng/mg P/hr)

Figure 19: Effect of 3HP on LHRH-induced FSH (∞) and LH (\therefore) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr after treatment with 0 (C:Control), 10^{-16} , 10^{-14} , 10^{-12} , 10^{-10} , 10^{-8} , 10^{-6} or 10^{-4} M 3HP plus 10 nM LHRH after which medium was removed for analysis of gonadotropins by RIA. Bars represent the mean±SEM of n=4-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr. LHRH-induced FSH secretion was suppressed by 3HP in a dose-response manner (p<0.001; ANOVA). Regression analysis showed the relationship to have an R² value of 0.86. *p<0.05 and **p<0.001 compared to control (t-test)

^ap<0.01 and ^bp<0.001 compared to basal control (Fig. 18; t-test)



FSH SECRETION (ng/mg P/hr)

Treatment	Basal		LHRH-Induced		
	FSH	LH	FSH	LH	
Male:				<u> </u>	
Control	3.51±0.24	20.53± 3.39	4.01±2.00	16.1±2.00	
ЗНР	3.64±0.51	18.50± 4.85	3.30±0.32	16.70±3.09	
Female:				2	
Control	14.99±2.33	155.80±11.27	14.88±0.52	36.50±1.35 ^a	
3HP	10.70±1.97	119.67±12.47	11.33±1.83	26.36±2.72 ^b	

Table 4: Effect of 3HP and luteinizing hormone-releasing hormone (LHRH) on cell content of gonadotropins in cultured male and female anterior pituitary cells.

Pituitary cells were derived from mature male or female rats and preincubated for 72 hr before treatment. 3HP was used at concentration of 5 nM (male) or 10 nM (female) and LHRH was either 30 nM (male) or 10 nM (female). Samples were taken 4 h after treatment as described (Section 2.4). Results shown are the mean \pm SEM of n=4-6 replicates and are expressed as ng RP-2/mg total cell protein/hr. These data are from the same experiments shown in Figures 16 and 17.

^ap<0.001 compared to basal control ^bp<0.05 compared to LHRH control

1

hr treatment with 3HP (Table 4) while a reduction in FSH release occurred (Figure 17), again suggesting that 3HP inhibits FSH synthesis as well as release. Treatment with LHRH significantly reduced intracellular LH levels in female pituitary cells (p<0.05) due to increased LH release. Cell levels of FSH in female cultures, and both gonadotropins in male cultures, remained constant indicating a stimulation of gonadotropin synthesis, since more hormone is released under LHRH stimulation, by LHRH in these cells.

3.2.2 Other Gonadal Hormones

3HP is a product of the male gonads, specifically the Sertoli cells. In order to compare 3HP action <u>in vitro</u> with other gonadal hormones, anterior pituitary cells fro⁷ adult female rats were incubated for 24 hr after treatment with various gonadal steroids, with or without challenge by 10 nM LHRH.

Progesterone (also a possible product of 3HP metabolism) was introduced to primary cultures of anterior pituitary cells at concentrations of 0, 0.001, 0.1, 10 and 1000 nM in the medium in the presence or absence of 10 nM LHRH. Figure 20 shows that progesterone significantly increased basal FSH secretion at doses of 0.1 (p<0.05) and 1000 nM (p<0.001), up to 3.5-fold at the highest dose and, although 10 nM progesterone had no significant effect, the overall trend is toward increasing basal FSH levels. LHRH-induced FSH and basal LH secretion were unaffected by progesterone alone and LHRH-induced LH secretion was significantly (p<0.01) reduced by 10 nM progesterone (Figure 20).


The 5a-reduced form of progesterone, 5a-dihydroprogesterone, is a gonadal hormone which may also be a metabolic product of 3HP. Cultures

Figure 20: Effect of progesterone (Prog) on basal FSH (\bigotimes) and LH (\boxdot) secretion and on LHRH-induced FSH (\bigotimes) and LH (\boxdot) secretion by primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with 0 (C:Control), 0.001, 0.1, 10 or 1000 nM Prog and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the mean±SEM of n=4-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

b, basal

L, LHRH-induced

*p<0.05, **p<0.01 and ***p<0.001 compared to respective control $a_p<0.05$ and $b_p<0.001$ compared to basal control



of rat anterior pituitary cells treated with 0.001, 0.1, 10 or 1000 nM 5a-dihydroprogesterone showed elevated basal LH levels (p<0.05) at all doses while basal FSH secretion was unaffected (Figure 21). 5a-dihydroprogesterone (10 and 100 nM) inhibited LHRH-induced release of FSH (p<0.01) and none of the doses influenced LHRH induction of LH secretion.

Testosterone, a product of Leydig cells in the male rat, was introduced into cultures of anterior pituitary cells with or without 10 nM LHRH. Concentrations of 0.1 (p<0.001), 10 (p<0.01) and 1000 (p<0.05) nM testosterone stimulated basal FSH release with the lowest dose having the greatest effect (a 170% increase over basal control) (Figure 22). Testosterone, 10 and 1000 nM, also increased LHRH-induced FSH secretion by about 50% (p<0.05). LH secretion showed no response to treatment with testosterone.

Dihydrotestosterone is a metabolite of testosterone and a potent inhibitor of <u>in vivo</u> gonadotropin secretion. Anterior pituitary cells were treated with 0, 0.001, 0.1, 10 or 1000 nM dihydrotestosterone and half of these challenged by 10 nM LHRH. None of the doses of dihydrotestosterone tested affected <u>in vitro</u> LH secretion (Figure 23). Basal FSH secretion was elevated 30-50% by 10 and 1000 nM dihydrotestosterone (p<0.05 and p<0.01, respectively) while treatment with 0.1 nM dihydrotestosterone slightly depressed the LHRH-induced release of FSH (p<0.05).


Sertoli cells also produce 20a-hydroxy-4-pregnen-3-one. Treatment of cultured pituitary cells with 0, 0.001, 0.1, 10 or 1000 nM 20ahydroxy-4-pregnen-3-one resulted in a slight suppression of basal LH secretion by 0.1 and 10 nM 20a-hydroxy-4-pregnen-3-one (p<0.01) and no Figure 21: Effect of 5α -dihydroprogesterone (5α -DHP) on basal FSH (\boxed{N}) and LH ($\boxed{\Box}$) secretion and on LHRH-induced $\mathbb{T}SH$ ($\boxed{22}$) and LH ($\boxed{\Box}$) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with 0 (C:Control), 0.001, 0.1, 10 or 1000 nM 5α -DHP and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the mean±SEM of n=4-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

B, basal

L, LHRH-induced

*p<0.05 and **p<0.01 compared to respective control</pre>

ap<0.05 and **b**p<0.001 compared to basal control



FSH SECRETION (ng/mg P/hr)

Figure 22: Effect of testosterone (T) on basal FSH (\bigotimes) and LH (\boxdot) secretion and on LHRH-induced FSH (\bigotimes) and LH (\bigotimes) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with 0 (C:Control), 0.001, 0.1, 10 or 1000 nM T and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the mean±SEM of n=5-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

- B, basal
- L, LHRH-induced

*p<0.05, **p<0.01 and ***p<0.001 compared to respective control $a_p<0.05$ and $b_p<0.001$ compared to basal control





Figure 23: Effect of dihydrotestosterone (DHT) on basal FSH (\bigotimes ` and LH (\boxdot) secretion and on LHRH-induced FSH (\bigotimes) and LH (\bigotimes) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with 0 (C:Control), 0.001, 0.1, 10 or 1000 nM DHT and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the meantSEM of n=5-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

B, basal

L, LHRH-induced

*p<0.05 and **p<0.01 compared to respective control $a_p<0.05$ and $b_p<0.001$ compared to basal control



effect on LHRH-induced LH release (Figure 24). Levels of FSH in the medium after stimulation of cells by 10 nM LHRH were further increased by 10 and 1000 nM 20a-hydroxy-4-pregnen-3-one (p<0.05) and Figure 24 indicates that this increase appears to be dose-related. None of the 20a-hydroxy-4-pregnen-3-one treatments affected basal FSH.

Estrogen (17 β -estradiol) was employed at concentrations of 0, 0.001, 0.1, 10 and 1000 nM in the medium with or without 10 nM LHRH. Table 5 shows the results of this experiment. Basal FSH release was unmodified by 17 β -estradiol and only one dose, 10 nM, decreased LHRHinduced FSH release, to 73% of the control level (p<0.05). A concentration of 1000 nM 17 β -estradiol slightly increased the basal secretion of LH (p<0.05) while LHRH-induced LH release was not influenced by 17 β -estradiol in this experiment.

Inhibin is a gonadal protein which has been shown to inhibit FSH secretion. Porcine follicular fluid inhibin (PFF-I) was generously supplied by M.R. Sairam and the culture model adjusted to correspond with the technique of Sairam <u>et al</u> (1984). Cultures were prepared from adult female anterior pituitaries as in Section 2.4.1 but the experimental medium used was serum-free M199 supplemented with 4 mM glutamine, 10 nM 17β -estradiol and 1000 nM progesterone. The steroids were added to increase basal secretion of gonadotropins (Sairam <u>et al</u>, 1984). An earlier experiment, using the routine treatment technique described in Section 2.4.5 and used for all previous experiments, showed that the published effects of PFF-I could not be observed (results not shown) without the above-mentioned modifications. The effect of 300 μ M PFF-I and/or 10 nM 3HP on basal and LHRH-induced (10 nM) gonadotropin secretion in this model system were compared and the results presented


Figure 24: Effect of 20a-hydroxy-4-pregnen-20-one (20aHP) on basal FSH (\bigotimes) and LH (\bigotimes) secretion and on LHRH-induced FSH (\bigotimes) and LH (\bigotimes) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with 0 (C: Control), 0.001, 0.1, 10 or 1000 nM 20aHP and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the mean±SEM of n=5-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

B, basal

L, LHRH-induced

#p<0.05 and ##p<0.01 compared to respective control</pre>

 $a_{p<0.05}$ and $b_{p<0.001}$ compared to basal control



Treatment	Basal		LHRH-Induced		
	FSH	LH	FSH	LH	
Control	1.67±0.20	19.65±1.02	2.59±0.15 ^b	28.11±2.16 ^b	
0.001 nM	1.58±0.07	20.91±0.90	2.63±0.22	30.3! .2.24	
0.1 nM	1.40±0.11	21.96±1.23	2.12±0.17	27.63±1.38	
10 nM	1.58±0.05	21.31±1.18	1.90±0.16 ^a	25.55±0.98	
1000 nM	1.62±0.10	23.15±0.76 ^a	2.17±0.13	27.76±1.25	

Table 5: Effect of 17β -estradiol on gonadotropin secretion in cultures of female anterior pituitary cells.

Cultures were derived from mature female rats and were preincubated for 72 hr before treatment. 17β -Estradiol (at doses indicated) and/or LHRH (10 nM) were given and media sampled 24 hr later (see Section 2.4). Results shown are the mean±SEM of n=4-6 replicates and are expressed as ng RP-2/mg total culture protein/hr.


^ap<0.05 compared to respective control ^bp<0.01 compared to basal control. in Figure 25. 3HP alone selectively inhibited LHRH-induced FSH secretion (p<0.01) but had no effect on basal FSH. This may be due to the synergistic stimulating effect of 17β -estradiol and progesterone present in the treatment medium. PFF-I, on the other hand, selectively inhibited basal FSH release by 40% under these experimental conditions (p<0.05) but did not differentiate between gonadotropins and suppressed LHRH-induced FSH (p<0.001) and LH (p<0.05) secretion (Figure 25). Treatment with either 3HP or PFF-I elicited a slight increase in basal LH levels (p<0.05), an unusual finding. In cultures treated with both 3HP and PFF-I, basal FSH levels were reduced (p<0.01) compared to control) by the same amount as PFF-I alone, while the combination of 3HP and PFF-I inhibited LHRH-induced FSH secretion to 52% of the control level (p<0.001; Figure 25). The combined inhibitory effect of 3HP and PFF-I was greater than that produced by either 3HP or PFF-I alone (p<0.05).

The possible interaction of 3HP with the gonadal steroids dihydrotestosterone, 17β -estradiol and progesterone in the regulation of <u>in vitro</u> gonadotropin secretion was examined (Table 6). Treatment with 10 nM 3HP resulted in a 33% reduction of basal FSH secretion (p<0.05) with no effect on basal LH. LHRH-induced FSH release was also selectively suppressed by 3HP (p<0.01). Dihydrotestosterone (10 nM), in the presence of 10 nM 3HP, increased the basal and LHRH-induced secretion of FSH (p<0.01). This stimulation of basal FSH release is similar to that seen with dihydrotesoterone alone (Figure 23). When cultures were treated with 10 nM 17 β -estradiol and 3HP, both basal FSH (p<0.01) and LH (p<0.05) secretion were stimulated. Enhancement of basal LH secretion by 17 β -estradiol was noted previously (Table 5). Estrogen showed no synergism or additive effect with 3HP in reducing LHRH-induced Figure 25: Comparison of the effect of 3HP and porcine follicular fluid inhibin (PFF-I) on basal FSH (\bigotimes) and LH (\square) secretion and on LHRH-induced FSH (\bigotimes) and LH (\bigotimes) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared as described (Section 4.2) and treated as follows. Treatment medium was M199 containing 10 nM estradiol-17 β and 1000 nM progesterone to increase basal gonadotropin secretion levels. Treatments were with/without 3HP (10 nM) and/or LHRH (10 nM) and/or PFF-I (300 μ M) and cells were incubated a further 24 hr. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the mean±SEM of n=5-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

B, basal

L, LHkH-induced

*p<0.05, **p<0.01 and ***p<0.001 compared to respective control $a_p<0.05$ and $b_p<0.001$ compared to basal control $c_p<0.05$ compared to 3HP alone $d_P<0.05$ compared to PFF-I alone



Treatment	Basal		LHRH-Induced		
	FSH	LH	FSH	LH	
Control	3.21±0.31	4.15±0.24	3.38±0.07	14.34±2.94 ^d	
ЗНР	2.16±0.13 ^a	3.82±0.26	2.87±0.06 ^b	13.11±3.17	
3HP+ 1pM DHT	4.00±0.74	4.02±0.30	3.33±0.27	10.96±1.99	
3HP+10nM DHT	6.29±0.80 ^b	4.64±0.71	5.33±0.47 ^b	13.44±3.27	
3HP+ 1pM E ₂	4.13±0.81	4.34±0.21	3.27±0.14	25.64±3.75	
3HP+10nM E ₂	7.23±0.89 ^b	6.82±1.07 ^a	3.66±0.31	18.67±4.22	
3HP+100pM Prog	3.08±0.44	4.29±0.31	3.04±0.15	11.95±1.30	
3HP+1uM Prog	7.23±0.96 ^b	6.40±0.23 ^c	3.37±0.47	12.11±1.90	

Table 6: Effect of 3HP and dihydrotestosterone (DHT) or 17β -estradiol (E₂) or progesterone (Prog) on gonadotropin secretion in cultures of female anterior pituitary cells.

Cultures were derived from mature female rats and preincubated for 72 hr before treatment. 3HP and LHRH were used at 10 nM and media samples taken 24 hr after treatment (see Section 2.4). Results show the mean \pm SEM of n=4-6 replicates and are expressed as ng RP-2/mg total culture protein/hr.

 $a_{p<0.05}$, $b_{p<0.01}$ and $c_{p<0.001}$ compared to respective control $d_{p<0.05}$ compared to basal control

FSH secretion even though both steroids are capable of such an effect (Table 5, Table 6). The combination of 10 nM 3HP with 1 μ M progesterone in the culture medium resulted in increases in the basal release of LH (p<0.001) and FSH (p<0.01) similar to the trend seen with progesterone alone in Figure 20. It therefore appears that the other gonadal steroids have the ability to oppose the action of 3HP in vitro.

3.2.3 Structural Isomers of 3HP and Other C₂₁ Steroids


It was of interest to study the effects on cultured pituitary cells of various metabolites of 3HP as well as steroids which are structurally related to 3HP, to determine if 3HP is responsible for the FSHsuppressing effect, or if a metabolite is the active form.

The isomer, 3β -hydroxy-4-pregnen-20-one (3 β HP), was employed in primary cultures of rat anterior pituitary cells at doses of 0, 0.001, 0.1, 10 and 1000 nM in the presence or absence of 10 nM LHRH and secreted gonadotropin levels examined after 24 hr. 3 β HP had no effect on either basal or LHRH-induced FSH secretion (results not shown) but it did affect the secretion of LH. Figure 26 shows that the highest dose of 3 β HP (1000 nM) significantly increased basal LH secretion (p<0.05) while the same dose inhibited LHRH-induced LH secretion (p<0.001) to 42% of the LHRH-control level.

Other pregnenes and one androstene compound were examined in this model culture system for FSH-suppressing activity. 3a,20a-dihydroxy-4pregnene had no significant effect on <u>in vitro</u> gonadotropin secretion (Table 7) but a downward trend in the secretion of basal and LHRHinduced FSH secretion is evident. Another pregnene-diol, $3a,20\beta$ dihydroxy-4-pregnene did not modify FSH secretion in cultured anterior Figure 26: Effect of 3β -hydroxy-4-pregnen-20-one (36HP) on basal (:) and LHRH-induced (:) LH secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with 0 (C: Control), 0.001, 0.1, 10 or 1000 nM 36HP and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the meantSEM of n=5-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr. Results for FSH are not shown since 36HP had no effect on FSH secretion.

#p<0.05 and ###p<0.001 compared to respective control</pre>

^ap<0.001 compared to basal control





Steroid/Dose	Bas	sal	LHRH-I	LHRH-Induced	
	FSH	LH	FSH	LH	
3a, 20a-Dihydroxy-4-	pregnene				
Control	4.5±0.80	14.3±1.22	10.5±0.45 ^c	29.4±1.02 ^c	
0.001 nM	3.6±0.33	12.3±0.82	10.0±0.54	38.1±5.30	
0.1 nM	5.9±1.12	14.3±1.47	9.7±1.61	29.5±1.95	
10 nM	3.9±0.28	12.5±0.53	9.0±1.48	35.8±11.2	
1000 nM	4.3±0.18	12.3±1.35	8.0±1.16	51.0±13.4	
3a, 20β-Dihydroxy-4-	pregnene				
Control	3.4±0.07	21.9±1.89	5.3±0.22 ^c	43.9±1.89 ^c	
0.001 nM	3.6±0.41	23.0±0.62	5.6±0.33	32.9±1.43	
0.1 nM	3.6±0.18	18.8±1.29	5.1±0.26	39.3±5.88	
10 nM	3.3±0.20	18.6±1.58	5.3±0.39	40.7±4.30	
1000 nM	3.9±0.21	22.5±1.85	5.5±0.34	60.9±6.35 ^a	
20β-Hydroxy-4-pregne	n-3-one				
Control	1.9±0.14	9.7±0.38	$2.8 \pm 0.10^{\circ}$	19.0±1.38 ^c	
0.001 nM	1.9±0.16	9.7±0.69	3.3±0.26	24.5±2.32	
0.1 nM	1.8±0.11	8.4±0.63	2.4±0.18	20.7±0.88	
10 nM	2.0±0.15	12.4±0.86	2.7±0.08	19.6±1.59	
1000 nM	2.4±0.17	10.2±0.92	2.8±0.19	17.2±0.95	
3a-Hydroxy-4-androst	en-17-one				
Control	1.1±0.04	6.5±0.30	2.4±0.23 ^c	14.8±0.61 ^c	
0.001 nM	1.0±0.06	6.2±0.18	1.99±0.18	13.5±0.70	
0.1 nM	0.9±0.10	5.9±0.09	2.5±0.27	14.4±0.69	
10 nM	1.0±0.10	6.1±0.32	2.3±0.19	15.4±0.59	
1000 nM	1.6±0.11 ^b	5.8±0.24	3.5±0.33 ^a	11.9±0.52 ^b	

Table 7: Effect of pregnenes and androstene structurally-related to 3HP on gonadotropin secretion in primary cultures of female anterior pituitary cells.

Cultures were derived from mature female rats and preincubated for 72 hr before treatment. Steroids were used at the indicated doses, LHRH employed at 10 nM and media samples taken 24 hr after treatment (see Section 2.4). Results shown the mean±SEM of n=4-6 replicates and are expressed as ng RP-2/mg total culture protein/hr.

 $a_p<0.05$ and $b_p<0.01$ compared to respective control $c_p<0.001$ compared to basal control


pituitary cells, but the highest dose (1000 nM) augmented LHRH-induced LH secretion 1.4-fold (p<0.05; Table 7). <u>In vitro</u> release of gonadotropins was not affected by 208-Hydroxy-4-pregnen-3-one (Table 7). The C₁₉ steroid analagous in structure to 3HP, namely 3a-hydroxy-4androsten-17-one was examined for possible 3HP-like activity. Treatment with 3a-hydroxy-4-androsten-17-one actually increased the basal (p<0.01) and LHRH-induced (p<0.05) secretion of FSH at a culture concentration of 1000 nM (Table 7). LH secretion after LHRH challenge was decreased by 1000 nM 3a-hydroxy-4-androsten-17-one (p<0.01). No effect on the basal release of LH was noted after treatment with 3a-hydroxy-4-androsten-17one.

The 5a-reduced metabolite of 3HP, 3a-hydroxy-5a-pregnan-20-one, had no effect on the secretion of FSH from primary cultures of rat anterior pituitary cells (results not shown). This particular steroid did, however, stimulate the basal release of LH with the maximum effect occurring at a dose of 0.1 nM (p<0.001), where secretion was increased approximately 6-fold over the control (Figure 27). Note that, in this experiment, LH secretion rates are approximately one order of magnitude greater than in all other culture experiments. It is possible that the female rate used as the source of anterior pituitary cells were not random-cycling but were synchronous in a proestrous stage.

Cultures treated with 3β -hydroxy- 5β -pregnan-20-one did not exhibit any alteration in FSH secretion (results not shown). Treatment with 3β hydroxy- 5β -pregnan-20-one resulted in a dose-related effect on basal LH secretion which was significantly increased by culture concentrations of 10 (p<0.05) and 1000 (p<0.001) nM (Figure 28). No significant difference in LH secretion after challenge by LHRH was seen after Figure 27: Effect of 3a-hydroxy-5a-pregnan-20-one (3a-OH-5a-DHP) on basal (\square) and LHRH-induced (\square) LH secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with 0 (C: Control), 0.001, 0.1, 10 or 1000 nM 3a-hydroxy-5apregnan-20-one and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the meantSEM of n=4-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr. Data on FSH are not shown as 3a-hydroxy-5a-pregnan-20-one did not affect FSH secretion.

*p<0.05 and ***p<0.001 compared to respective control</pre>

^ap<0.001 compared to basal control




÷.,

CONCENTRATION OF 3α -OH- 5α -DHP (nM)

Figure 28: Effect of 3β -hydroxy- 5β -pregnan-20-one $(3\beta$ -OH- 5β -DHP) on basal (\square) and LHRH-induced (\square) LH secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with 0 (C: Control), 0.001, 0.1, 10 or 1000 nM 3β -hydroxy- 5β pregnan-20-one and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the meantSEM of n=5-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr. FSH data are not shown since 3β -hydroxy- 5β -pregnan-20-one had no effect on FSH secretion.

*p<0.05 and ***p<0.001 compared to respective control</pre>

^ap<0.001 compared to basal control



CONCENTRATION OF 3B-OH-5B-DHP (nM)

steroid treatment.

The remaining pregnanes examined were employed in cultures of anterior pituitary cells at doses of 0, 0.001, 0.1, 10 and 1000 nM with or without 10 nM LHRH. The secretion of FSH and LH were not influenced by 3β -hydroxy-5a-prenan-20-one (Table 8). However, 5β -pregnane-3,20dione stimulated the basal secretion of FSH at doses of 0.001 (p<0.05), 10 (p<0.001) and 1000 nM (p<0.01) with maximum stimulation occurring at 10 nM (2.9-fold). No other effect was observed with this steroid. Basal LH secretion was reduced by 28% by a dose of 0.1 nM 3a-hydroxy-5 β pregnan-20-one (p<0.05; Table 8).

3.2.4 Studies on the Mechanism of Action of 3HP

Since LHRH stimulates gonadotropin secretion by a mechanism involving the opening of membrane calcium channels (allowing a calcium influx) and the activation of protein kinase C (PKC) (see Section 1.4.1) it was of interest to determine whether 3HP, in its FSH-suppressing activity, interacts with these signal transduction systems in primary cultures of rat anterior pituitary cells.

Cultures of rat anterior pituitary cells were treated with 100 μ M A23187 (a calcium ionophore) and/or 10 nM 3HP in the presence or absence of 10 nM LHRH and the medium was sampled for gonadotropins after 24 hr. Treatment with 3HP alone selectively inhibited basal and LHRH-induced FSH secretio¹. (p<0.05; Figure 29). A23187 mimicked the effects of LHRH and not only stimulated the basal release of FSH and LH (p<0.001), but further stimulated the secretion of FSH after LHRH induction (p<0.001; Figure 29). When 3HP and A23187 treatments were combined, basal (p<0.001 compared to control) and LHRH-induced FSH secretion was midway between

Steroid/Dose	Basal		LHRH-Induced	
	FSH	LH	FSH	LH
 3β-Hydroxy-5α-pregnan-20)-one			<u></u>
Control	3.17±0.11	5.85±0.17	4.60±0.42 ^d	16.08±0.65 ^e
0.001 nM	3.04±0.20	5.80±0.24	3.91±0,42	16.61±0.74
0.1 nM	3.05±0.08	6.22±0.12	4.90±0.24	16.44±0.24
10 nM	3.09±0.12	5.44±0.37	5.20±0.27	16.84±0.43
1000 nM	3.42±0.04	6.43±0.24	5.10±0.37	17.00±0.41
5β-Pregnane-3,20-dione				
Control	0.66±0.04	4.92±0.47	1.70±0.09 ^e	21.55±0.54 ^e
0.001 nM	1.52±0.33 ^a	5.78±0.47	1.93±0.12	20.46±1.75
0.1 nM	1.01±0.29	4.77±0.24	1.67±0.09	21.38±1.36
10 nM	1.91 ± 0.19^{c}	4.80±0.36	1.55±0.16	22.89±0.91
1000 nM	1.78±0.28 ^b	5.35±0.25	1.96±0.21	22.22±2.11
3α-Hydroxy-5β-pregnan-20)-one			
Control	3.54±0.39	14.18±1.29	6.17±0.38 ^e	48.89±3.58 ^e
0.001 nM	3.32±0.30	11.87±1.07	6.30±0.63	53.20±1.53
0.1 nM	3.08±0.59	10.14±1.12 ^a	5.34±0.58	57.51±1.98
10 nM	3.88±0.39	12.49±1.11	4.75±0.30	40.11±4.45
1000 nM	2.43±0.45	12.33±0.93	6.96±0.25	55.91±3.08

Table 8: Effect of pregnanes structurally-related to 3HP on gonadotropin secretion in female anterior pituitary cells in culture.

Cultures were derived from mature female rats and preincubated for 72 hr before treatment. Steroids were used at the doses indicated, LHRH was used at 10 nM and media were sampled 24 hr after treatment (see Section 2.4). Results show the mean±SEM of n=4-6 replicates and are expressed as ng RP-2/mg total culture protein/hr.

 $a_p<0.05$, $b_p<0.01$ and $c_p<0.001$ compared to respective control $d_p<0.01$ and $e_p<0.001$ compared to basal control

Figure 29: Effect of 3HP and the calcium ionophore, A23187, on basal FSF (\bigotimes) and LH (\boxdot) secretion and on LHRH-induced FSH (\bigotimes) and LH (\boxdot) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with/without 10 nM 3HP and/or 100 μ M A23187 and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the meantSEM of n=4-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

B, basal

L, LHRH-induced

'p<0.05, **p<0.01 and ***p<0.001 compared to respective control</pre>


^ap<0.01 compared to basal control

^bp<0.05 compared to A23187 alone

cp<0.001 compared to 3HP alone

Factorial analysis showed the following main effects and interactions on FSH secretion: 3HP (p<0.001); A23187 (p<0.001); LHRH (p<0.05); LHRH and 3HP (p<0.001); A23187 and LHRH (p<0.01).

Factorial analysis showed the following main effects and interactions on LH secretion: A23187 (p<0.001); LHRH (p<0.001).



that seen under conditions of either 3HP or A23187 alone (ie. 3HP opposed the stimulating effect of A23187 or vice versa (p<0.05)). 3HP did not oppose the A23187 stimulation of basal LH secretion. Factorial analysis confirmed the main effects of 3HP or A23187 (p<0.001) or LHRH (p<0.05) on FSH release and showed a significant interaction between A23187 and LHRH (p<0.01) and, 3HP and LHRH (p<0.001). The main effects of LHRH or A23187 (p<0.001) on LH secretion were confirmed and no interactions between treatments were seen with similar analysis.

The dihydropyridine-sensitive calcium channel antagonist, verapamil (100 µM), was employed along with 3HP and LHRH in the same experiment as the calcium ionophore A23187 (the control and 3HP treatments are the same as those above and therefore will not be repeated here). Figure 30 shows that verapamil inhibited both the basal and LHRH-induced secretion of LH (p<0.01 and p<0.001, respectively). Verapamil stimulated the basal release of FSH (p<0.01) and did not reduce LHRH-induced FSH release. When 3HP and verapamil were used together in culture, basal FSH release was again stime sted (p<0.01 compared to basal control or 3HP alone) and, although basal LH was somewhat reduced by this treatment, the level of LH in the medium was not significantly different from any of the other treatments. The combined treatment (3HP + verapamil) resulted in inhibition of LHRH-induced LH release (p<0.001) that was not different from that produced by verapamil alone. The effect of 3HP and verapamil on LHRH-induced FSH secretion was dramatic and FSH release was reduced to about 7% of the control level (p<0.001; Figure 30) which was significantly less than either 3HP or verapamil alone (p<0.001). Analysis of these results using the factorial method confirmed the main effects of 3HP or verapamil (p<0.001) or LHRH (p<0.5) on FSH secretion Figure 30: Effect of 3HP and the dihydropyridine calcium channel antagonist, Verapamil, on basal FSH (\bigotimes) and LH (\boxdot) secretion and on LHRH-induced FSH (\bigotimes) and LH (\boxdot) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with/without 10 nM 3HP and/or 100 μ M Verapamil and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the meantSEM of n=4-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

B, basal

L, LHRH-induced

*p<0.05, **p<0.01 and ***p<0.001 compared to respective control</pre>


^ap<0.01 compared to basal control

^bp<0.001 compared to Verapamil alone

 $c_{p<0.001}$ and $d_{p<0.01}$ compared to 3HP alone

Factorial analysis showed the following main effects and interactions on FSH secretion: 3HP (p<0.001); verapamil (p<0.001); LHRH (p<0.05); 3HP and verapamil (p<0.01); 3HP and LHRH (p<0.001); 3HP and verapamil and LHRH (p<0.001).

Factorial analysis showed the following main effects and interactions on LH secretion: verapamil (p<0.001); LHRH (p<0.01); verapamil and LHRH (p<0.001).



and showed interactions between verapamil and 3HP (p<0.01), LHRH and 3HP (p<0.001) and between LHRH, verapamil and 3HP (p<0.001) on FSH release. Similar analysis of the LH data confirmed the effect of either verapamil (p<0.001) or LHRH (p<0.01) on LH secretion and showed a significant interaction between the effects of LHRH and verapamil on LH secretion (p<0.001).

Another dihydropyridine-sensitive calcium channel antagonist, nifedipine, was employed in a similar experiment. Nifedipine (100 μ M) significently reduced basal (p<0.05) and LHRH-induced (p<0.001) secretion of LH (Figure 31). Nifedipine treatment resulted in significant increases in both basal (p<0.01) and LHRH-induced (p<0.05)FSH release (Figure 31). When 100 µM nifedipine and 10 nM 3HP were combined in a single treatment, LHRH-induced LH secretion was reduced in comparison to the LHRH-treated control (p<0.05) but not as markedly as when cultures were treated with nifedipine alone (p<0.01). Basal LH secretion was not significantly different from controls after treatment with both 3HP and nifedipine, but was slightly greater than in cultures treated with nifedipine alone (p<0.05). Basal FSH release was enhanced over controls in the combined treatment (p<0.01) where nifedipine appeared to oppose the FSH-suppressing effect of 3HP (p<0.01). In combination, 3HP and nifedipine markedly depressed LHRH-induced FSH release by cultured pituitary cells (p<0.001) to about 9% of the control level (Figure 31). This inhibition was significantly greater than that induced by 3HP alone (p<0.001) and resulted in FSH levels lower than those seen after incubation with nifedipine alone (p<0.001). Again, analysis by factorials confirmed the main effects of 3HP or nifedipine (p<0.001) or LHRH (p<0.05) on FSH release and indicated that there is a

Figure 31: Effect of 3HP and the dihydropyridine calcium channel antagonist, Nifedipine, on basal FSH (\bigotimes) and LH (\boxtimes) secretion and on LHRH-induced FSH (\bigotimes) and LH (\boxtimes) secretion in primary cultures of adult female rat anterior ppituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with/without 10 nM 3HP and/or 100 μ M Nifedipine and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicated. Bars represent the mean±SEM of n=4-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

B, basal

L, LHRH-induced

*p<0.05, **p<0.01 and ***p<0.001 compared to respective control</pre>


^ap<0.01 compared to basal control

 $\mathbf{b}_{p<0.01}$ and $\mathbf{c}_{p<0.001}$ compared to 3HP alone

 $\mathbf{d}_{p<0.001}$, $\mathbf{e}_{p<0.05}$ and $\mathbf{f}_{p<0.01}$ compared to Nifedipine alone

Factorial analysis showed the following main effects and interactions on FSH secretion: 3HP (p<0.001); nifedipine (p<0.001); LHRH (p<0.05); 3HP and nifedipine (p<0.01); 3HP and LHRH (p<0.001); LHRH and nifedipine (p<0.001); 3HP and LHRH and nifedipine (p<0.001).

Factorial analysis showed the following main effects and interactions on LH secretion: nifedipine (p<0.001); LHRH (p<0.001); 3HP and nifedipine (p<0.01); 3HP and nifedipine and LHRH (p<0.01).



LH SECRETION (ng/mg P/hr)

significant interaction between 3HP and nifedipine, 3HP and LHRH, nifedipine and LHRH and, between all 3 treatments (p<0.001). The main effects of nifedipine and LHRH (p<0.001) on LH secretion were upheld by factorial analysis which also showed an interaction between 3HP and nifedipine or 3HP and nifedipine and LHRH (p<0.01). These interactions were not seen with t-test.

In a separate experiment, an attempt was made to specifically activate or inhibit protein kinase C (PKC) in cultures of anterior pituitary cells treated with 10 nM 3HP, with or without 10 nM LHRH. Figure 32 (and Figure 33) show that 3HP selectively inhibited basal (p<0.01) and LHRH-induced (p<0.001) FSH secretion by cultured pituitary cells without affecting LH secretion. LHRH stimulated the secretion of both gonadotropins (p<0.001).

The specific PKC inhibitor, 1-(5-isoquinolinesulfonly)-2methylpiperazine dihydrochloride (H-7; Kawamoto and Hidaka, 1984; Ho <u>et</u> a<u>1</u>, 1988; Ito <u>et a1</u>, 1988), when used at a concentration of 50 µM, slightly elevated the basal secretion of FSH (p<0.05). and had no effect on basal LH secretion by pituitary cells in culture (Figure 32). H-7 inhibited LHRH induction of gonadotropin secretion (p<0.001). When combined in a single treatment, 3HP and H-7 suppressed LHRH-induced FSH secretion (p<0.001) to a level lower than that produced by H-7 alone (p<0.05) but not significantly different from 3HP alone (Figure 32). LHRH-induced LH secretion was also reduced by combined (3HP + H-7) treatment (p<0.001) but this reduction was similar in magnitude to that achieved by H-7 alone and the level of LH in the medium was much less than that when 3HP alone was employed (p<0.001). Analysis of factorials confirmed the main effects of 3HP or LHRH (p<0.001) or H-7 (p<0.05) on Figure 32: Effect of 3HP and the protein kinase C inhibitor, H-7, on basal FSH (\bigotimes) and LH (\boxdot) secretion and on LHRH-induced FSH (\bigotimes) aud LH (\boxdot) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with/withhout 10 nM 3HP and/or 50 μ M H-7 and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the mean±SEM of n=5-6 replicates and results are expressed as ng RP-2 secreted/mg total culture protein (P)/hr.

B, basal

L, LHRH-induced

*p<0.05, **p<0.01 and ***p<0.001 compared to respective control</pre>

^ap<0.001 compared to basal control

bp<0.05 compared to 3HP alone

cp<0.05 compared to H-7 alone

dp<0.001 compared to 3HP alone

Factorial analysis showed the following main effects and interactions on FSH secretion: 3HP (p<0.001); H-7 (p<0.05); LHRH (p<0.001); 3HP and LHRH (p<0.01); 3HP and H-7 (p<0.01); H-7 and LHRH (p<0.01); 3HP and H-7 and LHRH (p<0.01).

Factorial analysis showed the following main effects and interactions on LH secretion: H-7 (p<0.001); LHRH (p<0.001); H-7 and LHRH (p<0.001).




Figure 33: Effect of 3HP and the specific protein kinase C activator, SC-9, on basal FSH (\bigotimes) and LH (\boxdot) secretion and on LHRH-induced FSH (\bigotimes) and LH (\boxdot) secretion in primary cultures of adult female rat anterior pituitary cells. Cultures were prepared and treated as described (Section 2.4) and incubated for 24 hr following treatment with/without 10 nM 3HP and/or 100 μ M SC-9 and/or 10 nM LHRH. Medium was collected for analysis of gonadotropins by RIA and assayed in duplicate. Bars represent the mean±SEM of n=5-6 replicates and results are exppessed as ng RP-2 secreted/mg total culture protein (P)/hr.

B, basal

L, LHRH-induced


*p<0.05, **p<0.01 and ***p<0.001 compared to respective control</pre>

^ap<0.001 compared to basal control

^bp<0.01 compared to 3HP alone

Factorial analysis showed the following main effects and interactions on FSH secretion: 3HP (p<0.001); SC-9 (p<0.05); LHRH (p<0.001); 3HP and LHRH (p<0.001); 3HP and SC-9 (p<0.01).

Factorial analysis showed the following main effects and interactions on LH secretion: SC-9 (p<0.01): LHRH (p<0.001); SC-9 and LHRH (p<0.001); SC-9 and LHRH and 3HP (p<0.01).



FSH secretion and showed that there was indeed a significant interaction between 3HP and H-7, and 3HP and H-7 and LHRH (p<0.001) as well as the expected interaction between 3HP and LHRH (p<0.001). Factorial analysis confirmed the t-test results with respect to LH secretion, H-7 or LHRH have significant effects individually (p<0.001) and interact together (p<0.001).

An attempt was made to activate PKC in cultured pituitary cells with 100 µM N-(phenylhexyl)-5-chloro-l-naphthalenesulfonamide (SC-9; Ito et al, 1986; Nishino et al, 1986). Gonadotropes did not respond to activation of PKC by SC-9 with any elevation of FSH secretion at either the basal or LHRH-induced level (Figure 33). Activation of PKC by SC-9 stimulated the basal release of LH (p<0.05) and inhibited LHRH-induced LH secretion (p<0.01). This inhibition of LHRH-induced LH secretion by SC-9 may be due to some sort of down-regulatory phenomenon. The FSHsuppressing action of 3HP was opposed by SC-9 when both 3HP and SC-9 were employed together: basal FSH secretion was not significantly different from the control and was significantly greater than the level seen when 3HP alone was used (p<0.01); LHRH-induced FSH secretion also was not significantly different from control (Figure 33). When used together, SC-9 and 3HP significantly reduced LHRH-induced LH secretion (p<0.05) but this result was not significantly different from the effect of SC-9 alone. Analysis of factorials confirmed the results obtained with t-test in this experiment: 1) 3HP (p<0.01) or SC-9 (p<0.05; not where t -test) or LHRH (p<0.001) significantly affect FSH secretion; 2) 3HP and LHRH and, 3HP and SC-9 interact to affect FSH secretion (p<0.01); 3) SC-9 (p<0.01) or LHRH (p<0.001) affect LH secretion and 4) SC-9 and LHRH interact to affect LH secretion (p<0.001).

DISCUSSION

Evidence has accumulated since 1932 to suggest that a seminiferous tubular factor is involved in the regulation of pituitary FSH secretion. McCullagh (1932) argued that organic extracts of testis restore only the androgen-dependent secondary sex characters in castrated rats while aqueous extracts prevent the associated pituitary hypertrophy and therefore, the testis has dual endocrine activity. Lacy and Pettitt (1970) suggested that since Sertoli cells have steroidogenic activity which is under the control of FSH, perhaps the products of Sertoli cell metabolism play a role in the negative feedback regulation of FSH. In a study of men with complete azoospermia it was determined that the Sertoli cell or early germinal elements were responsible for inhibiting FSH secretion since these men had four-fold higher levels of FSH (and no difference in LH) than normal men (VanThiel et al, 1972). FSH levels did not rise in germ cell only-depleted rats, which again suggests the involvement of a Sertoli cell factor in FSH regulation (Krueger et al, 1974). It is now well-established that at least one product of Sertoli cell metabolism, namely inhibin, is capable of regulating FSH secretion both in vivo and in vitro (Steinberger and Steinberger, 1976; Massicotte et al, 1984a; Thomas and Nikitovich-Winer, 1984) but it has also been argued that inhibin alone cannot fully account for FSH inhibition (Decker et al, 1981; Sheth and Vijayalakshmi, 1981) and that inhibin may be a significant regulator of FSH secretion only in the prepubertal male (Summerville and Schwartz, 1981; Hermans et al, 1980; Ultee-vanGessel and deJong, 1987). The evidence presented here indicates that the Sertoli cell steroid, 3a-hydroxy-4-pregnen-20-one (3HP) selectively suppresses FSH secretion both in vivo and in vitro and may be an

integral part of the rat FSH regulatory system.

4.1 3HP SELECTIVELY SUPPRESSES FSH SECRETION IN VIVO

The evidence presented herein shows definitively that 3HP selectively suppresses FSH secretion in the intact and castrate prepubertal male, ovariectomized prepubertal female and castrate adult male rat.

The sensitivity of the male pituitary to 3HP is in place by 10 days of age, the age at which Sertoli cell production of 3HP starts to rise (Wiebe, 1982). At this age the male pituitary is already sensitive to other gonadal steroids (McEwen, 1981; MacLusky and Naftolin, 1981) and inhibin (Ultee-VanGessel and deJong, 1987). Inhibin production by Sertoli cells is also greatest at this time (Rivier et al, 1988). Notably, the greatest suppression of FSH was seen in the gonadectomized adult male, suggesting that pituitary sensitivity to 3HP is more fully developed in the adult as is true for the other gonadal steroids (MacLusky and Naftolin, 1981). It may also be that, in the adult castrate rat, the post-castration rise in serum gonadotropins has not yet reached a plateau and that 3HP is preventing the rise in serum FSH. Some suppression of FSH was also seen in the 55 day old intact male although variability in the data precluded statistical significance. The additional complication of testicular factors present in the adult intact rat may have influenced or modified the effect of 3HP.

The suppression of FSH secretion by 3HP is a unique (among steroids) biological property. An examination of the relevant literature shows that the gonadal steroids, testosterone, dihydrotestosterone and 17β -estradiol suppress both gonadotropins in the castrate male rat but

that the inhibition of LH invariably exceeds that of FSH (see Table 1). This is consistent with the results obtained for dihydrotestosterone, 17β -estradiol and 17α -hydroxyprogesterone in this study where only the highest dose showed inhibition of FSH along with LH.

Progesterone has no effect in the gonadectomized male rat while the glucocorticoids actually increase FSH secretion in either intact or GX rats (Table 1). Although 3HP can be metabolized <u>in vivo</u> to 3a-hydroxy-5a-pregnan-20-one which is reported to increase serum LH (Murphy and Mahesh, 1984b), 3a-hydroxy-5a-pregnan-20-one did not increase serum LH in the intact male rat in this study. This suggests that the increase in serum LH in the intact male after treatment with 3HP was not due to its metabolism to 3a-hydroxy-5a-pregnan-20-one. The LH increasing effect of 3HP was observed on only a few occassions and may be spurious result due to natural variation among the animals. Previous studies used the ovariectomized prepubertal female rat primed with 17β -estradiol and before treatment with 3a-hydroxy-5a-pregnan-20-one, therefore the procedures are not entirely analogous. 5a-pregnane-3,20-dione also increased serum LH in the intact male, a finding not previously reported (Swerdloff <u>et al</u>, 1973).

The activity of 3HP appears to be related to the 3α ,4-keto structure of the molecule, since neither the 5α -reduced 3HP, 3α -hydroxy- 5α -pregnan-20-one, nor the 3 β epimer of 3HP, 3β -hydroxy-4-pregnen-20one, resulted in decreased FSH secretion. In fact, 3β -hydroxy-4-pregnen-20-one increased serum FSH in the intact male, further suggesting that the 3α -allylic structure of 3HP is important in its action on gonadotropin release from the pituitary.

A hormone must act in a dose-dependent fashion to qualify as a true

physiological regulator. Figure 11 shows that 3α -hydroxy-4-pregnen-20one-3-acetyl (3HPA) acts in a dose-related manner in castrate rats. 3HPA was also shown to act dose-dependently in intact male rats and not to have an androgenic (stimulation of accessory sex structures) effect (Wiebe and Wood, 1987). 3HPA suppression of FSH occurs at doses as low as 0.5 ug/100 g BW which is considered physiological for most steroids (Gay and Dever, 1971; Eldridge <u>et al</u>, 1974; Dohler and Wuttke, 1975) and is much lower than the dose of testosterone, dihydrotestosterone or 17βestradiol required to inhibit FSH secretion. It should be noted that until 3HP has been detected in serum, the 3HP effect under discussion may be pharmacological in nature. That is, 3HP may be exerting its FSHsuppressing effect at a site other than a specific 3HP receptor, although this is unlikely in view of the unique properties of 3HP compared to closely related steroids.

In all of the <u>in vivo</u> studies, 3HP selectively reduced FSH secretion with the lowest dose (20 ug/100 g BW) having maximum effect. This finding was somewhat unusual and the switch to the more stable 3acetyl derivative (3HPA) and the regular use of a lower dose range resulted in consistent, dose-related responses.

4.2 3HP SELECTIVELY SUPPRESSES FSH SECRETION IN VITRO

Primary cultures of rat anterior pituitary cells have been frequently employed to study the influence of gonadal hormones on pituitary gonadotropin secretion. This study shows that 3HP inhibits both the basal and LHRH-induced secretion of FSH in a dose-dependent manner from cultured male and female anterior pituitary cells, with no apparent effect on LH release (Section 3.2.1). Extremely low doses of 3HP (10-16 M) appear to have an FSH-suppressing action. Although this dose gives the availability of about 0.2 molecules 3HP per cell, it could be that 3HP mainly affects FSH gonadotropes (approximately 11% of total population; Childs <u>et al</u>, 1981), thus increasing the overall availability of the steroid to FSH-secreting cells.

4.2.1 Comparison With Other Gonadal Steroids

Previous studies have shown that the gonadal steroids testosterone, dihydrotestosterone, 17β -estradiol and progesterone increase the basal release of FSH <u>in vitro</u> (Table 2). These findings are substantiated by the results presented herein (Figures 20, 22, 23 and Table 5). Dihydrotestosterone, 17β -estradiol and progesterone, at high doses, are all capable of stimulating FSH secretion in the presence of 3HP but 3HP antagonizes (or cancels out) the stimulatory effect of these steroids when used at lower doses (Table 6).

Glucocorticoids are also thought to increase basal FSH secretion (Table 2), while other C_{21} steroids are thought to be inhibitory to FSH secretion <u>in vitro</u>. Reports suggest that 20a-hydroxy-4-pregnen-3-one decreases basal FSH secretion in cultured female pituitary cells (Tang and Spies, 1975) but the present study does not support this finding (Figure 24). Progesterone decreases the basal synthesis and secretion of FSH in ovine pituitary cell cultures (Batra <u>et al</u>, 1986). It is quite interesting to discover from the literature and the results in this study that, with respect to steroid hormones, only C_{21} steroids have been shown to selectively affect (generally stimulate) basal FSH release <u>in vitro</u> and that 3HP is also a C_{21} steroid. Only 3HP is selectively inhibitory to basal FSH secretion <u>in vitro</u> (Figures 16, 17 and 18).

Induction of gonadotropin secretion with LHRH is a commonly used tool in the elucidation of gonadal hormone effects on pituitary secretion. Several reports indicate that, in vitro, testosterone, dihydrotestosterone, 17β -estradiol and progesterone all increase the LHRH-induced secretion of FSH while the androgens described decrease, and 178-estradiol increases, the LHRH-induced secretion of LH (Table 2). However, one report suggests that dihydrotestosterone and testosterone suppress LHRH-induced FSH and LH secretion in cultured pituitary cells (Table 2). The present study has shown a trend similar to the concensus with respect to gonadal steroids: dihydrotestosterone and testosterone do indeed stimulate LHRH-induced FSH secretion (Figures 22 and 23) although no significant effect on LH secretion was noted. The gonadal steroids 5a-pregnane-3,20-dione and 20a-hydroxy-4-pregnen-3-one also appear to affect gonadotropin secretion in vitro (Figures 21 and 24) but in a non-selective manner. In contrast to all these steroids, 3HP differentially inhibits the secretion of FSH after LHRH-stimulation in primary cultures of rat anterior pituitary cells (Figures 16, 17, 18 and 19). This study has also shown that 3HP depresses the synthesis of FSH along with its effect on secretion (Table 4).

4.2.2 3HP and Inhibin Effects In Vitro


Considerable attention has been focussed on inhibin (a Sertoli cell polypeptide) which appears to play a role in the modulation of pituitary FSH secretion. However, inhibin does not modulate the pituitary response to LHRH <u>in vivo</u> consistently (Morris and Asmatullah, 1982) and, although inhibin has been shown to selectively inhibit basal FSH secretion <u>in</u> vitro, it is unanimously agreed that inhibin suppresses the LHRH- stimulated release of both FSH and LH (Table 2). Bovine inhibin appears to depress basal LH secretion as well (Farnworth <u>et al</u>, 1988). Porcine follicular fluid inhibin (PFF-I), used in this study, was incapable of selectively suppressing basal FSH secretion unless gonadotropes were first stimulated with progesterone and 17β -estradiol to increase gonadotropin secretion (Figure 25). 3HP did not decrease basal FSH secretion in this system, possibly due to the opposing effects of progesterone and 17β -estradiol, but did selectively inhibit LHRH-induced FSH. PFF-I was not capable of a similar selective FSH reduction under both basal and LHRH-stimulated conditions. Therefore, it appears that only 3HP is capable of a consistent selective reduction of both basal and LHRH-induced FSH secretion <u>in vitro</u>.

Until recently, evidence regarding the role of inhibin was largely circumstantial, relying on data such as Sertoli cell production, or rete testis fluid concentration, of inhibin as indicators of circulating inhibin since serum levels could not be detected (McLachlan <u>et al</u>, 1987). Other lines of evidence included the dependence of inhibin production on FSH and the ability of rather large amounts of follicular fluid or rete testis fluid to inhibit <u>in vivo</u> FSH secretion (Hermans <u>et <u>al</u>, 1980; Thomas and Nikitovich-Winer, 1984). Measurement of inhibin has now been achieved and it appears that plasma inhibin is highest in the prepubertal male, 1800 fmole/ml, and relatively low in the mature adult, 400 fmole/ml (Rivier <u>et al</u>, 1988). deKretser and Robertson (1989) have shown that, in the adult, females have higher levels of circulating inhibin (10 U/ml) than males (1.5 U/ml). This recent work underscores the hypothesis that in the male, inhibin is important prepubertally to regulate FSH secretion while in the female, inhibin has a role in the</u>

adult. Evidence regarding the role of 3HP in the regulation of FSH secretion is also somewhat circumstantial at this point in time. This line of thought relies on the production of 3HP by isolated Sertoli cells which is stimulated by FSH (Wiebe, 1982) and the effect of exogenous 3HP on FSH secretion both in vivo and in vitro (Wiebe and Wood, 1987; Wood and Wiebe, 1989). It seems likely then, that both 3HP and inhibin have role; in the regulation of FSH secretion and that perhaps each is primarily functional, or important, at different times or on different aspects of FSH secretion. Figure 34 presents a modified view of the negative feedback relationships in the hypothalamicpituitary-gonadal axis of the rat. Work is progressing in this laboratory towards developing a specific antibody to 3HP and ultimately developing a specific radioimmunoassay to measure endogenous levels of 3HP, particularly with regard to establishing the likelihood that 3HP is capable of being transported to, or formed in, the brain and/or pituitary of the rat. 3HP has been detected in normal rat serum (Wiebe pers. comm.) and it is hoped that endogenous levels of 3HP will be correlated to circulating FSH and the age-related sensitvity to 3HP.

4.2.3 Specificity of 3HP Action

The FSH-suppressing activity of 3HP is related to the 3α -allylic and C₂₀ keto configuration. Comparison of the <u>in vitro</u> activity of 3HP to structurally related steroids shows that none of the possible metabolites or variants of 3HP structure is capable of producing a similar selective FSH reduction <u>in vitro</u> (see Section 3.2.3). These result: strongly suggest that 3HP itself is the active molecule and that it is not metabolized before acquiring activity as is the case with Figure 34: A modified view of the hypothalamic-pituitary-gonadal axis in the rat. Luteinizing hormone-releasing hormone (LHRH) is secreted from the hypothalamus and is transported to the anterior pituitary via the hypophysial portal system. In the anterior pituitary, LHRH stimulates LH, and to a lesser extent FSH, secretion. LH stimulates steroidogenesis in the gonad and the products of this metabolism, testosterone or 178-estradiol, provide negative feedback control of LH secretion at both the hypothalamic and pituitary levels. FSH stimulates gametogenesis and, more importantly here, the production of 3a-hydroxy-4-pregnen-20-one (3HP) and inhibin in the gonad. 3HP and inhibin are both capable of negatively-regulating pituitary FSH secretion, although 3HP suppresses FSH secretion more consistently than does inhibin. Whether either hormone regulates FSH secretion at the hypothalamic level is unknown at this time.



testosterone, which can be reduced to dihydrotestosterone or aromatized to 17β -estradiol (McEwen, 1981; MacLusky and Naftolin, 1981), or progesterone, which can also be metabolized before acquiring activity (Murphy and Mahesh, 1984a and b). Another line of corroborating evidence is that 3HP is effective <u>in vitro</u> at concentrations that may be considered physiological (10^{-16} and 10^{-14} M) (Dohler and Wuttke, 1975; Massicotte <u>et al</u>, 1984a and b).

Of some interest is the observation that all the structurally related steroids examined had no effect on FSH secretion <u>in vitro</u> and only affected LH secretion. Generally speaking, 3β -hydroxy-4-pregnen-20one, 3α -hydroxy-5 α -pregnan-20-one and 3β -hydroxy-5 β -pregnan-20-one all increased the basal release of LH, while 3β -hydroxy-4-pregnen-20-one decreased, and 3α , 20β -dihydroxy-4-pregnene increased the LHRH-induced release of LH, findings that have not been previously reported in <u>in</u> <u>vitro</u> studies. The C₁₉ steroid structurally comparable to 3HP, 3α hydroxy-4-androsten-17-one, only affected LH secretion (Table 7) suggesting that all 21 carbons are required for the FSH-suppressing activity of 3HP. These data further support the notion that 3HP is a physiological regulator of FSH secretion since there appears to be a specific receptor for 3HP. Confirming evidence may be obtained by identifying 3HP in rat serum.

The classic pharmacological approach, the evaluation of structurefunction relationships, was employed in this study to examine the specificty of 3HP action. Current work in this laboratory is aimed at perfecting the synthesis of labelled (ie ${}^{3}\text{H}$ - or ${}^{14}\text{C}$ -) 3HP. Once a label is available a more direct approach may be taken, that is, specific binding of $[{}^{3}\text{H}]$ -3HP to either whole pituitary homogenates or isolated

cells in culture can be assessed to determine the presence of specific 3HP receptors. Subsequently, any specific binding sites can be characterized. Metabolism of $[^{14}C]$ -3HP in cultured pituitary cells can be examined to determine what the time-course and products of 3HP metabolism in the pituitary are.

4.3 DIFFERENTIAL REGULATION OF FSH AND LH SECRETION: A BRIKF CONSIGNT

Much attention has recently focussed on the differential regulation of the two pituitary gonadotropins, FSH and LH. Denef et al (1980) demonstrated that testosterone or dihydrotestosterone increased LHRHinduced FSH secretion in pituitary cultures and that this differential effect could be assigned to different functional subpopulations of gonadotropes. In the young male rat, pituitary content of LH increases as expected but FSH content decreases following castration (Vogel and Sherins, 1984). More information has been disclosed by treatment of castrate rats with LHRH antagonists. These studies show that LH secretion is decreased much more than FSH after LHRH antagonist treatment (ie. FSH is less dependent on LHRH than is true for LH) and that several steroids selectively affect FSH secretion only after treatment with LHRH antagonists (Bhasin et al, 1987; Kartun and Schwartz, 1987). Recent work with intact and castrate rats has shown that pulses of secreted LH closely follow those of LHRH while pulsatile FSH secretion is not directly related to LHRH pulses (Levine and Duffy, 1988). The finding in the present study that LHRH has a greater stimulating effect on LH than FSH also suggests that LHRH is not solely responsible for FSH secretion. McCann et al (1983) offer a good review of differential control of FSH secretion. The opinions on this topic are

not unanimous since Wise <u>et al</u> (1979) claim that some doses of LHRH selectively stimulate FSH secretion while Urbanski's group (1988) showed that FSH secretion does follow LHRH pulses suggesting that there is no differential regulation of pituitary gonadotropin secretion.

A number of suggestions as to how differential regulation occurs have been put forth: 1) a separate FSH-releasing factor may exist, but there is not much support for this hypothesis (Levine and Duffy, 1988; Urbanski et al, 1988); 2) considerable evidence supports the contention that basal FSH secretion is dependent on hypothalamic LHRH but that FSH pulsatility is independent of LHRH (DePaolo, 1985; Berardo and DePaolo, 1986; Culler and Negro-Vilar, 1987; Levine and Duffy, 1988); 3) different subcellular processing of the LHRH signal leading to separate effects on FSH and LH secretion (Levine and Duffy, 1988; Strobl and Levine, 1988; Kotsuji et al, 1988); 4) and related to number 3, gonadal steroids have differential feedback mechanisms where the intrapituitary response to LHRH is altered (Levine and Duffy, 1988; Strobl and Levine, 1988; Kotsuji et al, 1988). The work of Vogel and Sherins (1984) suggests that intracellular synthesis, processing and storage of gonadotropins may be the point of differential control. 3HP is a steroid capable of differential regulation of FSH secretion both in vivo and in vitro in a dose-dependent manner and may operate at the intrapituitary level in its heterogeneous effect on gonadotropin secretion.

4.4 INSIGHT INTO THE MECHANISM OF 3HP ACTION

In an effort to further examine the nature of 3HP action, activation and inhibition of the calcium and protein kinase C (PKC) signals of LHRH were carried out in the presence or absence of 3HP

and/or LHRH (Section 3.2.4).

A number of useful observations with respect to the calcium signal were obtained: 1) the calcium ionophore A23187 stimulates basal and LHRH-induced FSH secretion to a similar high level (a level greater than that achieved by LHRH alone) but does not increase LH secretion beyond the level attained with LHRH alone (Figure 29); 2) 3HP is inhibitory to the A23187-induced increase in secreted FSH; 3) inhibition of calcium uptake by verapamil or nifedipine (Figures 30 and 31) reduces the basal and LHRH-induced release of LH ; 4) FSH secretion is either not affected or actually increased by verapamil or nifedipine and, in the presence of both 3HP and verapamil or nifedipine, LHRH-induced FSH secretion drops sharply while basal FSH remains elevated under these conditions.

The first observation suggests that FSH secretion is less responsive than LH to the calcium signal produced by LHRH since the supranormal intracellular calcium concentrations produced by A23187 resulted in greater secretion of FSH, but not LH, than LHRH alone. 3HP opposes the effect of both LHRH and A23187 on FSH secretion suggesting that 3HP interacts with the calcium signal or subsequent cellular events. The third observation (along with the first) confirms the role of the calcium signal in the induction of LH secretion by LHRH (Conn <u>et</u> <u>al</u>,1987; Clayton, 1989). The fourth observation is the most surprising, that being that lowered intracellular calcium does not interfere with either basal FSH secretion or its induction by LHRH suggesting that FSH secretion is rather insensitive to lowered calcium levels and that LHRH may act on FSH via a primarily calcium-independent mechanism. 3HP is not effective in reducing basally secreted FSH in a low calcium environment but, together with verapamil or nifedipine, has a strongly negative effect on LHRH-induced FSH secretion. The enhancement of the FSHsuppressing activity of 3HP by the calcium channel antagonists, verapamil and nifedipine, is somewhat similar to the enhancement or facilitation of the analgesic effect of 3HP when verapamil and nifedipine are administered parenterally and 3 H P intracerebroventricularly (Wiebe and Kavaliers, 1988). All of this suggests that, unlike LH, basal FSH secretion is somewhat independent of calcium but can be stimulated by elevated intracellular calcium and further suggests that LHRH induction of FSH secretion does not occur chiefly via the calcium signal. As for 3HP, it appears that this steroid may be acting to increase the calcium requirement for FSH secretion. thus its apparent synergistic effect with the calcium channel antagonists and its opposing effect on LHRH- or A23187- induced FSH secretion. These insights further support the notion that there is, indeed, a differential control mechanism for the secretion of FSH and LH and that, similar to 17β -estradiol (Liu and Jackson, 1987), 3HP acts on the post-receptor mechanisms, particularly the calcium-generated postreceptor events, to selectively reduce LHRH-induced FSH secretion.

Protein kinase C (PKC) also plays a clear role in the secretion of gonadotropins <u>in vitro</u>. Attempted inhibition of PKC does not inhibit basal gondotropin secretion since, in the non-activated cell, basal PKC activity is already low (Nishizuka, 1986). Attempted PKC inhibition did, however, decrease the LHRH-induced secretion of both gonadotropins suggesting that PKC is not only involved in the long-term attenuation of the LH response to LHRH (Conn <u>et al</u>, 1987; Clayton, 1989) but plays a similar role for FSH. 3HP appears to interact with H-7 in suppressing FSH secretion (decrease in variability), although FSH levels are suppressed to the level seen with 3HP alone and not further. Perhaps the interaction of 3HP with the calcium signal, with specific regard to FSH secretion, is also related to this interaction with PKC inhibition (H-7) since PKC activity is enhanced by calcium. PKC activation stimulates the basal release of LH as has been reported (Conn et al, 1987; Clayton, 1989). The decrease in LHRH-induced LH secretion brought about by PKC activation (with or without 3HP) may be due to an internal down-regulation of PKC (Nishizuka, 1986). PKC activation does appear to oppose 3HP inhibition of basal and LHRH-induced FSH secretion. These data suggest that 3HP does not act via an inhibition of PKC component can antagonize the FSH-supple:essing effect of 3HP.

The above studies into the mechanism of 3HP suppresssion of FSH have only scratched the surface and future studies will hopefully further illuminate the mechanisms governing differential secretion of FSH and the role of 3HP in this process.

Finally, 3HP is likely similar to other steroids in its action and plays a role in the ultimate regulation of FSH gene expression by one of the following mechanisms: suppression of FSH gene transcription; downregulation of mRNA processing within the nucleus; inhibition of mRNA translation in the cytoplasm or increased degradation of FSH stored in secretory granules. Evidence on this point is indirect: 3HP selectively decreases FSH secretion <u>in vivo</u> and <u>in vitro</u> and decreases the cell content of FSH suggesting an overall reduction in FSH synthesis as well as release. Further investigations in this line (ie. the identification of a specific binding protein or receptor for 3HP localized to the nucleus of gonadotropes) should allow for more detailed studies such as the incorporation of [3-H]-uracil into newly synthesized messenger ribonucleic acid for FSH before and after 3HP treatment, and the incorporation of $[^{35}-S]$ -methionine into nascent FSH polypeptides under similar conditions.

SUPPLARY

1) 3HP selectively suppresses FSH secretion <u>in vivo</u> in male and female, intact and castrate rats.

2) The FSH-suppressing effect of 3HP is dose-related and therefore is probably of physiological significance.

3) The senesitivity of the male rat pituitary to 3HP is in place by 10 days of age. 3HP has its greatest FSH-suppressing effect in the adult castrated male rat.

4) The <u>in vivo</u> FSH-suppressing effect of 3HP is unique compared to other gonadal and structurally-related steroids.

5) In anterior pituitary cells in culture, 3HP selectively inhibits both basal and LHRH-induced FSH secretion, without affecting LH secretion, at doses as low as 10^{-14} M.

6) The <u>in vitro</u> FSH-suppressing effect of 3HP is dose-related and occurs in the range of 10^{-16} - 10^{-6} M 3HP, the physiological range for most steroids.

7) The action of 3HP in vitro is specific to its structure and is not due to the effect of a functionally or structurally-related steroid.

8) 3HP and inhibin probably act together, and perhaps at different

times, or on different aspects, to regulate FSH secretion in the rat.

9) The mechanism of the FSH-suppressing effect of 3HP most likely involves gene regulation (of the FSH gene) and appears to be concerned with the post-receptor signal of LHRH, specifically increasing the calcium requirement for, or otherwise altering the effect of increased intracellular calcium on, FSH secretion.

REFERENCES

Andrews VW, Staley DD, Huckle WR and Conn PM 1986 Stimulation of luteinizing hormone (LH) release and phospholipid breakdown by guanosine triphosphate in permeabilized pituitary gonadotrophs: antagonist action suggests association of a G protein and gonadotropin-releasing hormone receptor. Endocrinology 119:2537

Attardi B 1984 Progesterone modulation of the luteinizing hormone surge: regulation of hypothalamic and pituitary progestin receptors. Endocrinology 115:2113

Au CL, Robertson DM and deKretser DM 1986 Measuremennt of inhibin and an index of inhibin production by rat testes during postnatal development. Biol Reprod 35:37

Baba Y, Matsuo H and Schally AV 1971 Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analysis. Biochem and Biophys Res Comm 44:459

Barnea A, Cho G and George F 1988 The maturational process of gonadotropin-releasing hormone neurons in the male rat: a role for the adrenal gland in the increase in secretory function. Endocrinology 123:2730

Barrack ER 1984 Nuclear acceptor sites in steroid hormone action: the nuclear matrix. In: Labrie F and Proulx L (eds) <u>Endocrinolgy:</u>

<u>Proceedings of the 7th International Congress of Endocrinolgy</u>. Elsevier Science Publishing Co, New York, p 107

Barrack ER 1987 Steroid hormone receptor localization in the nuclear matrix: interaction with acceptor sites. J Steroid Biochem 27:115

Batra SK and Miller WL 1985 Progesterone inhibits basal production of follicle-stimulating hormone in ovine pituitary cell culture. Endocrinology 117:3443

Batra SK, Britt JH and Miller WL 1986 A direct pituitary action of progesterone on basal secretion of follicle-stimulating hormine in ovine cell culture: dependence on ovaries <u>in vivo</u>. Endocrinology 119:1929

Beato M, Arnemann J, Chalepakis G, Slater E and Willmann T 1987 Gene regulation by steroid hormones. J Steroid Biochem 27:9

Berardo PV and DePaolo LV 1986 Different neuroendocrine mechanisms regulate the acute pituitary follicle-stimulating hormone response to orchidectomy and ovariectomy. Neuroendocrinology 43:511

Bhasin S, Fielder TJ and Swerdloff RS 1987 Testosterone selectively increases serum follicle-stimulating hormone (FSH) but not luteinizing hormone (LH) in gonadotropin-releasing hormone antagonist-treated male rats: evidence for differential regulation of LH and FSH secretion. Biol Reprod 37:55 Bourguinon JP, Gerard A, Debougnoux G, Rose J and Franchimont P 1987 Pulsatile release of gonadotropin-releasing hormone (GnRH) from the rat hypothalamus <u>in vitro</u>: calcium and glucose dependency and inhibition by superactive GnRH analogs. Endocrinology 121:993

Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248

Bression D, Michard M, LeDafniet M, Pagesy P and Peillon F 1986 Evidence for a specific estradiol binding site on rat pituitary membranes. Endocrinology 119:1048

Burgos MH, Vitale-Calpe R and Agustin A 1970 Fine structure of the testis and its functional significance. In:Gomes WR and Vandemark NL (eds) <u>The Testis</u>, Vol. 1. Academic Press, New York, p 551

Calderon JJ, Muldoon TG and Mahesh VB 1987 Receptor-mediated interrelationships between progesterone and estradiol action on the anterior pituitary-hypothalamic axis of the ovariectomized immature rat. Endocrinology 120:2428

Campen CA and Vale W 1988 Interaction between purified ovine inhibin and steroids on the release of gonadotropins from culture rat pituitary cells. Endocrinology 123:1320

Carreras A, Mendoza C, Ortega E and Ruiz E 1987 Testosterone implants

into the lateral septum of male rats, a positive effect on LH and FSH secretion. Brain Res Bull 19:149

Chambon P, Gaub MP, Lepennec JP, Dierich A and Astinotti D 1984 Steroid hormones relieve repression of the ovalbumin gene promoter in chick oviduct tubular gland cells. In: Labrie F and Proulx L (eds) <u>Endocrinology: Proceedings of the 7th International Congress of</u> <u>Endocrinology. Elsevier Science Publishing Co., New York, p 3</u>

Chang JP, McCoy EE, Graeter J, Tasaka K and Catt KJ 1986 Participation of voltage-dependent calcium channels in the action of gonadotropinreleasing hormone. J Biol Chem 261:9105

Chang JP, Stojilkovic SS, Graeter JS and Catt KJ 1988 Gondadotropinreleasing hormone stimulates luteinizing hormone secretion by extracellular calcium-dependent and -independent mechanisms. Endocrinology 122:87

Childs (Moriarty) G, Ellison D, Foster L and Ramaley JA 1981 Postnatal maturation of gonadotropes in the male rat pituitary. Endocrinology 109:1683

Clark CR 1984 The cellular distribution of steroid hormone receptors: have we got it right? TIBS 9:101

Clayton RN 1989 Gonadotrophin-releasing hormone: its actions and receptors. J Endocrinol 120:11

Conn PM, McArdle CA, Andrews WV and Huckle WR 1987 The molecular basis of gonadotropin-releasing hormone (GnRH) action in the pituitary gonadotrope. Biol Reprod 36:17

Conn PM, Rogers DC and Sheffield T 1981 Inhibition of gonadotropin releasing hormone stimulated release by pimozide: evidence for a site of action after calcium mobilization. Endocrinology 109:1122

Culler MD and Negro-Vilar A 1987 Pulsatile follicle-stimulating hormone secretion is independent of luteinizing hormone-releasing hormone (LHRH): pulsatile rep!acement of LHRH bioactivity in LHRHimmunoneutralized rats. Endocrinology 120:2011

Culler MD, Valenca MM, Merchenthaler I, Flerkc " and Negro-Vilar A 1988 Orchidectomy induces temporal and regional changes in the processing of the luteinizing hormone-releasing hormone prohormone in the rat brain. Endocrinology 122:1968

Debeljuk L and deRettori VB 1982 Gonadal hormones and gonadotropin secretion. In: DeNicola A, Blaquier J and Soto RJ (eds) <u>Physiopathology</u> of Hypophysial Disturbances and Diseases of Reproduction. Alan R. Liss, Inc., New York, p 33

Debeljuk L, Khar A and Jutisz M 1978 Effects of gonadal steroids and cyclohexamide on the release of gonadotrophins by rat pituitary cells in culture. J Endocrinol 77:409

Decker MH, Loriaux DL and Cutler GB 1981 A seminiferous tubular factor is not obligatory for regulation of plasma follicle-stimulating hormone in the rat. Endocrinology 108:1035

deKretser DM and Robertson DM 1989 The isolation and physiology of inhibin and related proteins. Biol Reprod 40:33

Demoulin A, Thieblot P and Franchimont P 1973 Influence de differents steroides et de la prostaglandine E_1 sur le taux des gonadotrophines seriques chez le rat male castre. C R Soc Biol 167:1684

Denef C, Hautekeete E, Dewals R and deWolf A 1980 Differential control of luteinizing hormone and follicle-stimulating hormone seecretion by androgens in rat pituitary cells in culture: functional diversity of subpopulations separated by unit gravity sedimentation. Endocrinology 106:724

DePaolo LV 1985 Differential regulation of pulsatile luteinizing (LH) and follicle-stimulating horwone secretion in ovariectomized rats disclosed by treatment with a LH-releasing hormone antagonist and phenobarbital. Endocrinology 117:1826

Dohler KD and Wuttke W 1975 Changes with age in levels of serum gonadotropins, prolactin and gonadal steroids in prepubertal male and female rats. Endocrinology 97:898

Drouin J and Labrie F 1976 Selective effect of androgens on LH and FSH

release in anterior pituitary cells in culture. Endocrinology 98:1528

Dufy-Barbe L and Franchimont P 1972 Influence des differents steroides gonadiques sur le taux de la FSH et de la LH chez le rat castre. C R Soc Biol 166:960

Duncan JA, Dalkin AC, Barkan A, Regiani S and Marshall JC 1983 Gonadal regulation of pituitary gonadotropin-releasing hormone receptors during sexual maturation in the rat. Endocrinology 113:2238

Eik-Nes KB 1975 Biosynthesis and secretion of testicular steroids. In: Hamilton DW and Greep RO (eds) <u>Handbook of Physiology, Section 7:</u> <u>Endocrinology, Vol. V: Male Reproductive System</u>. Waverly Press, Baltimore, p 95

Eldridge JC, Dmowski WP and Mahesh VB 1974 Effects of castration of immature rats on serum FSH and LH, and of various steroid treatments after castration. Biol Reprod 10:438

Farnworth PG, RoLartson DM, deKretser DM and Burger HG 1988 Effects of 31 kilodalton bovine inhibin on follicle-stimulating hormone and luteinizing hormone in rat pituitary cells <u>in vitro</u>: actions under basal conditions. Endocrinology 122:207

Fink G and Henderson SR 1977 Steroids and pituitary responsiveness in female, androgenized female and male rats. J Endocrinol 73:157

Fortune JE and Armstrong DT 1979 Androgen production by isolated components of rat ovarian follicles. In: Midgley AR and Sadler WA (eds) <u>Ovarian Follicular Development and Function</u>. Raven Press, New York, p 193

Fukuda M, Miyamoto K, Hasegawa Y, Ibuki Y and Igarishi M 1987 Action mechanism of inhibin <u>in vitro</u>-cycloheximide mimics inhibin actions on pituitary cells. Mol Cell Endocrinol 51:41

Fu⁻ıda M, Miyamaoto K, Hasegawa Y, Noinura M, Igarashi M, Kangawa K and Matsuo H 1986 Isolation of bovine follicular fluid inhibin of about 32 KDa. Mol Cell Endocrinol 44:55

Garcia T, Buchou T, Jung-Testas I, Renoir JM and Baulieu EE 1987 Chick oviduct progesterone receptor phosphorylation: characterization of a copurified kinase and phosphorylation in primary cultures. J Steroid Biochem 27:227

Garcia-Segura LM, Olmos G, Tranque P and Naftolin F 1987 Rapid effects of gonadal steroids upon hypothalamic neuronal membrane ultrastructure. J Steroid Biochem 27:615

Gay VL and Dever NW 1971 Effects of testosterone propionate and estradiol benzoate-alone or in combination-on serum LH and FSH in orchidectomized rats. Endocrinology 89:161

Girre A, Gaubicher J and Rault B 1980 Influence in vitro du 5a-

androstane-3 β , 17 β -diol sur la liberation de l'hormone folliculostimulante (FSH) induite par LHRH. C R Soc Biol 174:948

Gore-Langton RE and Armstrong DT 1988 Follicular steroidogenesis and its control. In: Knobil E and Neill J (eds) <u>The Physiology of</u> <u>Reproduction</u>. Raven Press, New York, p 331

Gray GD, Smith ER and Davidson JM 1980 Gonadotropin regulation in middle-aged male rats. Endocrinology 107:2021

Hadley ME 1984 Endocrinology. Prentice-Hall, Englewood Cliffs, 547 pp

Harlan RE 1988 Regulation of neuropeptide gene expression by steroid hormones. Mol Neuro 2:183

Hermans WP, vanLeeuwen ECM, Debets MHM and deJong FH 1980 Involvement of inhibin in the regulation of follicle-stimulating hormone concentrations in prepubertal and adult, male and female rats. J Endocrinol 86:79

Hiatt ES, Valadka RJ and Schwartz NB 1987 Sex differences following gonadectomy in basal gonadotropin secretion rate of rat pituitary fragments in vitro. Biol Reprod 37:1114

Hirschfield AN 1979 The role of FSH in the recruitment of large follicles. In: Midgley AR and Sadler WA (eds) <u>Ovarian Follicular</u> Development and Function. Raven Press, New York, p 19 Ho AK, Chik CL and Klein DC 1988 Effects of protein kinase inhibitor (1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7) on protein kinase C activity and adrenergic stimulatation of cAMP and cGMP in rat pinealocytes. Biochem Pharmacol 37:1015

Hsueh AJW, Erickson GF and Yen SSC 1979 The sensitizing effect of estrogens and catechol estrogen on cultured pituitary cells to luteinizing hormone-releasing hormone: its antagonism by progestins. Endocrinology 104:807

Huckle WR and Conn PM 1987 The relationship between gonadotropinreleasing hormone-stimulated luteinizing hormone release and inositol phosphate production: studies with calcium antagonists and protein kinase C activators. Endocrinology 120:160

Ito M, Tanaka T, Inagaki M, Nakanishi K and Hidaka H 1986 N-(6phenylhexyl)-5-chloro-1-naphthalenesulfonamide, a novel activator of protein kinase C. Biochemistry 25:4179

Ito M, Tanabe F, Sato A, Takami Y and Shigeta S 1988 A potent inhibitor of protein kinase C inhibits natural killer activity. Int J Immunopharm 19:211

Jinnah HA and Conn PM 1985 GnRH-stumulated LH release from rat anterior pituitary cells in culture: refractoriness and recovery. Am J Physiol 249 (Endocrinol and Metab 12):E619 Kamel F and Kubajak CL 1987 Modulation of gonadotropin secretion by corticosterone: interaction with gonadal steroids and mechanism of action. Endocrinology 121:561

Kao LWL and Weisz J 1975 Direct effect of testosterone and its 5areduced metabolites on pituitary LH and FSH release <u>in vitro</u>: changes in pituitary responsiveness to hypothalamic extract. Endocrinology 96:253

Karanth S, Gill MK, Dutta A and Juenja HS 1984 Studies on the effects of low doses of 5a-dihydrotestosterone (DHT) on the basal levels of serum gonadotropins and the sensitivity of the pituitary to luteinizing hormone releasing hormone (LHRH) in adult male rats. Horm Metab Res 16:32

Karavolas HJ, Hoiges D and O'Brien D 1976 Uptake of $[{}^{3}$ H]progesterone and $[{}^{3}$ H]5a-dihydroprogesterone by rat tissues <u>in vivo</u> and analysis of accumulated radioactivity: accumulation of 5a-dihydroprogesterone by pituitary and hypothalamic tissues. Endocrinolgy 98:164

Karsch FJ, Cummins JT, Thomas GB and Clarke IJ 1987 Steroid feedback inhibition of pulsatile secretion of gonadotropin-releasing hormone in the ewe. Biol Reprod 36:1207

Kartun K and Schwartz NB 1987 Effects of a potent antagonist to gonadotropin-releasing hormone on male rats: luteinizing hormone is suppressed more than follicle-stimulating hormone. Biol Reprod 36:103 Katt JA, Duncan JA, Herbon L, Barkan A and Marshall JC 1985 The frequency of gonadotropin-releasing hormone stimulation determines the number of pituitary gonadotropin-releasing hormone receptors. Endocrinology 116:2113

Kavaliers M and Wiebe JP 1987 Analgesic effects of the progesterone metabolite, 3a-hydroxy-5a-pregnan-20-one, and possible modes of action in mice. Brain Res 415:393

Kawamoto S and Hidaka H 1984 1-(5-isoquinolinesulphonyl)-2methylpiperazine (H-7) is a selective inhibitor of protein kinase C in rabbit platelets. Biochem Biophys Res Comm 125:258

Kennedy J and Chappel S 1985 Direct pituitary effects of testosterone and luteinizing hormone-releasing hormone upon follicle-stimulating hormone: analysis by radioimmuno and radioreceptor assay. Endocrinology 116:741

Keogh EJ, Lee VWK, Rennie GC, Burger HG, Hudson B and deKretser DM 1976 Selective suppression of FSH by testicular extracts. Endocrinolgy 98:997

Kiesel I Helm K, Bertges K, Maier C, Rube T and Runnebaum B 1987 Contraceptive progestins and gonadotropin secretion <u>in vitro</u>. J Steroid Biochem 27:995

Kim WH, Swerdloff RS and Bhasin S 1988 Regulation of alpha and luteinizing hormone beta subunit messenger ribonucleic acids during stimulatory and downregulatory phases of gonadotropin-releasing hormone action. Biol Reprod 39:847

King WJ and Greene GL 1984 Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307:745

Kotsuji F, Winters SJ, Attardi B, Keeping HS, Oshima H and Troen P 1988 Effects of gonadal steroids on gonadotropin secretion in males: studies with perifused rat pituitary cells. Endocrinology 123:2683

Kraulis I, Traikov H, Ruf KB and Naftolin F 1978 Steroid induction of gonadotropin surges in the immature rat. II. Triggering ability of progesterone metabolites, adrenocortical hormones and adrenocorticotrophin. Endocrinology 103:1829

Krueger PM, Hodgen GD and Sherrins RJ 1974 New evidence for the role of the Sertoli cell and spermatogonia in feedback control of FSH secretion in male rats. Endocrinology 95:955

Labrie F, Drouin J, Ferland L, Lagace L, Beaulieu M, DeLean A, Kelly P, Caron MG and Raymond V 1978 Mechanism of action of hypothalamic hormones in the anterior pituitary gland and specific modulation of their activity by sex steroids and thyroid hormones. Rec Prog Horm Res 34:25

Lacy D and Pettit AJ 1970 Sites of hormone production in the mammalian testis, and their significance in the control of male fertility. Br Med

Lagace L, Massicotte J and Labrie F 1980 Acute stimulatory effects of progesterone on luteinizing hormone and follicle-stimulating hormone release in rat anterior pituitary cells in culture. Endocrinology 106:684

Lagace L, Labrie F, Lorenzen J, Schwartz NB and Channing CP 1979 Selective inhibitory effect of procine follicular fluid on folliclestimulating hormone secretion in anterior pituitary cells in culture. Clin Endocrinol 10:401

Lambert JJ, Peters JA and Cottrell GA 1987 Actions of synthetic and endogenous steroids on the GABA, receptor. TIPS 8:224

Leveque NW and Grotjan HE 1982 Interaction of progesterone with testosterone and dihydrotestosterone on follicle-stimulating hormone release by cultures of rat anterior pituitary cells. Biol Reprod 27:110

Levine JE and Duffy MT 1988 Simultaneous measurement of luteinizing hormone (LH)-releasing hormone, LH and follicle-stimulating hormone release in intact and short-term castrate rats. Endocrinology 122:2211

Limonta P, Ladizhenskaya A, Gunsalus GL, Bardin CW and Thau RB 1986 Regulation of pituitary gon_dotropin-releasing hormone receptors by androgens in the male rabbit. Endocrinology 118:340

Ling N, Ying SY, Ueno N, Esch F, Denoroy L and Guillemin R 1985

167

Isolation and partial characterization of a Mr 32,000 protein with inhibin activity from porcine follicular fluid. Proc Natl Acad Sci 82:7217

Lipner H and Dhanarajan P 1984 The role of inhibin in adult male rats: the effect of inhibin deficiency and androgen antagonism on serum and pituitary gonadotrophins. Acta Endocrinol 105:302

Liu TC and Jackson GL 1984 Long term superfusion of rat anterior pituitary cells: effects of repeated pulses of gonadotropin-releasing hormone at different doses, durations and frequencies. Endocrinology 115:605

Liu TC and Jackson GL 1987 Stimulation by phorbol ester and diacylglycerol of luteinizing hormone glycosylation and release by rat antericr pituitary cells. Endocrinology 121:1589

Liu TC and Jackson GL 1988 Actions of 17^β-estradiol on gonadotropin release induced by drugs that activate signal transduction mechanisms in rat anterior pituitary cells. Biol Reprod 39:787

Lorenzen JR and Ramaley JA 1981 Ontogeny of sex differences in LH and FSH levels 48 h after castration in the rat. Am J Physiol 241 (Endocrinol and Metab 4):E460

Loseva LA, Degtiar VG and Isachenkov VA 1980 5α -Androstane-3 β ,17 β -diol in feedback between gonads and hypothalamo-pituitary system of male rats. J Steroid Biochem 13:939

MacLusky NJ and Naftolin F 1981 Sexual differentiation of the central nervous system. Science 211:1294

Mah ">h VB and Muldoon TG 1987 Integration of the effects of estradiol and progesterone in the modulation of gonadotropin secretion. J Steroid Biochem 27:665

Majewska Md and Schwartz RD 1987 Pregnenolone-sulphate: and endogenous antagonist of the (gamma)-amminobutyric acid receptor complex in brain? Brain Res 404:355

Marrone BL, Wiebe JP, Buckingham KD and Hertelendy F 1985 Analysis of steroid metabolites produced by theca cells from the adult domestic hen. J Steroid Biochem 23:375

Martin GB, Wallace JM, Taylor PL, Fraser HM, Tsonis CG and McNielly AS 1986 The roles of inhibin and gonadotropin-releasing hormone in the control of gonadotropin secretion in the ewe. J Endocrinol 111:287

Mason WT and Waring DW 1986 Patch clamp recordings of single ion channel activation by gonadotropin-releasing hormone in ovine pituitary gonadotrophs. Neuroendocrinology 43:205

Massicotte J, Lagace L, Labrie F and Dorrington JH 1984a Modulation of gonadotropin secretion by Sertoli cell inhibin, LHRH and sex steroids.

169

Am J Physiol 247 (Endocrinol and Metab 10):E495

Massicotte J, Lagace L, Godbut M and Labrie F 1984b Modulation of rat pituitary gonadotrophin secretion by porcine granulosa cell "inhibin", LH rleasing hormone and sex steroids in rat anterior pituitary cells in culture. J Endocrinol 100:133

Matt DW, LaPolt PS, Judd HL and Lu JKH 1986 Estrogen exposure affects the post-ovariectomy increases in both LH and FSH release in female rats. Neuroendocrinology 42:21

McArdle CA, Huckle WR, Johnson LA and Conn PM 1988 Enhanced responsiveness of gonadotropes after protein kinase C activation: postreceptor regulation of gonadotropin-releasing hormone action. Endocrinology 122:1905

McCann SM, Mizunuma H, Samson WK and Lumpkin MD 1983 Differential hypothalamic control of FSH secretion: a review. Psychoneuroendocrinolgy 8:299

McCullagh DR 1932 Dual endocrine activity of the testes. Science 76:19

McEwen BS 1981 Neural gonadal steroid actions. Science 211:1303

McLachlan RI, Robertson DM, deKretser DM and Burger HG 1987 Inhibin-a non-steroidal regulator of pituitary follicle-stimulating hormone. Clin Endocr and Metab 1:89 170

McLean BK, Rubel A and Nikitovich-Winer MB 1977 Diurnal variation of follicle-stimulating hormone (FSH) in the male rat. Neuroendocrinology 23:23

McPherson JC, Costoff A and Mahesh VB 1975 Influence of estrogenprogesterone combinations on gonadotropin secretion in castrate female rats. Endocrinology 97:771

McPherson JC and Mahesh VB 1982 Induction of luteinizing hormone, follicle-stimulating hormone surge in the estrogen-primed castrated male rat by progesterone. Biol Reprod 27:1222

Means AR 1975 Biochemical effects of follicle-stimulating hormone on the testis. In: Hamilton DW and Greep RO (eds) <u>Handbook of Physiology</u> <u>Section 7: Endocrinology Vol V: Male Reproductive System</u>. Waverly Press, Baltimore, p 203

Means AR, Dedman JR, Tash JS, Tindall DJ, vanSickle M and Welsh MT 1980 Regulation of the testis Sertoli cell by follicle-stimulating hormone. Ann Rev Physiol 42:59

Meiri H 1986 Is synaptic transmission modulated by progesterone? Brain Res 285:193

Melrose P, Gross L, Cruse I and Ruch M 1987 Isolated gonadotropinreleasing hormone neurons harvested from adult male rats secreted biologically active neuropeptide in a regular repetitive manner. Miller WL and Wu J 1981 Estrogen regulation of follicle-stimulating hormone production <u>in vitro</u>: species variation. Endocrinology 108:673

Mittler JC, Ertel NH and Ourednik J 1981 Positive feedback effect of dihydrotestosterone on follicle-stimulating hormone secretion in the male rat: implications and a possible relation to the onset of puberty. Horm Metab Res 13:569

Morris ID and Azmatullah S 1982 The release of pituitary gonadotrophins by luteinizing hormone releasing hormone in the intact, castrated and aspermatogenic rat. Life Sci 31:2717

Motta M 1982 Effects of sex steroids on gonadotropin secretion. In: Fuji T and Channing CP (eds) <u>Non-steroidal Regulators in Reproductive</u> Biology and Medicine. Academic Press, New York, p 27

Motta M, Celotti F, Massa M, Zanisi M and Martini L 1981 Effects of sex hormone metabolites on the secretion of gonadotropins. In: Wuttke W and Horowski R (eds) <u>Gonadal Steroids and Brain Function</u>. Springer-Verlag, New York, p 80

Mougdal NR, Muralidhar K and Madhwa Raj HG 1978 Pituitary gonadotropins. In: Jaffe BM and Behrman HR (eds) <u>Methods of Hormone</u> Radioimmunoassay. Academic Press, New York, p 1/3 Murphy LL and Mahesh VB 1984a Selective release of follicle-stimulating hormone by 5a-dihydroprogesterone in immature ovariectomized estrogenprimed rats. Biol Reprod 30:594

Murphy LL and Mahesh VB 1984b Selective release of luteinizing hormone by 3a-hydroxy-5a-pregnan-20-one in immature ovariectomized estrogenprimed rats. Biol Reprod 30:795

Nakamura F, Taya K, Sasamoto S and Yoshimura F 1985 Relationship between characteristics of immunoreactive LH/FSH cells and the levels of gonadotropin in the female rat. Acta Anat 124:104

Naor Z, Azrad A, Limor R, Zakut H and Lotan M 1986 gonadotropinreleasing hormone activates a rapid Ca²⁺-independent phosphodiester hydrolysis of polyphosphoinositides in pituitary gonadotropes. J Biol Chem 261:12506

Naor Z and Childs GV 1986 Binding and activation of gonadotropinreleasing hormone receptors in pituitary and gonadal cells. Int Rev Cytol 103:147

Nazian SJ 1982 Role of adrenal in control of gonadotropin secretion in the immature male rat. Arch Androl 8:37

Negro-Vilar A and Lapentina EG 1985 1,2-Didecanoylglycerol and phorbol 12,13-dibutyrate enhance anterior pituitary hormone secretion <u>in</u> <u>vitro</u>. Endocrinology 117:1559 Nieschlag E, Usadel KH and Kley HK 1975 Active immunization with steroids as an approach to investigating testicular and adrenal feedback control. J Steroid Biochem 6:537

Nishino H, Kitigawa K, Iwashima A, Ito M, Tanaka T and Hidaka H 1986 N-(6-phenylhexyl)-5-chloro-1-naphthalenesulfonamide is one of a new class of activators for Ca²⁺-activated, phospholipid-dependent protein kinase. Biochem Biophys Acta 889:236

Nishizuka Y 1986 Studies and perspectives of protein kinase C. Science 235:305

O'Malley BW and Schrader WT 1976 The receptors of steroid hormones. Sci Amer 234:32

Paxinos G and Watson C 1986 <u>The Rat Brain in Stereotaxic Coordinates</u>, 2nd Ed. Academic Press, Montreal

Pohl CR, Guilinger RA and VanThiel DH 1987 Inhibitory action of ethanol on luteinizing hormone secretion by rat anterior pituitary cells in culture. Endocrinology 120:849

Ringstrom SJ and Schwartz NB 1985 Cortisol suppresses the LH, but not the FSH, response to gonadotropin-releasing hormone after orchidectomy. Endocrinology 116:472

Rivier C, Cajander S, Vaughan J, Hsueh AJ and Vale W 1988 Age-dependent

changes in physiological action, content and immunostaining of inhibin in male rats. Endocrinology 123:120

Sairam MR, Kato K, Manjunath P and Ramasharma K 1984 Isolation and characterization of a protein with inhibin like activity from pig follicular fluid. Jn: Sairam MR and Atkinson LE (eds) <u>Gonadal Proteins</u> <u>and Peptides and Their Biological Significance</u>. World Scientific, Singapore, p 65

Salhanick AI and Wiebe JP 1980 FSH receptors in isolated Sertoli cells: changes in concentration of binding sites at the onset of sexual maturation. Life Sci 26:2281

Schally AV, Kastin AJ and Arimura A 1977 Hypothalamic hormones: the link between brain and body. Amer Sci 65:712

Schally AV, Kastin AJ and Coy DH 1976 LH-releasing hormone and its analogues: recent basic and clinical investigations. Int J Fertil 21:1


Schwaninger M, Knepel W, Dohler KD and Sandow J 1987 Release of dynorphin-like immunoreactivity from rat adenohypophysis <u>in vitro</u> during inhibition of anterior pituitary hormone secretion from individual cell types. Endocrinology 121:167

Shahmanesh M, Sedigh M, Azedeh B, Sheikholeslami MK and Nair NKV 1980 Feedback control of FSH secretion in the male rat. Horm Res 12:266



ومريقه

OF/DE



.





Sheth AR, Vanage GR, Vaze AY and Thakur AN 1980 Negative feedback of secretion of follicle-stimulating hormone by the pituitary gland of developing male rats. J Endocrinol 87:401

Sheth AR and Vijayalakshmi S 1981 Selective suppression of FSH as a possible approach for fertility regulation. Arch Androl 7:109

Shikita M and Hall PF 1967 The action of human chorionic gonadotropin <u>in vivo</u> upon microsomal enzymes of immature rat testis. Biochem Biophys Acta 136:484

Shupnik MA, Gharib SD and Chin WW 1988 Estrogen suppresses rat gonadotropin gene transcription <u>in vivo</u>. Endocrinology 122:1842

Solano AR, Sanchez ML, Sardanons ML, Dada L and Podesta EJ 1988 Luteinizing hormone triggers a molecular association between its receptor and the major histocompatibility complex class I antigen to produce cell activation. Endocrinology 122:2080

Spelsberg TC, Goldberger A, Horton M and Hora J 1987 Nuclear acceptor sites for sex steroid hormone receptors in chromatin. J Steroid Biochem 27:133

Spelsberg TC, Rories C, Regman JJ, Goldberger A, Fink K, Lau CK, Colvard DS and Wiseman G 1989 Steroid action on gene expression: possible roles of regulatory genes and nuclear acceptor sites. Biol Reprod 40:54

Stanzec A, Counis R and Jutisz M 1986 Gonadotropin-releasing hormone stimulates the synthesis of the polypeptide chains of luteinizing hormone. Endocrinology 119:561

Steinberger A and Steinberger E 1976 Secretion of an FSH-inhibiting factor by cultured Sertoli cells. Endocrinology 99:918

Steinberger E and Chowdhury M 1977 The effects of testosterone propionate and estradiol benzoate on the <u>in vitro</u> synthesis of FSH. Biol Reprod 16:403

Strobl FJ and Levine JE 1988 Estrogen inhibits luteinizing hormone (LH), but not follicle-stimulating hormone secretion in hypophysectomized pituitary-grafted rats receiving pulsatile LHreleasing hormone infusions. Endocrinology 123:622

Summerville JW and Schwartz NB 1981 Suppression of serum gonadotropin levels by testosterone and porcine follicular fluid in castrate male rats. Endocrinology 109:1442

Suter DE and Schwartz NB 1985 Effects of glucocorticoids on secretion of luteinizing hormone and follicle-stimulating hormone by female rat pituitary cells <u>in vitro</u>. Endocrinology 117:849

Swerdloff RS, Grover RK, Jacobs HS and Bain J 1973 Search for a substance which selectively inhibits FSH-effects of steroids and prostaglandins on serum FSH and LH levels. Steroids 21:703

Swerdloff RS and Walsh PC 1973 Testosterone and oestradiol suppression of LH and FSH in adult male rats: duration of castration, duration of treatment and combined treatment. Acta Endocrinol 73:11

Tang LKL and Spies HG 1975 Effects of gonadal steroids on the basal LRF-induced gonadotropin secretion by cultures of rat pituitary. Endocrinology 96:349

Thomas CL and Nikitovich-Winer MA 1984 Complete suppression of plasma follicle-stimulating hormone in castrated male and female rats during continuous administration of porcine follicular fluid. Biol Reprod 30:427

Tilbe KS and Wiebe JP 1981 Sertoli cell capacity to metabolize progesterone: variation with age and the effect of follicle-stimulating hormone. Endocrinology 108:597

Towle AC and Sze PY 1983 Steroid binding to synaptic plasma membrane: differential binding of glucocorticoids and gonadal steroids. J Steroid Biochem 18:135

Ultee-vanGessel AM and deJong FH 1987 Inhibin-like activity in Sertoli cell culture media and testicular homogenates from rats of various ages. J Endocrinol 113:103

Urbanski HF, Pickle RL and Ramirez VD 1988 Simultaneous measurement of gonadotropin-releasing hormone, luteinizing hormone and follicle-

stimulating hormone in the orchidectomized rat. Endocrinology 123:413

Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P, Petraglia F, Yu J, Plotsky P, Spiess J and Rivier J 1988 Chemical and biological characterization of the inhibin family of protein hormones. Rec Prog Horm Res 44:1

van derMolen HJ, deBruijn WA, Cooke BA, deJong FH and Rommerts FFG 1973 Regulation of the production of testicular steroids. In: James VHT, Serio M and Marini L (eds) <u>Endocrine Function of the human testis</u>. Academic Press, New York, p 459

VanThiel DH, Sherrins RJ, Myers GH and DeVita VT 1972 Evidence for a specific seminiferous tubule factor affecting follicle-stimulating hormone secretion in man. J Clin Invest 51:1009

Verjans HL and Eik-Nes KB 1977 Comparison of effects of C_{19} (androstene or androstane) steroids on serum gonadotrophin concentrations and on accessory reproductive organ weights in gonadectomized, adult male rats. Acta Endocrinol 84:829

Vogel DL and Sherrins RJ 1984 Orchidectomy in young rats results in differential regulation of follicle-stimulating hormone and luteinizing hormone content. J Androl 5:80

Wang F, Farnworth PG, Findlay JK and Burger HG 1988 Effect of purified 31K bovine inhibin in the specific binding of gonadotropin-releasing hormone to rat anterior pituitary cells in culture. Endocrinology 123:2161

Wang QF, Farnworth PG, Findlay JK and Burger HG 1989 Inhibitory effect of pure 31-kilodalton bovine inhibin on gonadotropin-releasing hormone (GnRE)-induced up-regulation of GnRH ginding sites in cultured rat anterior pituitary cells. Endocrinology 124:363

Welsh MJ and Wiebe JP 1976 Sertoli cells from immature rats: <u>in vitro</u> stimulation of steroid metabolism by FSH. Biochem Biophys Res Comm 69:936

Welsh MJ and Wiebe JP 1978 Sertoli cell capacity to metabolize C₁₉ steroids: variation with age and the effect of follicle-stimulating hormone. Endocrinology 103:838

Welshons WV, Krummel BM and Gorski J 1985 Nuclear localization of unoccupied receptors for glucocorticoids, estrogens and progesterone in GH₃ cells. Endocrinology 117:2140

Wiebe JP 1978a Steroidogenesis in rat Leydig cells: effect of gonadotropins on the activity of 5-ane and 5-ene 3α - and 3β hydroxysteroid dehydrogenases during sexual maturation. Endocrinology 102:775

Wiebe JP 1978b Isolated Sertoli cells from immature rats produce 20ahydroxy-pregn-4-en-3-one from progesterone and 38,20a-dihydroxy-5apregnane from pregnenolone. Biochem Biophys Res Comm 84:1003

Wiebe JP 1982 Identification of a unique Sertoli cell steroid as 3ahydroxy-4-pregnen-20-one (3a-dihydroprogesterone: 3a-DHP). Steroids 39:259

Wiebe JP 1985 Steroidogenesis: what happens in the vertebrate testis at the onset of puberty? In: Lofts B and Holmes WN (eds) <u>Current Trends in</u> <u>Comparative Endocrinology, Vol 1</u>. Hong Kong University Press, Hong Kong, p 273

Wiebe JP, Buckingham KD, Wood PH and Campbell SMC 1988 Relative steroidogenic activity of Sertoli and Leydig cells and role of the Sertoli cell steroid, 3a-hydroxy-4-pregnen-20-one, in spermatogenesis and FSH secretion. In: Parvinen M, Huhtaniemi I and Pelliniemi LJ (eds) <u>Development and Function of the Reproductive Organs, Vol II</u>. Ares-Serono Symposia, Rome, p 39

Wiebe JP, Dave V and Stothers JB 1986 Synthesis and characteristics of allylic 4-pregnene-3,20-diols found in gopadal and breast tissues. Steroids 47:249

Wiebe JP, Deline C, Buckingham KD, Dave V and Stothers JB 1985 Synthesis of the allylic gonadal steroids, 3a-hydroxy-4-pregnen-20-one and 3a-hydroxy-4-androsten-17-one, and of 3a-hydroxy-5a-pregnam-20-one. Steroids 45:39 Wiebe JP and Kavaliers M 1988 Analgesic effects of the putative FSHsuppressing gonadal steroid, 3α -hydroxy-4-pregnen-20-one: possible modes of action. Brain Res 461:150

Wiebe JP and Tilbe KS 1979 <u>De novo</u> synthesis of steroids (from acetate) by isolated rat Sertoli cells. Biochem Biophys Res Comm 889:1107

Wiebe JP, Tilbe KS and Buckingham KD 1980 An analysis of the metabolites of progesterone produced by isolated Sertoli cells at the onset of gametogenesis. Steroids 35:561

Wiebe JP and Wood PH 1987 Selective suppression of follicle-stimulating hormone by 3a-hydroxy-4-pregnen-20-one, a steroid found in Sertoli cells. Endocrinology 120:2259

Wierman ME, Rivier JE and Wang C 1989 Gonadotropin-releasing hormonedependent regulation of gonadotropin subunit messenger ribonucleic acid levels in the rat. Endocrinology 124:272

Winter SJ and Troen P 1985 Evidence for a role of endogenous estrogen in the hypothalamic control of gonadotropin secretion in men. J Clin Endocr Metab 61:842

Wise PM, Rance N, Barr GD and Barraclough CA 1979 Further evidence that luteinizing hormone-releasing hormone also is follicle-stimulating hormone-releasing hormone. Endocrinology 104:940 Wood PH and Wiebe 1989 Selective suppression of follicle-stimulating hormone secretion in anterior pituitary cells by the gonadal steroid, 3a-hydroxy-4-pregnen-20-one (3HP). Endocrinology 125:In press

Wynn PC, Suarez-Quian CA, Childs GV and Catt KJ 1986 Pituitary binding and internalization of radioiodinated gonadotropin-releasing hormone agonist and antagonist ligands <u>in vitro</u> and <u>in vivo</u>. Endocrinology 119:1852

Zanisi M, Motta M and Martini L 1973 Feedback activity of testosterone and of its 5a-reduced metabolites. In: James VHT, Serio M and Martini L (eds) <u>The Endocrine Function of the Human Testis, Vol 1</u>. Academic Press, New York, p 431